WO2016065582A1 - Inhibitors of the renal outer medullary potassium channel - Google Patents
Inhibitors of the renal outer medullary potassium channel Download PDFInfo
- Publication number
- WO2016065582A1 WO2016065582A1 PCT/CN2014/089930 CN2014089930W WO2016065582A1 WO 2016065582 A1 WO2016065582 A1 WO 2016065582A1 CN 2014089930 W CN2014089930 W CN 2014089930W WO 2016065582 A1 WO2016065582 A1 WO 2016065582A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- oxo
- mmol
- diazaspiro
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 21
- 102000004257 Potassium Channel Human genes 0.000 title description 10
- 108020001213 potassium channel Proteins 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 234
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- 206010020772 Hypertension Diseases 0.000 claims abstract description 16
- 206010019280 Heart failures Diseases 0.000 claims abstract description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- -1 methoxy-d3 Chemical class 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- OWPIIGLZPMUHEG-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(2-methoxypyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NC(=NC=C2)OC)CC1)C=1C(=C2COC(C2=CC=1)=O)C OWPIIGLZPMUHEG-IBGZPJMESA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 claims description 4
- AEQJLXICIKRMCT-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C AEQJLXICIKRMCT-IBGZPJMESA-N 0.000 claims description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 3
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 239000005480 Olmesartan Substances 0.000 claims description 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 3
- 229960002576 amiloride Drugs 0.000 claims description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 3
- 230000002497 edematous effect Effects 0.000 claims description 3
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 3
- 229960004563 eprosartan Drugs 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 claims description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- AEQJLXICIKRMCT-WROXPGLTSA-N 2-(1-methyl-6-oxopyridazin-3-yl)-8-[(2R)-1,1,2-trideuterio-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@](C(N1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)([2H])[2H])(C=1C(=C2COC(C2=CC=1)=O)C)[2H] AEQJLXICIKRMCT-WROXPGLTSA-N 0.000 claims description 2
- JICUUUBHBGKHQQ-AOMKIAJQSA-N 8-[(1R,2S)-1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H]([C@H](C)N1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C JICUUUBHBGKHQQ-AOMKIAJQSA-N 0.000 claims description 2
- JICUUUBHBGKHQQ-KSFYIVLOSA-N 8-[(1S,2S)-1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@H]([C@H](C)N1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C JICUUUBHBGKHQQ-KSFYIVLOSA-N 0.000 claims description 2
- UMVYPSXZCLWWSG-SFHVURJKSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(1,2-thiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=CC=NS2)CC1)C=1C(=C2COC(C2=CC=1)=O)C UMVYPSXZCLWWSG-SFHVURJKSA-N 0.000 claims description 2
- NKEFKGGAZSWXRD-NRFANRHFSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(2-methoxypyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=CC(=NC=C2)OC)CC1)C=1C(=C2COC(C2=CC=1)=O)C NKEFKGGAZSWXRD-NRFANRHFSA-N 0.000 claims description 2
- VXJMKKDFKLQCQL-KRWDZBQOSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(3-methoxy-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NC(=NS2)OC)CC1)C=1C(=C2COC(C2=CC=1)=O)C VXJMKKDFKLQCQL-KRWDZBQOSA-N 0.000 claims description 2
- DZXBVRHVPOKTJP-SFHVURJKSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(3-methyl-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NC(=NS2)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C DZXBVRHVPOKTJP-SFHVURJKSA-N 0.000 claims description 2
- AVNUHUISPNHKBL-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(3-methyl-1,2-thiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=CC(=NS2)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C AVNUHUISPNHKBL-IBGZPJMESA-N 0.000 claims description 2
- DFAVOQJDABJWRE-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-[2-(methylamino)pyrimidin-4-yl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NC(=NC=C2)NC)CC1)C=1C(=C2COC(C2=CC=1)=O)C DFAVOQJDABJWRE-IBGZPJMESA-N 0.000 claims description 2
- RSXZHMMKTWSARQ-NRFANRHFSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-pyridin-4-yl-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=CC=NC=C2)CC1)C=1C(=C2COC(C2=CC=1)=O)C RSXZHMMKTWSARQ-NRFANRHFSA-N 0.000 claims description 2
- OUYWOLIUUOAXQV-NRFANRHFSA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-pyridin-4-yl-2,8-diazaspiro[4.5]decan-3-one Chemical compound O[C@@H](CN1CCC2(CC(N(C2)C2=CC=NC=C2)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C OUYWOLIUUOAXQV-NRFANRHFSA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims description 2
- 208000024940 Dent disease Diseases 0.000 claims description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- 108010066671 Enalaprilat Proteins 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 206010020852 Hypertonia Diseases 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 229950007884 alacepril Drugs 0.000 claims description 2
- 229960000528 amlodipine Drugs 0.000 claims description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 208000006752 brain edema Diseases 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229950005749 ceronapril Drugs 0.000 claims description 2
- 229960005025 cilazapril Drugs 0.000 claims description 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229960005227 delapril Drugs 0.000 claims description 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960002680 enalaprilat Drugs 0.000 claims description 2
- 230000008694 endothelial dysfunction Effects 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 229960001195 imidapril Drugs 0.000 claims description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- 229950006549 moveltipril Drugs 0.000 claims description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005117 olmesartan Drugs 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 229960001455 quinapril Drugs 0.000 claims description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 229960002909 spirapril Drugs 0.000 claims description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims description 2
- 108700035424 spirapril Proteins 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- 229960004084 temocapril Drugs 0.000 claims description 2
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims description 2
- 229960002051 trandolapril Drugs 0.000 claims description 2
- 229960001288 triamterene Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- DJERTQOCMXDCEK-KRWDZBQOSA-N 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-4-(3-methoxy-1,2,4-thiadiazol-5-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-5-one Chemical compound O[C@@H](CN1CCC2(C(N(CCO2)C2=NC(=NS2)OC)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C DJERTQOCMXDCEK-KRWDZBQOSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 abstract description 13
- 230000001882 diuretic effect Effects 0.000 abstract description 8
- 108091006146 Channels Proteins 0.000 abstract description 7
- 238000011321 prophylaxis Methods 0.000 abstract description 5
- 102100033056 ATP-sensitive inward rectifier potassium channel 1 Human genes 0.000 abstract description 4
- 101000944272 Homo sapiens ATP-sensitive inward rectifier potassium channel 1 Proteins 0.000 abstract description 4
- 208000029422 Hypernatremia Diseases 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000002833 natriuretic agent Substances 0.000 abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 214
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 210
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 187
- 239000000203 mixture Substances 0.000 description 113
- 239000000243 solution Substances 0.000 description 103
- 239000000543 intermediate Substances 0.000 description 102
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 94
- 235000019439 ethyl acetate Nutrition 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 90
- 239000011541 reaction mixture Substances 0.000 description 87
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 53
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 239000002904 solvent Substances 0.000 description 43
- 239000012043 crude product Substances 0.000 description 40
- 239000012044 organic layer Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- 239000012267 brine Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 25
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 150000001412 amines Chemical class 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 20
- 239000007832 Na2SO4 Substances 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 18
- 150000002118 epoxides Chemical class 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 17
- 238000000926 separation method Methods 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 0 *C1=CC=NN(*)C1=O Chemical compound *C1=CC=NN(*)C1=O 0.000 description 14
- YQLAZVRXBCSLAI-JTQLQIEISA-N 4-methyl-5-[(2r)-oxiran-2-yl]-3h-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1[C@@H]1CO1 YQLAZVRXBCSLAI-JTQLQIEISA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 14
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 229910052716 thallium Inorganic materials 0.000 description 14
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 14
- 239000003480 eluent Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 239000002002 slurry Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000004808 supercritical fluid chromatography Methods 0.000 description 11
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 230000004907 flux Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 229910052700 potassium Inorganic materials 0.000 description 10
- 239000011591 potassium Substances 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000012746 preparative thin layer chromatography Methods 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ADPIEGXXCABJCH-UHFFFAOYSA-N tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(=O)NCC1 ADPIEGXXCABJCH-UHFFFAOYSA-N 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 7
- 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- MDZWBGRDSNZGHF-UHFFFAOYSA-N 2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound CN1N=C(C=CC1=O)N1C(C2(CC1)CCNCC2)=O MDZWBGRDSNZGHF-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 6
- 229940011051 isopropyl acetate Drugs 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 5
- ZBOIJDYZCFRHJL-UHFFFAOYSA-N 2-ethenyl-5-(tetrazol-1-yl)pyrazine Chemical compound C1=NC(C=C)=CN=C1N1N=NN=C1 ZBOIJDYZCFRHJL-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012160 loading buffer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 5
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VEUQZWVGMYVTMY-UHFFFAOYSA-N (4-methyl-1-oxo-3h-2-benzofuran-5-yl) trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C(C)=C2COC(=O)C2=C1 VEUQZWVGMYVTMY-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZOZBUARKIICXDG-SFHVURJKSA-N 5-[(1R)-2-(3,9-diazaspiro[5.5]undecan-3-yl)-1-hydroxyethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCC2(CC1)CCNCC2)C=1C(=C2COC(C2=CC=1)=O)C ZOZBUARKIICXDG-SFHVURJKSA-N 0.000 description 4
- IRAKZLQFUGTIGE-UHFFFAOYSA-N 5-bromo-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(Br)C(C)=C2COC(=O)C2=C1 IRAKZLQFUGTIGE-UHFFFAOYSA-N 0.000 description 4
- ZZVTUADLCFBPGZ-UHFFFAOYSA-N 5-iodo-2-methylpyridazin-3-one Chemical compound CN1N=CC(I)=CC1=O ZZVTUADLCFBPGZ-UHFFFAOYSA-N 0.000 description 4
- KDZJDTWUSLHWQN-UHFFFAOYSA-N 6-bromo-2-methylpyridazin-3-one Chemical compound CN1N=C(Br)C=CC1=O KDZJDTWUSLHWQN-UHFFFAOYSA-N 0.000 description 4
- VYKRCBMUYUVPEZ-SNVBAGLBSA-N 6-methyl-5-[(2s)-oxiran-2-yl]-3h-2-benzofuran-1-one Chemical compound CC1=CC=2C(=O)OCC=2C=C1[C@H]1CO1 VYKRCBMUYUVPEZ-SNVBAGLBSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- LSFWBZSLBJNFEJ-KRWDZBQOSA-N O[C@@H](CN1CCC2(CCNC2)CC1)C=1C(=C2COC(C2=CC=1)=O)C Chemical compound O[C@@H](CN1CCC2(CCNC2)CC1)C=1C(=C2COC(C2=CC=1)=O)C LSFWBZSLBJNFEJ-KRWDZBQOSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 239000007819 coupling partner Substances 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- IIKFXOLJMNWWCH-UHFFFAOYSA-N piperidine-1,4-dicarboxylic acid Chemical compound OC(=O)C1CCN(C(O)=O)CC1 IIKFXOLJMNWWCH-UHFFFAOYSA-N 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 4
- 229960003081 probenecid Drugs 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- MBQIYARHJCKSLC-SNVBAGLBSA-N tert-butyl (3r)-3-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound O=C1N[C@H](C)CC11CCN(C(=O)OC(C)(C)C)CC1 MBQIYARHJCKSLC-SNVBAGLBSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- XYDXDWXAAQXHLK-UHFFFAOYSA-N (3-bromo-2-methylphenyl)methanol Chemical compound CC1=C(Br)C=CC=C1CO XYDXDWXAAQXHLK-UHFFFAOYSA-N 0.000 description 3
- JOHACZIJRYJTSY-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-(2-oxopropyl)piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1(CC(C)=O)CCN(C(=O)OC(C)(C)C)CC1 JOHACZIJRYJTSY-UHFFFAOYSA-N 0.000 description 3
- GGFOQOWFRMNKMJ-UHFFFAOYSA-N 2-[6-(tetrazol-1-yl)pyridin-3-yl]acetaldehyde Chemical compound N1=CC(CC=O)=CC=C1N1N=NN=C1 GGFOQOWFRMNKMJ-UHFFFAOYSA-N 0.000 description 3
- XSWVQBHVHVYSBX-UHFFFAOYSA-N 2-[6-(tetrazol-1-yl)pyridin-3-yl]ethanol Chemical compound N1=CC(CCO)=CC=C1N1N=NN=C1 XSWVQBHVHVYSBX-UHFFFAOYSA-N 0.000 description 3
- ATCBCXMAOKHYCI-UHFFFAOYSA-N 2-bromo-5-(tetrazol-1-yl)pyrazine Chemical compound C1=NC(Br)=CN=C1N1N=NN=C1 ATCBCXMAOKHYCI-UHFFFAOYSA-N 0.000 description 3
- QWFILMGCTBJAQQ-UHFFFAOYSA-N 3-(hydroxymethyl)-2-methylphenol Chemical compound CC1=C(O)C=CC=C1CO QWFILMGCTBJAQQ-UHFFFAOYSA-N 0.000 description 3
- PDSCMDDTWSGTDE-UHFFFAOYSA-N 3-ethenyl-6-(tetrazol-1-yl)pyridazine Chemical compound N1=NC(C=C)=CC=C1N1N=NN=C1 PDSCMDDTWSGTDE-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- PCIBNCRQRIUZMN-UHFFFAOYSA-N 4-bromo-3-(hydroxymethyl)-2-methylphenol Chemical compound CC1=C(O)C=CC(Br)=C1CO PCIBNCRQRIUZMN-UHFFFAOYSA-N 0.000 description 3
- UZWMMCWOUBWROK-UHFFFAOYSA-N 4-iodo-1h-pyridazin-6-one Chemical compound IC=1C=NNC(=O)C=1 UZWMMCWOUBWROK-UHFFFAOYSA-N 0.000 description 3
- PYFRWRLVRDXGPN-GWYZVRNTSA-N 4-methyl-5-(1,2,2-trideuterioethenyl)-3H-2-benzofuran-1-one Chemical compound CC1=C2COC(C2=CC=C1C(=C([2H])[2H])[2H])=O PYFRWRLVRDXGPN-GWYZVRNTSA-N 0.000 description 3
- YQLAZVRXBCSLAI-SNVBAGLBSA-N 4-methyl-5-[(2s)-oxiran-2-yl]-3h-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1[C@H]1CO1 YQLAZVRXBCSLAI-SNVBAGLBSA-N 0.000 description 3
- JIIIQRGCXJSLAU-UHFFFAOYSA-N 5-(1,2-dihydroxypropyl)-4-methyl-3h-2-benzofuran-1-one Chemical compound CC(O)C(O)C1=CC=C2C(=O)OCC2=C1C JIIIQRGCXJSLAU-UHFFFAOYSA-N 0.000 description 3
- BHTMKHGHJQFVPH-UHFFFAOYSA-N 5-(1-butoxyethenyl)-4-methyl-3h-2-benzofuran-1-one Chemical compound CCCCOC(=C)C1=CC=C2C(=O)OCC2=C1C BHTMKHGHJQFVPH-UHFFFAOYSA-N 0.000 description 3
- GAHGGBYSEOQNER-UHFFFAOYSA-N 5-(2-bromoacetyl)-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(C(=O)CBr)C(C)=C2COC(=O)C2=C1 GAHGGBYSEOQNER-UHFFFAOYSA-N 0.000 description 3
- PYFRWRLVRDXGPN-UHFFFAOYSA-N 5-ethenyl-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(C=C)C(C)=C2COC(=O)C2=C1 PYFRWRLVRDXGPN-UHFFFAOYSA-N 0.000 description 3
- UBWGLLJSEKEDSU-NRFANRHFSA-N 6-[9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-3,9-diazaspiro[5.5]undecan-3-yl]-2-methylpyridazin-3-one Chemical compound O[C@@H](CN1CCC2(CCN(CC2)C=2C=CC(N(N=2)C)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C UBWGLLJSEKEDSU-NRFANRHFSA-N 0.000 description 3
- VYKRCBMUYUVPEZ-UHFFFAOYSA-N 6-methyl-5-(oxiran-2-yl)-3h-2-benzofuran-1-one Chemical compound CC1=CC=2C(=O)OCC=2C=C1C1CO1 VYKRCBMUYUVPEZ-UHFFFAOYSA-N 0.000 description 3
- HIDCJQXDCRDZSF-INIZCTEOSA-N 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-1-oxa-4,9-diazaspiro[5.5]undecan-5-one Chemical compound O[C@@H](CN1CCC2(C(NCCO2)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C HIDCJQXDCRDZSF-INIZCTEOSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YTYQDVJWAZLLPH-UHFFFAOYSA-N BrC=1C=NSC=1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O Chemical compound BrC=1C=NSC=1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O YTYQDVJWAZLLPH-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- 229910002666 PdCl2 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- JEOZIDLBISCBKN-UHFFFAOYSA-N S1N=CC=C1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O Chemical compound S1N=CC=C1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O JEOZIDLBISCBKN-UHFFFAOYSA-N 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000001743 benzylic group Chemical group 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000002084 enol ethers Chemical class 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 230000001452 natriuretic effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- NJORMFNJZLXLCN-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate Chemical compound CCOC(=O)C=C1CCN(C(=O)OC(C)(C)C)CC1 NJORMFNJZLXLCN-UHFFFAOYSA-N 0.000 description 3
- AJNCHUMJVPZDCG-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(C[N+]([O-])=O)CC1 AJNCHUMJVPZDCG-UHFFFAOYSA-N 0.000 description 3
- GJVKAMGQWQDJPF-UHFFFAOYSA-N tert-butyl 8-[2-(5-cyano-4-methoxypyridin-2-yl)-2-hydroxyethyl]-2,8-diazaspiro[4.5]decane-2-carboxylate Chemical compound C(#N)C=1C(=CC(=NC=1)C(CN1CCC2(CCN(C2)C(=O)OC(C)(C)C)CC1)O)OC GJVKAMGQWQDJPF-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YTQVHRVITVLIRD-UHFFFAOYSA-L thallium sulfate Chemical compound [Tl+].[Tl+].[O-]S([O-])(=O)=O YTQVHRVITVLIRD-UHFFFAOYSA-L 0.000 description 3
- 229910000374 thallium(I) sulfate Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RJDCNEDYDTWYCM-HNNXBMFYSA-N (1R)-2-(3,9-diazaspiro[5.5]undecan-3-yl)-1-[6-(tetrazol-1-yl)pyridin-3-yl]ethanol Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC2(CC1)CCNCC2)O RJDCNEDYDTWYCM-HNNXBMFYSA-N 0.000 description 2
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
- LYXHWHHENVLYCN-QMDOQEJBSA-N (1z,5z)-cycloocta-1,5-diene;rhodium;tetrafluoroborate Chemical compound [Rh].F[B-](F)(F)F.C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 LYXHWHHENVLYCN-QMDOQEJBSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- CRCFDMMRNPZPJY-UHFFFAOYSA-N 1-(3-bromophenyl)tetrazole Chemical compound BrC1=CC=CC(N2N=NN=C2)=C1 CRCFDMMRNPZPJY-UHFFFAOYSA-N 0.000 description 2
- KAFILPNMNXQTDL-UHFFFAOYSA-N 1-(3-ethenylphenyl)tetrazole Chemical compound C=CC1=CC=CC(N2N=NN=C2)=C1 KAFILPNMNXQTDL-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- YZHPGDMQKSSMGJ-VIFPVBQESA-N 1-[3-[(2r)-oxiran-2-yl]phenyl]tetrazole Chemical compound C1O[C@@H]1C1=CC=CC(N2N=NN=C2)=C1 YZHPGDMQKSSMGJ-VIFPVBQESA-N 0.000 description 2
- YZHPGDMQKSSMGJ-SECBINFHSA-N 1-[3-[(2s)-oxiran-2-yl]phenyl]tetrazole Chemical compound C1O[C@H]1C1=CC=CC(N2N=NN=C2)=C1 YZHPGDMQKSSMGJ-SECBINFHSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OZQKUZWSOGLHGS-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-(2-oxoethoxy)piperidine-1,4-dicarboxylate Chemical compound O=CCOC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1 OZQKUZWSOGLHGS-UHFFFAOYSA-N 0.000 description 2
- UQRMOFVFJWSNEV-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-(cyanomethyl)piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1(CC#N)CCN(C(=O)OC(C)(C)C)CC1 UQRMOFVFJWSNEV-UHFFFAOYSA-N 0.000 description 2
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 2
- ORHWCQDLPRLEEU-UHFFFAOYSA-N 1-oxa-4,9-diazaspiro[5.5]undecan-5-one Chemical compound O=C1NCCOC11CCNCC1 ORHWCQDLPRLEEU-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-APAIHEESSA-N 2,2,3-trideuteriooxirane Chemical compound O1C(C1[2H])([2H])[2H] IAYPIBMASNFSPL-APAIHEESSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- DLQSUWJKWQAKJH-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decan-1-one;hydrochloride Chemical compound Cl.O=C1NCCC11CCNCC1 DLQSUWJKWQAKJH-UHFFFAOYSA-N 0.000 description 2
- JDVFOGHGNSAVME-UHFFFAOYSA-N 2-(1-methyl-6-oxopyridazin-3-yl)-8-[2-[6-(tetrazol-1-yl)pyridazin-3-yl]ethyl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound N1(N=NN=C1)C1=CC=C(N=N1)CCN1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1 JDVFOGHGNSAVME-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PDRMCZOMKQFKLN-LURJTMIESA-N 2-[(2R)-oxiran-2-yl]-5-(tetrazol-1-yl)pyrazine Chemical compound O1[C@@H](C1)C1=NC=C(N=C1)N1N=NN=C1 PDRMCZOMKQFKLN-LURJTMIESA-N 0.000 description 2
- PDRMCZOMKQFKLN-ZCFIWIBFSA-N 2-[(2S)-oxiran-2-yl]-5-(tetrazol-1-yl)pyrazine Chemical compound O1[C@H](C1)C1=NC=C(N=C1)N1N=NN=C1 PDRMCZOMKQFKLN-ZCFIWIBFSA-N 0.000 description 2
- CTGKOZWOKCERFN-UHFFFAOYSA-N 2-[4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC(O)(CC(O)=O)CC1 CTGKOZWOKCERFN-UHFFFAOYSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- DNSNCMITRGXAPD-UHFFFAOYSA-N 2-chloro-6-(tetrazol-1-yl)-1H-pyridazine Chemical compound ClN1NC(=CC=C1)N1N=NN=C1 DNSNCMITRGXAPD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- HJJWVTCQHHDGLB-UHFFFAOYSA-N 2-pyridin-4-yl-2,8-diazaspiro[4.5]decan-1-one Chemical compound N1=CC=C(C=C1)N1C(C2(CC1)CCNCC2)=O HJJWVTCQHHDGLB-UHFFFAOYSA-N 0.000 description 2
- XLAKVMDAMKGUET-UHFFFAOYSA-N 3-bromo-1h-pyridazin-6-one Chemical compound BrC=1C=CC(=O)NN=1 XLAKVMDAMKGUET-UHFFFAOYSA-N 0.000 description 2
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 2
- KEXSKGCFSRJUEN-UHFFFAOYSA-N 4-methoxy-6-(oxiran-2-yl)pyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OC)=CC(C2OC2)=N1 KEXSKGCFSRJUEN-UHFFFAOYSA-N 0.000 description 2
- KEXSKGCFSRJUEN-VIFPVBQESA-N 4-methoxy-6-[(2R)-oxiran-2-yl]pyridine-3-carbonitrile Chemical compound COC1=CC(=NC=C1C#N)[C@H]1OC1 KEXSKGCFSRJUEN-VIFPVBQESA-N 0.000 description 2
- KEXSKGCFSRJUEN-SECBINFHSA-N 4-methoxy-6-[(2S)-oxiran-2-yl]pyridine-3-carbonitrile Chemical compound COC1=CC(=NC=C1C#N)[C@@H]1OC1 KEXSKGCFSRJUEN-SECBINFHSA-N 0.000 description 2
- YQLAZVRXBCSLAI-UHFFFAOYSA-N 4-methyl-5-(oxiran-2-yl)-3h-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1C1CO1 YQLAZVRXBCSLAI-UHFFFAOYSA-N 0.000 description 2
- YYBNAIPVTVYVFE-ONEGZZNKSA-N 4-methyl-5-[(e)-prop-1-enyl]-3h-2-benzofuran-1-one Chemical compound C\C=C\C1=CC=C2C(=O)OCC2=C1C YYBNAIPVTVYVFE-ONEGZZNKSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HNKMMDQAOADHTE-UHFFFAOYSA-N 5-(2,8-diazaspiro[4.5]decan-2-yl)-3-methoxy-1,2,4-thiadiazole Chemical compound COC1=NSC(=N1)N1CC2(CC1)CCNCC2 HNKMMDQAOADHTE-UHFFFAOYSA-N 0.000 description 2
- RDESXHSSRWYMNY-UHFFFAOYSA-N 5-(2-hydroxyethyl)-3h-2-benzofuran-1-one Chemical compound OCCC1=CC=C2C(=O)OCC2=C1 RDESXHSSRWYMNY-UHFFFAOYSA-N 0.000 description 2
- IXIUIHLFSGCQJN-UHFFFAOYSA-N 5-(2-hydroxyethyl)-6-iodo-3h-2-benzofuran-1-one Chemical compound C1=C(I)C(CCO)=CC2=C1C(=O)OC2 IXIUIHLFSGCQJN-UHFFFAOYSA-N 0.000 description 2
- CPAFRVZPLFANHK-UHFFFAOYSA-N 5-(oxiran-2-yl)-2-(tetrazol-1-yl)pyridine Chemical compound C1OC1C1=CC=C(N2N=NN=C2)N=C1 CPAFRVZPLFANHK-UHFFFAOYSA-N 0.000 description 2
- ZTRPJDGIBLRGCP-QFIPXVFZSA-N 5-[(1R)-1-hydroxy-2-(3-pyridin-2-yl-3,9-diazaspiro[5.5]undecan-9-yl)ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN1CCC2(CC1)CCN(CC2)C1=CC=CC=N1 ZTRPJDGIBLRGCP-QFIPXVFZSA-N 0.000 description 2
- YFWDNFXIXONSOG-IBGZPJMESA-N 5-[(1R)-1-hydroxy-2-[2-(3-methyl-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2)C2=NC(=NS2)C)CC1)C1=C(C2=C(C(OC2)=O)C=C1)C YFWDNFXIXONSOG-IBGZPJMESA-N 0.000 description 2
- CPAFRVZPLFANHK-ZETCQYMHSA-N 5-[(2R)-oxiran-2-yl]-2-(tetrazol-1-yl)pyridine Chemical compound O1[C@@H](C1)C=1C=CC(=NC1)N1N=NN=C1 CPAFRVZPLFANHK-ZETCQYMHSA-N 0.000 description 2
- CPAFRVZPLFANHK-SSDOTTSWSA-N 5-[(2S)-oxiran-2-yl]-2-(tetrazol-1-yl)pyridine Chemical compound C1O[C@H]1c1ccc(nc1)-n1cnnn1 CPAFRVZPLFANHK-SSDOTTSWSA-N 0.000 description 2
- XNONRNKAYRHZDJ-UHFFFAOYSA-N 5-bromo-1,2-thiazole Chemical compound BrC1=CC=NS1 XNONRNKAYRHZDJ-UHFFFAOYSA-N 0.000 description 2
- NDMZZQRNZFWMEZ-UHFFFAOYSA-N 5-bromo-1h-pyridin-2-one Chemical compound OC1=CC=C(Br)C=N1 NDMZZQRNZFWMEZ-UHFFFAOYSA-N 0.000 description 2
- YBMHJWFLYFYWBM-UHFFFAOYSA-N 5-bromo-2-(tetrazol-1-yl)pyridine Chemical compound N1=CC(Br)=CC=C1N1N=NN=C1 YBMHJWFLYFYWBM-UHFFFAOYSA-N 0.000 description 2
- UUWWGXPWPZJEMG-UHFFFAOYSA-N 5-bromo-2-chloro-4-methoxypyridine Chemical compound COC1=CC(Cl)=NC=C1Br UUWWGXPWPZJEMG-UHFFFAOYSA-N 0.000 description 2
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 2
- IJYKNWNBJDYCRK-UHFFFAOYSA-N 5-ethenyl-2-(tetrazol-1-yl)pyridine Chemical compound N1=CC(C=C)=CC=C1N1N=NN=C1 IJYKNWNBJDYCRK-UHFFFAOYSA-N 0.000 description 2
- XCLSUJASPNFYRV-UHFFFAOYSA-N 5-hydroxy-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=C2COC(=O)C2=C1 XCLSUJASPNFYRV-UHFFFAOYSA-N 0.000 description 2
- QKYFLLBEKCAKOL-UHFFFAOYSA-N 5-iodo-3-methoxy-1,2,4-thiadiazole Chemical compound IC1=NC(=NS1)OC QKYFLLBEKCAKOL-UHFFFAOYSA-N 0.000 description 2
- STHOMBUIKADCFV-UHFFFAOYSA-N 5-prop-2-enyl-3h-2-benzofuran-1-one Chemical compound C=CCC1=CC=C2C(=O)OCC2=C1 STHOMBUIKADCFV-UHFFFAOYSA-N 0.000 description 2
- UVKSKLHOFGQRNM-UHFFFAOYSA-N 6-(2-bromo-1-hydroxyethyl)-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC(C(O)CBr)=NC=C1C#N UVKSKLHOFGQRNM-UHFFFAOYSA-N 0.000 description 2
- QGEATODEGYRNCA-UHFFFAOYSA-N 6-chloro-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC(Cl)=NC=C1C#N QGEATODEGYRNCA-UHFFFAOYSA-N 0.000 description 2
- VYKRCBMUYUVPEZ-JTQLQIEISA-N 6-methyl-5-[(2r)-oxiran-2-yl]-3h-2-benzofuran-1-one Chemical compound CC1=CC=2C(=O)OCC=2C=C1[C@@H]1CO1 VYKRCBMUYUVPEZ-JTQLQIEISA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- UCWLQDQUAFSANL-UHFFFAOYSA-N 9-O-tert-butyl 1-O-(9H-fluoren-9-ylmethyl) 4-(1-methyl-6-oxopyridazin-3-yl)-5-oxo-1,4,9-triazaspiro[5.5]undecane-1,9-dicarboxylate Chemical compound CN1N=C(C=CC1=O)N1CCN(C2(C1=O)CCN(CC2)C(=O)OC(C)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 UCWLQDQUAFSANL-UHFFFAOYSA-N 0.000 description 2
- QQUSQTIEZXJTMQ-UHFFFAOYSA-N 9-benzyl-2,4-dioxo-3,9-diazaspiro[5.5]undecane-1,5-dicarbonitrile Chemical compound N#CC1C(=O)NC(=O)C(C#N)C11CCN(CC=2C=CC=CC=2)CC1 QQUSQTIEZXJTMQ-UHFFFAOYSA-N 0.000 description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- DQGZBRONPFTUSF-UHFFFAOYSA-N CC1=C2COC(C2=CC=C1B1OC(C(O1)(C)C)(C)C)=O Chemical compound CC1=C2COC(C2=CC=C1B1OC(C(O1)(C)C)(C)C)=O DQGZBRONPFTUSF-UHFFFAOYSA-N 0.000 description 2
- ATUQRNGXNVXBRV-UHFFFAOYSA-N CC=1C=NSC=1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O Chemical compound CC=1C=NSC=1N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O ATUQRNGXNVXBRV-UHFFFAOYSA-N 0.000 description 2
- OZRJADURNRLBAN-UHFFFAOYSA-N CN1N=C(C=CC1=O)N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O Chemical compound CN1N=C(C=CC1=O)N1C(C2(CC1)CCN(CC2)C(=O)OC(C)(C)C)=O OZRJADURNRLBAN-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- GSAWKLJDXFZPSD-UHFFFAOYSA-N O=C1N(CCC11CCN(CC1)C(=O)OC(C)(C)C)C1=CC=NC=C1 Chemical compound O=C1N(CCC11CCN(CC1)C(=O)OC(C)(C)C)C1=CC=NC=C1 GSAWKLJDXFZPSD-UHFFFAOYSA-N 0.000 description 2
- FSSAAMMIBRWQRX-UHFFFAOYSA-N O=C1NCCN(C11CCN(CC1)C(=O)OC(C)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 Chemical compound O=C1NCCN(C11CCN(CC1)C(=O)OC(C)(C)C)C(=O)OCC1C2=CC=CC=C2C=2C=CC=CC1=2 FSSAAMMIBRWQRX-UHFFFAOYSA-N 0.000 description 2
- QJHFYBPNKURYNA-INIZCTEOSA-N O[C@@H](CN1CCC2(CCNC2=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C Chemical compound O[C@@H](CN1CCC2(CCNC2=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C QJHFYBPNKURYNA-INIZCTEOSA-N 0.000 description 2
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 244000166550 Strophanthus gratus Species 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000012435 analytical chromatography Methods 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
- FINPLSBBDVRBPA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-methoxy-2-methylpropane;2-phenylethanamine Chemical compound [Pd+]Cl.COC(C)(C)C.NCCC1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FINPLSBBDVRBPA-UHFFFAOYSA-M 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- PUUPUDJVNOJWNP-UHFFFAOYSA-N ethyl 2-[1-benzyl-4-(2-ethoxy-2-oxoethyl)piperidin-4-yl]acetate Chemical compound C1CC(CC(=O)OCC)(CC(=O)OCC)CCN1CC1=CC=CC=C1 PUUPUDJVNOJWNP-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 125000005394 methallyl group Chemical group 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 2
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- 229960003343 ouabain Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- MBQIYARHJCKSLC-JTQLQIEISA-N tert-butyl (3s)-3-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound O=C1N[C@@H](C)CC11CCN(C(=O)OC(C)(C)C)CC1 MBQIYARHJCKSLC-JTQLQIEISA-N 0.000 description 2
- FRROFBJYHIEDPS-UHFFFAOYSA-N tert-butyl 1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OCCNC2 FRROFBJYHIEDPS-UHFFFAOYSA-N 0.000 description 2
- NFNCPNAVNRBDOU-UHFFFAOYSA-N tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC21CCNCC2 NFNCPNAVNRBDOU-UHFFFAOYSA-N 0.000 description 2
- DRHVZACUHDYOEK-UHFFFAOYSA-N tert-butyl 2-(3-methoxy-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound COC1=NSC(=N1)N1CC2(CC1)CCN(CC2)C(=O)OC(C)(C)C DRHVZACUHDYOEK-UHFFFAOYSA-N 0.000 description 2
- YLKHACHFJMCIRE-UHFFFAOYSA-N tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CCNCC1 YLKHACHFJMCIRE-UHFFFAOYSA-N 0.000 description 2
- MBQIYARHJCKSLC-UHFFFAOYSA-N tert-butyl 3-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound O=C1NC(C)CC11CCN(C(=O)OC(C)(C)C)CC1 MBQIYARHJCKSLC-UHFFFAOYSA-N 0.000 description 2
- YNTDSBJWBZVOCM-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)CC1(C[N+]([O-])=O)CCN(C(=O)OC(C)(C)C)CC1 YNTDSBJWBZVOCM-UHFFFAOYSA-N 0.000 description 2
- YADZDGIBSUOHJU-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-hydroxypiperidine-1-carboxylate Chemical compound CCOC(=O)CC1(O)CCN(C(=O)OC(C)(C)C)CC1 YADZDGIBSUOHJU-UHFFFAOYSA-N 0.000 description 2
- XYWCDAFPRBDRER-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(CN)CC1 XYWCDAFPRBDRER-UHFFFAOYSA-N 0.000 description 2
- UQADQTBQNVARAP-UHFFFAOYSA-N tert-butyl 4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1 UQADQTBQNVARAP-UHFFFAOYSA-N 0.000 description 2
- OVAVEVVJHZFRSE-FQEVSTJZSA-N tert-butyl 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2,8-diazaspiro[4.5]decane-2-carboxylate Chemical compound O[C@@H](CN1CCC2(CCN(C2)C(=O)OC(C)(C)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C OVAVEVVJHZFRSE-FQEVSTJZSA-N 0.000 description 2
- OXDOHLUZDITJKQ-NRFANRHFSA-N tert-butyl 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound O[C@@H](CN1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C OXDOHLUZDITJKQ-NRFANRHFSA-N 0.000 description 2
- KMUFRVQNWWVLCY-SFHVURJKSA-N tert-butyl 9-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1)O KMUFRVQNWWVLCY-SFHVURJKSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- 229940119523 thallium sulfate Drugs 0.000 description 2
- 239000005458 thiazide-like diuretic Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- VIYXXANHGYSBLY-UHFFFAOYSA-N trimethylsilyl 2,2,2-trifluoroacetate Chemical compound C[Si](C)(C)OC(=O)C(F)(F)F VIYXXANHGYSBLY-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- IYZRFOAPEUBNQP-JPZLKUPGSA-N (3s)-n-[(2s)-1-[[(5s)-5-amino-6-hydroxyhexyl]amino]-4-methyl-1-oxopentan-2-yl]-3-hydroxy-4-[[3-(1h-imidazol-5-yl)-2-[[3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanoyl]amino]propanoyl]amino]-6-methylheptanamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CC2=CC=CC=C2C=1CC(CC=1C2=CC=CC=C2C=CC=1)C(=O)NC(C(=O)NC(CC(C)C)[C@@H](O)CC(=O)N[C@@H](CC(C)C)C(=O)NCCCC[C@H](N)CO)CC1=CN=CN1 IYZRFOAPEUBNQP-JPZLKUPGSA-N 0.000 description 1
- FVEDGBRHTGXPOK-UHFFFAOYSA-N (5-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(F)=C1 FVEDGBRHTGXPOK-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- INLLPKCGLOXCIV-FUDHJZNOSA-N 1-bromo-1,2,2-trideuterioethene Chemical compound [2H]C([2H])=C([2H])Br INLLPKCGLOXCIV-FUDHJZNOSA-N 0.000 description 1
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- RMXZRZLNIAKLAS-UHFFFAOYSA-N 2-(1-methyl-6-oxopyridazin-3-yl)-8-[2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)CCN1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1 RMXZRZLNIAKLAS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HQYAQXFBWACPBK-UHFFFAOYSA-N 2-(4-bromo-1,2-thiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound BrC=1C=NSC=1N1C(C2(CC1)CCNCC2)=O HQYAQXFBWACPBK-UHFFFAOYSA-N 0.000 description 1
- FYPRCLAKUOWBSI-UHFFFAOYSA-N 2-(4-chloro-1,2-thiazol-5-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound ClC=1C=NSC=1N1C(C2(CC1)CCNCC2)=O FYPRCLAKUOWBSI-UHFFFAOYSA-N 0.000 description 1
- PDRMCZOMKQFKLN-UHFFFAOYSA-N 2-(oxiran-2-yl)-5-(tetrazol-1-yl)pyrazine Chemical compound C1OC1C1=CN=C(N2N=NN=C2)C=N1 PDRMCZOMKQFKLN-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- PMTPFBWHUOWTNN-UHFFFAOYSA-N 2-chloro-4-methoxypyridine Chemical compound COC1=CC=NC(Cl)=C1 PMTPFBWHUOWTNN-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- LRZBNSQQONJYKL-UHFFFAOYSA-N 2-methyl-6-(1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)pyridazin-3-one Chemical compound CN1N=C(C=CC1=O)N1CCOC2(C1)CCNCC2 LRZBNSQQONJYKL-UHFFFAOYSA-N 0.000 description 1
- DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BJGKVCKGUBYULR-UHFFFAOYSA-N 3-bromo-2-methylbenzoic acid Chemical compound CC1=C(Br)C=CC=C1C(O)=O BJGKVCKGUBYULR-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- DXFKQNBEJIACSQ-UHFFFAOYSA-N 3-bromo-6-chloropyridazine Chemical compound ClC1=CC=C(Br)N=N1 DXFKQNBEJIACSQ-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- VCFUTDUJFGHTKM-UHFFFAOYSA-N 3-chloro-5-methyl-1h-pyridazin-6-one Chemical compound CC1=CC(Cl)=NNC1=O VCFUTDUJFGHTKM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- RIERSGULWXEJKL-UHFFFAOYSA-N 3-hydroxy-2-methylbenzoic acid Chemical compound CC1=C(O)C=CC=C1C(O)=O RIERSGULWXEJKL-UHFFFAOYSA-N 0.000 description 1
- OJCCUUWVUOCZAA-UHFFFAOYSA-N 3-methoxy-1,2,4-thiadiazol-5-amine Chemical compound COC1=NSC(N)=N1 OJCCUUWVUOCZAA-UHFFFAOYSA-N 0.000 description 1
- DJKUIGPCSNRFRK-UHFFFAOYSA-N 3-methyl-1,2,4-thiadiazol-5-amine Chemical compound CC1=NSC(N)=N1 DJKUIGPCSNRFRK-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- BFHOSMVQVHFCSK-UHFFFAOYSA-N 4-bromo-2,6-dimethoxypyrimidine Chemical compound COC1=CC(Br)=NC(OC)=N1 BFHOSMVQVHFCSK-UHFFFAOYSA-N 0.000 description 1
- PVSARKGLAVSMNA-UHFFFAOYSA-N 4-bromo-2-methoxypyrimidine Chemical compound COC1=NC=CC(Br)=N1 PVSARKGLAVSMNA-UHFFFAOYSA-N 0.000 description 1
- TYSPDLZOMUDHQZ-UHFFFAOYSA-N 4-chloro-6-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC(Cl)=NC=N1 TYSPDLZOMUDHQZ-UHFFFAOYSA-N 0.000 description 1
- JWIBTPMTSDSVQR-UHFFFAOYSA-N 4-iodo-2-methoxypyridine Chemical compound COC1=CC(I)=CC=N1 JWIBTPMTSDSVQR-UHFFFAOYSA-N 0.000 description 1
- RTLUPHDWSUGAOS-UHFFFAOYSA-N 4-iodopyridine Chemical compound IC1=CC=NC=C1 RTLUPHDWSUGAOS-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- HYKCYPCRHDUFKS-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-iodo-3h-2-benzofuran-1-one Chemical compound OCCC1=CC=C2C(=O)OCC2=C1I HYKCYPCRHDUFKS-UHFFFAOYSA-N 0.000 description 1
- WKKYTNSSDPBBOU-UHFFFAOYSA-N 5-(3,9-diazaspiro[5.5]undecan-3-yl)-2-methylpyridazin-3-one Chemical compound CN1N=CC(=CC1=O)N1CCC2(CC1)CCNCC2 WKKYTNSSDPBBOU-UHFFFAOYSA-N 0.000 description 1
- LNQUANPLFJYYON-SFHVURJKSA-N 5-[(1R)-1-hydroxy-2-[2-(1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound S1N=CN=C1N1CC2(CC1)CCN(CC2)C[C@H](O)C=1C(=C2COC(C2=CC=1)=O)C LNQUANPLFJYYON-SFHVURJKSA-N 0.000 description 1
- ZCCIMEHKMLKGQJ-IBGZPJMESA-N 5-[(1R)-1-hydroxy-2-[2-(1,2-thiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2)C2=CC=NS2)CC1)C=1C(=C2COC(C2=CC=1)=O)C ZCCIMEHKMLKGQJ-IBGZPJMESA-N 0.000 description 1
- GNKCCVMHBQFUBP-SFHVURJKSA-N 5-[(1R)-1-hydroxy-2-[2-(3-methoxy-1,2,4-thiadiazol-5-yl)-2,8-diazaspiro[4.5]decan-8-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2)C2=NC(=NS2)OC)CC1)C=1C(=C2COC(C2=CC=1)=O)C GNKCCVMHBQFUBP-SFHVURJKSA-N 0.000 description 1
- XIUOKLSDVOANPC-IBGZPJMESA-N 5-[(1R)-1-hydroxy-2-[2-[6-(trifluoromethyl)pyrimidin-4-yl]-2,8-diazaspiro[4.5]decan-8-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2)C2=NC=NC(=C2)C(F)(F)F)CC1)C=1C(=C2COC(C2=CC=1)=O)C XIUOKLSDVOANPC-IBGZPJMESA-N 0.000 description 1
- WZDLOHAKDKFZDC-RMRYJAPISA-N 5-[(1R)-2-(2,8-diazaspiro[4.5]decan-8-yl)-1-hydroxyethyl]-4-methyl-3H-2-benzofuran-1-one dihydrochloride Chemical compound [Cl-].O[C@@H](C[NH+]1CCC2(CC[NH2+]C2)CC1)C=1C(=C2COC(C2=CC=1)=O)C.[Cl-] WZDLOHAKDKFZDC-RMRYJAPISA-N 0.000 description 1
- HYRYOCDDMHEKSR-NTEVMMBTSA-N 5-[(1R)-2-(3,9-diazaspiro[5.5]undecan-3-yl)-1-hydroxyethyl]-4-methyl-3H-2-benzofuran-1-one dihydrochloride Chemical compound Cl.Cl.Cc1c2COC(=O)c2ccc1[C@@H](O)CN1CCC2(CCNCC2)CC1 HYRYOCDDMHEKSR-NTEVMMBTSA-N 0.000 description 1
- CZOXLQBOCJAIIP-FQEVSTJZSA-N 5-[(1R)-2-[2-(2,6-dimethoxypyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-8-yl]-1-hydroxyethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound COC1=NC(=CC(=N1)N1CC2(CC1)CCN(CC2)C[C@H](O)C=1C(=C2COC(C2=CC=1)=O)C)OC CZOXLQBOCJAIIP-FQEVSTJZSA-N 0.000 description 1
- MLPMJIFZGTYCLU-QHCPKHFHSA-N 5-[(1R)-2-[3-(5-fluoropyridin-3-yl)-3,9-diazaspiro[5.5]undecan-9-yl]-1-hydroxyethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN1CCC2(CC1)CCN(CC2)C1=CC(F)=CN=C1 MLPMJIFZGTYCLU-QHCPKHFHSA-N 0.000 description 1
- FDAQZUNGXJSVMY-QFIPXVFZSA-N 5-[9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-3,9-diazaspiro[5.5]undecan-3-yl]-2-methylpyridazin-3-one Chemical compound O[C@@H](CN1CCC2(CCN(CC2)C2=CC(N(N=C2)C)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C FDAQZUNGXJSVMY-QFIPXVFZSA-N 0.000 description 1
- UBUUGFLYVXDUPG-UHFFFAOYSA-N 5-bromo-1,2,4-thiadiazole Chemical compound BrC1=NC=NS1 UBUUGFLYVXDUPG-UHFFFAOYSA-N 0.000 description 1
- KMAQQDDPRGOPRF-UHFFFAOYSA-N 5-bromo-1-(difluoromethyl)pyridin-2-one Chemical compound FC(F)N1C=C(Br)C=CC1=O KMAQQDDPRGOPRF-UHFFFAOYSA-N 0.000 description 1
- IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3h-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 1
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 1
- ILTLLMVRPBXCSX-UHFFFAOYSA-N 5-chloro-3-methyl-1,2,4-thiadiazole Chemical compound CC1=NSC(Cl)=N1 ILTLLMVRPBXCSX-UHFFFAOYSA-N 0.000 description 1
- JVCIBVDBGQRSFW-UHFFFAOYSA-N 5-ethenyl-6-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(C=C)C(C)=CC2=C1COC2=O JVCIBVDBGQRSFW-UHFFFAOYSA-N 0.000 description 1
- SQCBKDFMRDTACW-UHFFFAOYSA-N 5-iodo-3-methoxypyridazine Chemical compound IC=1C=C(N=NC=1)OC SQCBKDFMRDTACW-UHFFFAOYSA-N 0.000 description 1
- CROMKMCAZNXRCV-UHFFFAOYSA-N 5-iodo-3-methyl-1,2,4-thiadiazole Chemical compound CC1=NSC(I)=N1 CROMKMCAZNXRCV-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- OOQFRMSVCIQABN-HNNXBMFYSA-N 6-[(1S)-2-(2,8-diazaspiro[4.5]decan-8-yl)-1-hydroxyethyl]-4-methoxypyridine-3-carbonitrile Chemical compound O[C@@H](CN1CCC2(CCNC2)CC1)C1=NC=C(C#N)C(=C1)OC OOQFRMSVCIQABN-HNNXBMFYSA-N 0.000 description 1
- OOQFRMSVCIQABN-UHFFFAOYSA-N 6-[2-(2,8-diazaspiro[4.5]decan-8-yl)-1-hydroxyethyl]-4-methoxypyridine-3-carbonitrile Chemical compound OC(CN1CCC2(CCNC2)CC1)C1=NC=C(C#N)C(=C1)OC OOQFRMSVCIQABN-UHFFFAOYSA-N 0.000 description 1
- MYBKFTNRPNPUPE-UHFFFAOYSA-N 6-bromo-2-(difluoromethyl)pyridazin-3-one Chemical compound BrC=1C=CC(N(N=1)C(F)F)=O MYBKFTNRPNPUPE-UHFFFAOYSA-N 0.000 description 1
- QHOVHZIIMPSSDM-UHFFFAOYSA-N 6-bromo-2-cyclopropylpyridazin-3-one Chemical compound BrC=1C=CC(N(N=1)C1CC1)=O QHOVHZIIMPSSDM-UHFFFAOYSA-N 0.000 description 1
- LSDRHEVIBSQDKY-UHFFFAOYSA-N 6-bromo-2-ethylpyridazin-3-one Chemical compound CCN1N=C(Br)C=CC1=O LSDRHEVIBSQDKY-UHFFFAOYSA-N 0.000 description 1
- BOVMTTYMJWYEIV-UHFFFAOYSA-N 6-chloro-2,4-dimethylpyridazin-3-one Chemical compound CC1=CC(Cl)=NN(C)C1=O BOVMTTYMJWYEIV-UHFFFAOYSA-N 0.000 description 1
- VXPWLWCOKWSASM-UHFFFAOYSA-N 6-ethenyl-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC(C=C)=NC=C1C#N VXPWLWCOKWSASM-UHFFFAOYSA-N 0.000 description 1
- JICUUUBHBGKHQQ-ZHRRBRCNSA-N 8-[(1R,2R)-1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H]([C@@H](C)N1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)C=1C(=C2COC(C2=CC=1)=O)C JICUUUBHBGKHQQ-ZHRRBRCNSA-N 0.000 description 1
- VTSFSHDICXCEIS-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(1,2-thiazol-4-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C=2C=NSC=2)CC1)C=1C(=C2COC(C2=CC=1)=O)C VTSFSHDICXCEIS-IBGZPJMESA-N 0.000 description 1
- QJMUUAOMAAVJBB-IBGZPJMESA-N 8-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-pyrazin-2-yl-2,8-diazaspiro[4.5]decan-1-one Chemical compound O[C@@H](CN1CCC2(CCN(C2=O)C2=NC=CN=C2)CC1)C=1C(=C2COC(C2=CC=1)=O)C QJMUUAOMAAVJBB-IBGZPJMESA-N 0.000 description 1
- HNPLPVLVYXNSCE-UHFFFAOYSA-N 8-[2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-2-(1-methyl-6-oxopyridazin-3-yl)-2,8-diazaspiro[4.5]decan-1-one Chemical compound CC1=C2COC(C2=CC=C1CCN1CCC2(CCN(C2=O)C2=NN(C(C=C2)=O)C)CC1)=O HNPLPVLVYXNSCE-UHFFFAOYSA-N 0.000 description 1
- GEYNDOIWSGAQTK-IBGZPJMESA-N 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-4-(1-methyl-6-oxopyridazin-3-yl)-1,4,9-triazaspiro[5.5]undecan-5-one Chemical compound O[C@@H](CN1CCC2(C(N(CCN2)C2=NN(C(C=C2)=O)C)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C GEYNDOIWSGAQTK-IBGZPJMESA-N 0.000 description 1
- FJJLKANKFCRMQR-NRFANRHFSA-N 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-4-(2-methoxypyridin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-5-one Chemical compound O[C@@H](CN1CCC2(C(N(CCO2)C2=CC(=NC=C2)OC)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C FJJLKANKFCRMQR-NRFANRHFSA-N 0.000 description 1
- UYZKBTBLFKYXGS-IBGZPJMESA-N 9-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]-4-(2-methoxypyrimidin-4-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-5-one Chemical compound O[C@@H](CN1CCC2(C(N(CCO2)C2=NC(=NC=C2)OC)=O)CC1)C=1C(=C2COC(C2=CC=1)=O)C UYZKBTBLFKYXGS-IBGZPJMESA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 239000003861 C09CA09 - Azilsartan medoxomil Substances 0.000 description 1
- FOEKATHKHFNEHA-UTNPRCHOSA-N C=NN(/C=N\N)c1ncc([C@@H]2OC2)nc1 Chemical compound C=NN(/C=N\N)c1ncc([C@@H]2OC2)nc1 FOEKATHKHFNEHA-UTNPRCHOSA-N 0.000 description 1
- DTPWZYSUQQHRKD-VIUAGAKSSA-N CC(O)=O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O Chemical compound CC(O)=O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O DTPWZYSUQQHRKD-VIUAGAKSSA-N 0.000 description 1
- CGZDWVZMOMDGBN-UHFFFAOYSA-N CCc1ncc[s]1 Chemical compound CCc1ncc[s]1 CGZDWVZMOMDGBN-UHFFFAOYSA-N 0.000 description 1
- BIOUWZXUHTUFAY-UHFFFAOYSA-N COC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)OCCN(Cc1ccccc1)Cc1ccccc1 Chemical compound COC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)OCCN(Cc1ccccc1)Cc1ccccc1 BIOUWZXUHTUFAY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- PLXCRRSHKGZKMU-UHFFFAOYSA-N Cc1c(CCN(CC2)CCC2(CC2)CCN2c2cc(F)cnc2)ccc2c1COC2=O Chemical compound Cc1c(CCN(CC2)CCC2(CC2)CCN2c2cc(F)cnc2)ccc2c1COC2=O PLXCRRSHKGZKMU-UHFFFAOYSA-N 0.000 description 1
- BKBXHFMCYISKJF-UHFFFAOYSA-N Cc1c(CCN2CCC(CC3)(CN3c3cc(OC)ncc3)CC2)ccc2c1COC2=O Chemical compound Cc1c(CCN2CCC(CC3)(CN3c3cc(OC)ncc3)CC2)ccc2c1COC2=O BKBXHFMCYISKJF-UHFFFAOYSA-N 0.000 description 1
- YNRHXRGSDWKRDA-UHFFFAOYSA-N Cc1cc(-[n]2nnnc2)ccc1 Chemical compound Cc1cc(-[n]2nnnc2)ccc1 YNRHXRGSDWKRDA-UHFFFAOYSA-N 0.000 description 1
- AZKSPMSNHBBVOT-UHFFFAOYSA-N Cc1cc(-[n]2nnnc2)cnc1 Chemical compound Cc1cc(-[n]2nnnc2)cnc1 AZKSPMSNHBBVOT-UHFFFAOYSA-N 0.000 description 1
- UONIHAAVKUEUKN-UHFFFAOYSA-N Cc1ccc(-[n]2nnnc2)nn1 Chemical compound Cc1ccc(-[n]2nnnc2)nn1 UONIHAAVKUEUKN-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- 108010078772 ES 8891 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001047038 Homo sapiens Inward rectifier potassium channel 13 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100022843 Inward rectifier potassium channel 13 Human genes 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- MSWXCEVFHIHQTH-UHFFFAOYSA-N O=C1NCCOC11CCN(CC1)C(=O)OC(C)(C)C Chemical compound O=C1NCCOC11CCN(CC1)C(=O)OC(C)(C)C MSWXCEVFHIHQTH-UHFFFAOYSA-N 0.000 description 1
- YEMIKMJZICKSMV-UHFFFAOYSA-N OCC1(CC1)c(nc1)cnc1-[n]1nnnc1 Chemical compound OCC1(CC1)c(nc1)cnc1-[n]1nnnc1 YEMIKMJZICKSMV-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 1
- 229950000146 acifran Drugs 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940077379 adcirca Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960001211 azilsartan medoxomil Drugs 0.000 description 1
- QJFSABGVXDWMIW-UHFFFAOYSA-N azilsartan medoxomil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3NC(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C QJFSABGVXDWMIW-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1cnncc1 Chemical compound c1cnncc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- NQZFAUXPNWSLBI-UHFFFAOYSA-N carbon monoxide;ruthenium Chemical group [Ru].[Ru].[Ru].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] NQZFAUXPNWSLBI-UHFFFAOYSA-N 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229940117229 cialis Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- RVFZOTGUPNHVRA-UHFFFAOYSA-N dicyclohexyl-(1-phenylpyrrol-2-yl)phosphane Chemical compound C1CCCCC1P(C=1N(C=CC=1)C=1C=CC=CC=1)C1CCCCC1 RVFZOTGUPNHVRA-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BADWIIDKTXQYLW-UHFFFAOYSA-N ethenylstannane Chemical compound [SnH3]C=C BADWIIDKTXQYLW-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229950005203 fasidotril Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical class CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 238000005913 hydroamination reaction Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical compound C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 description 1
- 229950008292 laropiprant Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
- 229960003019 loprazolam Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
- 229950000109 niludipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004269 oxiran-2-yl group Chemical group [H]C1([H])OC1([H])* 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229960002310 pinacidil Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- RLDWVFWDURMTAV-SQQVDAMQSA-N potassium;trifluoro-[(e)-prop-1-enyl]boranuide Chemical compound [K+].C\C=C\[B-](F)(F)F RLDWVFWDURMTAV-SQQVDAMQSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- 229960004457 pramlintide acetate Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940039245 revatio Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229950001780 sampatrilat Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 108010069247 terlakiren Proteins 0.000 description 1
- SMOGGVSZSAELAA-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C(=O)OC(C)(C)C)CCC11CNC1 SMOGGVSZSAELAA-UHFFFAOYSA-N 0.000 description 1
- MGHFVXFMQGQAKJ-UHFFFAOYSA-N tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CNCC1 MGHFVXFMQGQAKJ-UHFFFAOYSA-N 0.000 description 1
- FUTMXISUVQILLR-UHFFFAOYSA-N tert-butyl 2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11OC(=O)NC1 FUTMXISUVQILLR-UHFFFAOYSA-N 0.000 description 1
- SABRTFCGXPHVTA-UHFFFAOYSA-N tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate;hydrochloride Chemical compound Cl.C1CN(C(=O)OC(C)(C)C)CCC11CCNCC1 SABRTFCGXPHVTA-UHFFFAOYSA-N 0.000 description 1
- HNMWIKVFYHYBKX-UHFFFAOYSA-N tert-butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(=O)NC1 HNMWIKVFYHYBKX-UHFFFAOYSA-N 0.000 description 1
- OVJBHWPNDUHIHN-UHFFFAOYSA-N tert-butyl 4,4-bis(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)CC1(CC(=O)OCC)CCN(C(=O)OC(C)(C)C)CC1 OVJBHWPNDUHIHN-UHFFFAOYSA-N 0.000 description 1
- YLZIAVGRNFLDGF-UHFFFAOYSA-N tert-butyl 4-(1-methyl-6-oxopyridazin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate Chemical compound CN1N=C(C=CC1=O)N1CCOC2(C1)CCN(CC2)C(=O)OC(C)(C)C YLZIAVGRNFLDGF-UHFFFAOYSA-N 0.000 description 1
- ITPNIORBIVFCKC-UHFFFAOYSA-N tert-butyl 5-oxo-1,4,9-triazaspiro[5.5]undecane-9-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)NCCN2 ITPNIORBIVFCKC-UHFFFAOYSA-N 0.000 description 1
- PMIWPHBWPSYUEP-UHFFFAOYSA-N tert-butyl 9-(1-methyl-6-oxopyridazin-4-yl)-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound CN1N=CC(=CC1=O)N1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1 PMIWPHBWPSYUEP-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
Definitions
- the Renal Outer Medullary Postassium (ROMK) channel Kir 1.1) see e.g., Ho, K., et al., Cloning and expression of an inwardly rectifying ATP-regulated potassium channel, Nature, 1993, 362 (6415) : p. 31-8.1, 2; and Shuck, M.E., et al., Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel, J Biol Chem, 1994, 269 (39) : p.
- TALH thick ascending loop of Henle
- CCD cortical collecting duct
- ROMK provides a pathway for potassium secretion that is tightly coupled to sodium uptake through the amiloride-sensitive sodium channel (see Reinalter, S.C., et al., Pharmacotyping of hypokalaemic salt-losing tubular disorders, Acta Physiol Scand, 2004, 181 (4) : p. 513-21; and Wang, W., Renal potassium channels: recent developments, Curr Opin Nephrol Hypertens, 2004, 13 (5) : p. 549-55).
- ROMK channel also referred to herein as inhibitors of ROMK or ROMK inhibitors
- ROMK channel also referred to herein as inhibitors of ROMK or ROMK inhibitors
- ROMK inhibitors are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo-or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.P., A.G. Gharavi, and D.S. Geller, Molecular mechanisms of human hypertension, Cell, 2001, 104 (4) : p. 545-56) .
- Human genetics Ji, W., et al., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat Genet, 2008, 40 (5) : p.
- Patent application publication number WO2010/129379 published November 11, 2010 having common representative Merck Sharp & Dohme Corp., (also published as US2010/0286123 on same date) , describes ROMK inhibitors having the generic formula:
- R 5 and R 6 are independently-H, -C 1-6 alkyl, -C 3-6 cycloalkyl, -CF 3 , -CHF 2 , -CH 2 F or -CH 2 OH;
- X is-H,-OH, -OC 1-3 alkyl, -F, oxo, NH 2 or-CH 3 ; and
- X 1 is -H or -CH 3 .
- Patent application publication number WO2012/058134 published May 3, 2012, having common representative Merck Sharp & Dohme Corp., describes ROMK inhibitors having the generic formula:
- a and B are mono and/or bicyclic aromatic groups; R 2 is -H,
- R 3 is -H, -C 1-6 alkyl, -C 3-6 cycloalkyl, -OH, -F, -OC 1-3 alkyl, or -CH 2 OH, or R 3 can be joined to R 10a to form a ring.
- Patent application publication number WO2012/058116 published May 3, 2012, having common representative Merck Sharp & Dohme Corp., describes ROMK inhibitors having the generic formula:
- R 5 and R 6 are independently -H, -C 1-6 alkyl or–C (O) OC 1-3 alkyl; and X, X 1 , Y and Y 1 are independently–H or-C 1-6 alkyl; or Y 1 can be joined together with Z 2 to form a fused ring system.
- Additional published patent applications to Merck Sharp and Dohme Corp., which describe ROMK inhibitors, include: WO2013/028474; WO2013/039802; WO2013/062892; WO2013/066714; WO2013/066717; WO2013/066718; and WO2013/090271.
- the compounds of Formula I and salts thereof of this invention are selective inhibitors of the ROMK channel and could be used for the treatment of hypertension, heart failure and other conditions where treatment with a diuretic or natriuretic would be beneficial.
- the present invention provides for compounds of the Formula of the formula
- Y is–O-, -NH-or a bond
- R is independently H, alkyl (e.g., methyl or ethyl) or haloalkyl (e.g., -CHF 2 or-CF 3 ) ;
- R 1 is H, D or-OH
- R 2 is H or D
- R 3 is H or D
- R 4 is H, D, or alkyl (e.g., methyl or ethyl) ;
- R 5 is independently oxo or alkyl optionally substituted by 1-5 fluorine atoms
- R 6 is H or alkyl (e.g., methyl or ethyl) ;
- R 7 is H or alkyl (e.g., methyl or ethyl) ;
- R 8 is H; halo; alkyl (e.g., methyl or ethyl) optionally substituted by–OR, –C (O) OR 12 , -OC (O) -R 12 , or 1-5 halogen atoms (e.g., -CHF 2 or-CF 3 ) ; -OR (e.g., methoxy or ethoxy) ; phenyl; -C (O) OR 13 ; -N(R 14 ) (R 15 ) ; furanyl; or–OCD 3 ;
- R 9 is H, alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., -CHF 2 or-CF 3 ) or cycloalkyl e.g. (cyclopropyl) ;
- R 10 is H, halo, or alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., -CHF 2 or-CF 3 ) ;
- R 11 is H, alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., methyl or ethyl) or–OR (e.g., methoxy or ethoxy) ;
- R 12 is H or alkyl (e.g., methyl or ethyl) ;
- R 13 is H or alkyl (e.g., methyl or ethyl) ;
- R 14 is H, alkyl (e.g., methyl or ethyl) ;
- R 15 is H or alkyl (e.g., methyl or ethyl) ;
- n 0, 1 or 2;
- o 1, 2 or 3;
- p 1 or 2.
- the compound of Formula I are inhibitors of the ROMK (Kir1.1) channel.
- the compounds of Formula I could be used in methods of treatment, inhibition or amelioration of one or more disease states that could benefit from inhibition of ROMK.
- the compounds of this invention could be used in methods of treatment which comprise administering a therapeutically or prophylactically effective amount of a compound of Formula I to a patient in need of a diuretic and/or natriuretic agent. Therefore, the compounds of Formula I could be valuable pharmaceutically active compounds for the therapy, prophylaxis or both of medical conditions, including, but not limited to, cardiovascular diseases such as hypertension and heart failure as well as chronic kidney disease, and conditions associated with excessive salt and water retention.
- the compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs which are useful for the treatment of hypertension, heart failure and conditions associated with excessive salt and water retention.
- the invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I.
- An embodiment of this invention is compounds of Formula I or pharmaceutically acceptable salts thereof.
- Another embodiment of this invention is a compound of Formula I having the structural formula
- R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , Z, and n are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula II having the structural formula:
- R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula II having the structural formula:
- R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is compound of Formula II having the structural formula:
- R a is H or alkyl
- R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is compound of Formula I having the structural formula:
- R 1 , R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is compound of Formula I having the structural formula:
- R a is H or oxo
- Y is–O-or–NH-
- R 1 , R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R a is H or oxo
- Y is –O-or–NH-
- R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 , R 3 , R 4 , R 6 , R 7 , and R 8 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 , R 7 , R 9 and R 10 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 , R 7 , R 9 and R 10 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 , R 3 , R 4 , R 6 , R 8 , R 9 , and R 10 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R a is H or oxo
- R, R 1 , R 8 , and R 10 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 and R 9 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 , R 7 , R 8 , R 9 , R 10 , and R 11 are as defined in Formula I.
- Another embodiment of this invention is a compound of Formula I having the structural formula:
- R 1 is H or–OH
- R 8 is as defined in Formula I.
- Another embodiment of the present invention is compounds of Formulae I, II, IIa, IIb, IIc, V, and VI above or their pharmaceutically acceptable salts wherein R 1 is–OH, R 3 is H and R 4 is H, R 6 is methyl and R 7 is H.
- Another embodiment of the present invention is compounds of Formulae I, X, XI, or XII or their pharmaceutically acceptable salts wherein R 1 is H.
- Another embodiment of the present invention is compounds of Formula I, II, IIa, IIb, IIc, III, IV, V.VII, VIII, IX and XII wherein Z is:
- Another embodiment is a compound which is:
- D refers to deuterium and when it is used with respect to a specific position in a formula or structure, it means that the dueterium in this position is enriched with deuterium that is above the level of naturally distribution of deuterium.
- Alkyl is intended to include both branched-and straight-chain saturated aliphatic hydrocarbon groups having , e.g., 1-12, 1-6 or 1-4 carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification.
- Halogen means a fluorine, chlorine, bromine or iodine atom. "Halo” means –F, -Cl, -Br, or –I. A non-limiting example includes fluorine or fluoro.
- Haloalkyl means a halo-alkyl group in which the halo and alkyl groups are as previously defined. The bond to the parent moiety is through the alkyl group. Non-limiting examples include–CH 2 CF 3 and-CF 3 .
- Cycloalkyl is a cyclized alkyl ring having 3-12 or 3-6 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- variables depicted in a structural formula with a "floating" bond such as R 5 and R 8 , are permitted on any available carbon atom in the ring to which the variable is attached.
- substituted shall be deemed to include multiple degrees of substitution by a named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
- the compounds of Formula I may have one or more chiral (asymmetric) centers.
- the present invention encompasses all stereoisomeric forms of the compounds of Formula I. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have (R) or (S) configuration.
- bonds to a chiral carbon are depicted as straight lines in the structural Formulas of the invention, or when a compound name is recited without an (R) or (S) chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of each such chiral carbon, and hence each enantiomer or diastereomer and mixtures thereof, are embraced within the Formula or by the name.
- the production of specific stereoisomers or mixtures thereof may be identified in the Examples where such stereoisomers or mixtures were obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof from being within the scope of this invention.
- the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
- enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
- the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
- the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
- a derivatization can be carried out before a separation of stereoisomers.
- the separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or it can be done on a final racemic product.
- Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration.
- absolute stereochemistry may be determined by Vibrational Circular Dichroism (VCD) spectroscopy analysis.
- VCD Vibrational Circular Dichroism
- compounds of this invention are capable of tautomerization, all individual tautomers as well as mixtures thereof are included in the scope of this invention.
- the present invention includes all such isomers, as well as salts, solvates (which includes hydrates) and solvated salts of such racemates, enantiomers, diastereomers and tautomers and mixtures thereof.
- Reference to the compounds of Formula I herein encompasses the compounds of Formulae I-XIII and all embodiments and classes thereof.
- Reference to the compounds of this invention as those of a specific formula or embodiment, e.g., Formulae I –XIII or embodiments thereof, or any other generic structural formula or specific compound described or claimed herein, is intended to encompass the specific compound or compounds falling within the scope of the Formula or embodiment, including salts thereof, particularly pharmaceutically acceptable salts, solvates (including hydrates) of such compounds and solvated salt forms thereof, where such forms are possible, unless specified otherwise.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of Formula I.
- different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H) .
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds within Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- the invention also includes the corresponding pharmaceutically acceptable salts.
- the compounds of Formula I which contain acidic groups can be used according to the invention as, for example but not limited to, alkali metal salts, alkaline earth metal salts or as ammonium salts.
- alkali metal salts alkaline earth metal salts or as ammonium salts.
- salts include but are not limited to sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
- Compounds of Formula I which contain one or more basic groups i.e.
- naphthalenedisulfonic acids oxalic acid, acetic acid, trifluoroacetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, etc.
- the compounds of Formula I simultaneously contain acidic and basic groups in the molecule the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions) .
- Salts can be obtained from the compounds of Formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts.
- the present invention also includes all salts of the compounds of Formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
- compounds of the present invention may exist in amorphous form and/or one or more crystalline forms, and as such all amorphous and crystalline forms and mixtures thereof of the compounds of Formula I are intended to be included within the scope of the present invention.
- some of the compounds of the instant invention may form solvates with water (i.e., a hydrate) or common organic solvents.
- solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the instant compounds are likewise encompassed within the scope of this invention, along with un-solvated and anhydrous forms.
- esters can optionally be made by esterification of an available carboxylic acid group or by formation of an ester on an available hydroxy group in a compound.
- labile amides can be made.
- Pharmaceutically acceptable esters or amides of the compounds of this invention may be prepared to act as pro-drugs which can be hydrolyzed back to an acid (or -COO-depending on the pH of the fluid or tissue where conversion takes place) or hydroxy form particularly in vivo and as such are encompassed within the scope of this invention.
- Examples of pharmaceutically acceptable pro-drug modifications include, but are not limited to, -C 1-6 alkyl esters and -C 1-6 alkyl substituted with phenyl esters.
- the compounds within the generic structural formulas, embodiments and specific compounds described and claimed herein encompass salts, all possible stereoisomers and tautomers, physical forms (e.g., amorphous and crystalline forms) , solvate and hydrate forms thereof and any combination of these forms, as well as the salts thereof, pro-drug forms thereof, and salts of pro-drug forms thereof, where such forms are possible unless specified otherwise.
- the compounds of Formula I according to the invention are inhibitors of ROMK, and therefore could be used as diuretic and/or natriuretic agents.
- ROMK inhibitors may be used to help to increase urination and increase urine volume and also to prevent or reduce reabsorption of sodium in the kidneys leading to increased excretion of sodium and water. Therefore, the compounds could be used for treatment or prophylaxis or both of disorders that benefit from increased excretion of water and sodium from the body. Accordingly, the compounds of this invention could be used in a method for inhibiting ROMK comprising administering a compound of Formula I in a ROMK-inhibitory effective amount to a patient in need thereof.
- This also encompasses the use of the compounds for inhibiting ROMK in a patient comprising administering a compound of claim 1 in a therapeutically effective amount to a patient in need of diueresis, natriuresis or both.
- the inhibition of ROMK by the compounds of Formula I can be examined, for example, in the Thallium Flux Assay described below.
- this invention also relates to the use of the compounds of Formula I or salts thereof to validate in vitro assays, for example but not limited to the Thallium Flux Assay described herein.
- the compounds of this invention could be used in a method for causing diuresis, natriuresis or both, comprising administering a compound of Formula I in a therapeutically effective amount to a patient in need thereof. Therefore, the compounds of Formula I of this invention could be used in methods for treatment of, prevention of or reduction of risk for developing medical conditions that benefit from increased excretion of water and sodium, such as but not limited to one or more of hypertension, such as essential hypertension (also known as primary or idiopathic hypertension) which is a form of hypertension for which no cause can be found, heart failure (which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure) and/or other conditions associated with excessive salt and water retention.
- hypertension such as essential hypertension (also known as primary or idiopathic hypertension) which is a form of hypertension for which no cause can be found
- heart failure which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure
- other conditions associated with excessive salt and water retention
- the compounds could also be used to treat hypertension which is associated with any of several primary diseases, such as renal, pulmonary, endocrine, and vascular diseases, including treatment of patients with medical conditions such as heart failure and/or chronic kidney disease.
- the compounds of Formula I could be used in methods for treatment of, prevention of or reduction of risk for developing one or more disorders such as pulmonary hypertension, particularly pulmonary arterial hypertension (PAH) , cardiovascular disease, edematous states, diabetes mellitus, diabetes insipidus, post-operative volume overload, endothelial dysfunction, diastolic dysfunction, systolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eclampsia, cerebral edema, nephropathy, glomerulonephritis, nephrotic syndrome, acute kidney in
- the compounds of Formula I may potentially have reduced liabilities (for example, hypo-or hyperkalemia, new onset of diabetes, dyslipidemia, etc. ) over currently used clinical agents. Also the compounds may have reduced risk for diuretic tolerance, which can be a problem with long-term use of loop diuretics.
- compounds that are ROMK inhibitors can be identified as those compounds which, when tested, have an IC 50 of 5 ⁇ M or less, preferably 1 ⁇ M or less, and more preferably 0.25 ⁇ M or less, in the Thallium Flux Assay, described in more detail further below.
- the dosage amount of the compound to be administered depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of Formula I. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is expected that the compound will be administered chronically on a daily basis for a length of time appropriate to treat or prevent the medical condition relevant to the patient, including a course of therapy lasting days, months, years or the life of the patient.
- a daily dose of approximately 0.001 to 100 mg/kg, preferably 0.001 to 30 mg/kg, in particular 0.001 to 10 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results.
- the daily dose is preferably administered in a single dose or can be divided into several, for example two, three or four individual doses, and may be, for example but not limited to, 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, etc., on a daily basis.
- the compound may be formulated for immediate or modified release such as extended or controlled release.
- patient includes animals, preferably mammals and especially humans, who use the instant active agents for the prophylaxis or treatment of a medical condition.
- Administering of the drug to the patient includes both self-administration and administration to the patient by another person.
- the patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for developing said disease or medical condition or developing long-term complications from a disease or medical condition.
- therapeutically effective amount is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- a prophylactically effective amount is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
- the terms “preventing, ” “prevention, ” “prophylactic” and derivatives of these terms as used herein refer to administering a compound to a patient before the onset of clinical symptoms of a condition not yet present in the patient.
- a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention or reduction of risk of myocardial infarction or prevention or reduction of risk for complications related to hypertension.
- the ROMK inhibitors may be administered via any suitable route of administration such as, for example, orally, parenterally, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous (IV) , intramuscular, intrasternal injection or infusion techniques.
- Oral formulations are preferred for treatment of chronic indications such as hypertension or chronic heart failure, particularly solid oral dosage units such as pills, tablets or capsules, and more particularly tablets. IV dosing is preferred for acute treatment, for example for the treatment of acute heart failure.
- compositions comprised of a compound of Formula I and a pharmaceutically acceptable carrier which is comprised of one or more excipients or additives.
- An excipient or additive is an inert substance used to formulate the active drug ingredient.
- the pharmaceutical compositions of this invention containing the active ingredient may be in forms such as pills, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- the excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, mannitol, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- compositions may also contain other customary additives, for example but not limited to, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
- Oral immediate-release and time-controlled release dosage forms may be employed, as well as enterically coated oral dosage forms. Tablets may be uncoated or they may be coated by known techniques for aesthetic purposes, to mask taste or for other reasons. Coatings can also be used to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or miscible solvents such as propylene glycol, PEGs and ethanol
- an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
- the instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining a compound of Formula I with a pharmaceutically acceptable carrier. Also encompassed is the pharmaceutical composition which is made by combining a compound of Formula I with a pharmaceutically acceptable carrier. Furthermore, a therapeutically effective amount of a compound of this invention can be used for the preparation of a medicament useful for inhibiting ROMK, for causing diuresis and/or natriuresis, and/or for treating, preventing or reducing the risk for any of the medical conditions described herein, in dosage amounts described herein.
- the amount of active compound of Formula I and/or its pharmaceutically acceptable salts in the pharmaceutical composition may be, for example but not limited to, from about 0.1 mg to 1 g, particularly 0.1 mg to about 200 mg, more particularly from about 0.1 mg to about 100 mg, and even more particularly from about 0.1 to about 50 mg, per dose on a free acid/free base weight basis, but depending on the type of the pharmaceutical composition, potency of the active ingredient and/or the medical condition being treated, it could also be lower or higher.
- Pharmaceutical compositions usually comprise about 0.5 to about 90 percent by weight of the active compound on a free acid/free base weight basis.
- the compounds of Formula I inhibit ROMK. Due to this property, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on ROMK is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples.
- the compounds of Formula I can also be employed as intermediates for the preparation of other pharmaceutically active compounds.
- One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I.
- the additional active agent (or agents) is intended to mean a medicinal compound that is different from the compound of Formula I, and which is a pharmaceutically active agent (or agents) that is active in the body, including pro-drugs, for example esterified forms, that convert to pharmaceutically active form after administration, and also includes free-acid, free-base and pharmaceutically acceptable salts of said additional active agents when such forms are sold commercially or are otherwise chemically possible.
- any suitable additional active agent or agents including but not limited to anti-hypertensive agents, additional diuretics, anti-atherosclerotic agents such as a lipid modifying compound, anti-diabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I in a single dosage formulation (a fixed dose drug combination) , or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents) .
- the one or more additional active agents include but are not limited to thiazide-like diuretics, e.g., hydrochlorothiazide (HCTZ or HCT) ; angiotensin converting enzyme inhibitors (e.g, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril) ; dual inhibitors of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) such as omapatrilat, sampatrilat and fasidotril; angiotensin II receptor antagonists,
- ACE an
- potassium sparing diuretics such as amiloride HCl, spironolactone, epleranone, triamterene, each with or without HCTZ; carbonic anhydrase inhibitors, such as acetazolamide; neutral endopeptidase inhibitors (e.g., thiorphan and phosphoramidon) ; aldosterone antagonists; aldosterone synthase inhibitors; renin inhibitors (e.g enalkrein; RO 42-5892; A 65317; CP 80794; ES 1005; ES 8891; SQ 34017; aliskiren (2(S) , 4 (S) , 5 (S) , 7 (S) -N- (2-carbamoyl-2-methylpropyl) -5-amino-4-hydroxy-2, 7-diisopropyl-8- [4-methoxy-3-(3-methoxypropoxy) -phenyl]
- calcium channel blockers e.g., amlodipine, nifedipine, verapamil, diltiazem, felodipine, gallopamil, niludipine, nimodipine, nicardipine, bepridil, nisoldipine
- potassium channel activators e.g., nicorandil, pinacidil, cromakalim, minoxidil, aprilkalim, loprazolam
- sympatholitics e.g., beta-adrenergic blocking drugs (e.g., acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, metoprolol tartate, nadolol, propranolol, sotalol, timolol)
- alpha adrenergic blocking drugs e.g., doxazocin, prazo
- lipid lowering agents e.g., HMG-CoA reductase inhibitors such as simvastatin and lovastatin which are marketed as and in lactone pro-drug form and function as inhibitors after administration, and pharmaceutically acceptable salts of dihydroxy open ring acid HMG-CoA reductase inhibitors such as atorvastatin (particularly the calcium salt sold in ) , rosuvastatin (particularly the calcium salt sold in ) , pravastatin (particularly the sodium salt sold in ) , and fluvastatin (particularly the sodium salt sold in ) ; a cholesterol absorption inhibitor such as ezetimibe and ezetimibe in combination with any other lipid lowering agents such as the HMG-CoA reductase inhibitors noted above and particularly with simvastatin or with atorvastatin calcium; ) and
- Spirocyclic amines may be free bases, or they may be salts, in which case a base such as triethylamine or N, N’ -diisopropylethylamine may be added.
- enantiopure chiral epoxides such as (R) -1 in Scheme 1) epoxide opening occurs with retention of stereochemistry in the benzylic position and individual isomer (R) -IA may be obtained (and if the (S) -epoxide is employed the alcohol produced will have the opposite stereochemistry to that shown) .
- chiral HPLC separation of enantiomers or diastereomers of IA may be performed to provide single enantiomers or diastereomers.
- Compounds of Formula IB can also be prepared by hydroamination between styrene 4 and spirocyclic amines 2 catalyzed by bis (1, 5-cyclooctadiene) rhodium (I) tetrafluoroborate and bis (2-diphenylphosphino-phenyl) ether.
- compounds of the Formula IA may be prepared by coupling of the NH in spirocycles 5 to an aromatic or heterocyclic coupling partner 6 (where A represents chloride, bromide, iodide, fluoride, boronic acid) .
- This coupling reaction may be accomplished in a variety of ways, depending upon the nature of of 4 and the coupling partner.
- this coupling can be achieved by thermal or microwave heating in one of a variety of potential solvents, such as DMF or dioxane, in the presence or absence of a base such as triethylamine or potassium carbonate, or cesium carbonate.
- the coupling can be accomplished using a catalyst-ligand system, for example heating with Xantphos and Pd 2 (dba) 3 in the presence of a base such as cesium carbonate in a solvent such as dioxane (Buchwald, S.L.; Yin, J. J. Am. Chem. Soc. 2002, 124, 6043) .
- a catalyst-ligand system for example heating with Xantphos and Pd 2 (dba) 3 in the presence of a base such as cesium carbonate in a solvent such as dioxane
- a base such as cesium carbonate
- a solvent such as dioxane
- Numerous other C-N coupling conditions known from the literature such as Pd-catalyzed (Review: Buchwald, S. L. Chem. Sci. 2011, 2, 27) and Cu (I) -catalyzed reactions (Buchwald, S.L. et al. J. Am. Chem. Soc. 2002,
- the epoxides 1 (and single enatiomers (R) -1 and (S) -1) can be prepared following the method detailed in Scheme 4.
- Treatment of 7 (where halide is chloride, bromide, iodide, or trifluoromethane sulfonate) with commercially available potassium vinyl trifluoroborate (Molander, G.; Luciana, A. Journal of Organic Chemistry, 2005, 70, 3950-3956) under palladium catalyzed coupling conditions with an appropriate phosphine ligand gives rise to styrene 4 (Molander, G.; Brown, A. Journal of Organic Chemistry, 2006, 71, 9681-9686) .
- styrenes 4 is the coupling partner used in Scheme 2. It can be converted to the corresponding epoxides 1 under various epoxidation conditions, for example, with mCPBA (Fringuelli, F. et al. Organic Preparations and Procedures International, 1989, 21, 757-761). The racemic epoxide 1 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers, which can be used in place of 1 according to Scheme 1.
- enantiopure epoxides (R) -1 or (S) -1 can be prepared as shown in Scheme 5.
- Treatment of 7 (where halide is bromide, iodide, or trifluoromethane sulfonate) with commercial available vinyl butylether 7 under palladium catalyzed conditions with a suitable ligand and base (for example Pd(OAc) 2 , DPPP, Et 3 N) can provide the enol ethers 9.
- Enol ethers may be prepared using other methods known to the chemist. Treatment of the resulting enol ethers 9 with NBS or other similar reagents affords the corresponding bromomethyl ketones 10.
- aldehyde 3 can be prepared by hydrogenation of intermediate epoxides (1, from Scheme 4) followed by oxidation with Dess-Martine periodinane.
- Amine 5 can be prepared in sequences described in Scheme 7. Treatment of epoxide (R) -1 with commercially available or unavailable amines 12 (commercially unavailable amines 12 are prepared as described in the experimental section below) under conventional or microwave heating conditions leads to form 13, which was then deprotected by TFA or HCl to give free amine 5 after treatment with ion-exchange column.
- amine 5 can be prepared through Scheme 8. Boc deprotection of spirolactams 14 with TFA or HCl, followed by treatment with ion-exchange column affords free amines 15. Epoxide opening reaction of (R) -1 by 15 under conventional or microwave heating conditions leads to amine 5.
- Spirocyclic amines 2 can be prepared as described in Scheme 9.
- Spirocyclic diamines or amino lactams (where R represents a carbonyl group) 14, protected with Boc group, can be coupled to electrophiles 6 (where A represents I, Cl, Br or OTf) in a variety of ways, depending upon the nature of coupling partners. For example, in some cases this coupling can be achieved by thermal or microwave heating in the presence or absence of a base, such as DIPEA. Sometime the coupling can be achieved using a catalyst-ligand system, for example Pd 2 (dba) 3 and Xantphos.
- Some spirocyclic diamines or amino lactams 14 described herein are commercially available; others can prepared as described in the experimental section below.
- halides 6 are commercially available; some can be prepared as described in the examples below.
- Intermediates 16 are converted to spirocyclic amines 2 by removal of the protective group; for example, tert-butoxycarbonyl can be removed with TFA or HCl.
- reactions sensitive to moisture or air were performed under nitrogen or argon using anhydrous solvents and reagents.
- the progress of reactions was determined by either analytical thin layer chromatography (TLC) usually performed with E. Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm or liquid chromatography-mass spectrometry (LC-MS).
- TLC analytical thin layer chromatography
- LC-MS liquid chromatography-mass spectrometry
- the analytical LC-MS system used consisted of a Waters ZQ TM platform with electrospray ionization in positive ion detection mode with an Agilent 1100 series HPLC with autosampler.
- the column was usually a Water Xterra MS C18, 3.0 ⁇ 50 mm, 5 ⁇ m.
- the flow rate was 1 mL/min, and the injection volume was 10 ⁇ L.
- UV detection was in the range 210–400 nm.
- the mobile phase consisted of solvent A (water plus 0.06% TFA) and solvent B (acetonitrile plus 0.05% TFA) with a gradient of 100%solvent A for 0.7 min changing to 100% solvent B over 3.75 min, maintained for 1.1 min, then reverting to 100% solvent A over 0.2 min.
- Preparative HPLC purifications were usually performed using a mass spectrometry directed system. Usually they were performed on a Waters Chromatography Workstation configured with LC-MS System Consisting of: Waters ZQ TM single quad MS system with Electrospray Ionization, Waters 2525 Gradient Pump, Waters 2767 Injecto /Collector, Waters 996 PDA Detector, the MS Conditions of: 150-750 amu, Positive Electrospray, Collection Triggered by MS, and a Waters C-18 5 micron, 30 mm (id) x 100 mm column. The mobile phases consisted of mixtures of acetonitrile (10-100%) in water containing 0.1% TFA.
- TMS Tetramethylsilane
- J hertz
- Chiral analytical chromatography was performed on one of AS, AD, OD, IA, or OJ columns (250x4.6 mm) (Daicel Chemical Industries, Ltd. ) with noted percentage of either ethanol in hexane (%Et/Hex) or isopropanol in heptane (%IPA/Hep) as isocratic solvent systems.
- CHIRALPAK AS Chiral preparative chromatography was conducted on one of of CHIRALPAK AS, of CHIRALPAK AD, OD, IA, OJ columns (20x250 mm) (Daicel Chemical Industries, Ltd. ) with desired isocratic solvent systems identified on chiral analytical chromatography or by supercritical fluid (SFC) conditions.
- SFC supercritical fluid
- Pd (dppf) Cl 2 or PdCl 2 (dppf) is 1, 1′-Bis(diphenylphosphino) ferrocene] -dichloropalladium (II) which may be complexed with CH 2 Cl 2 ; tetra-n-butylammonium fluoride (TBAF) ; tert-butyldimethylsilyl chloride (TBS-Cl) ; triethylamine (TEA) ; trifluoroacetic acid (TFA) ; -SO 2 CF 3 (Tf) ; trifluoromethanesulfonic acid (triflic acid, TfOH) ; trifluoromethanesulfonic anhydride (triflic anhydride, (Tf) 2 O) ; 2-tetrahydrofuran (THF) ; N, N, N, N
- volume volume (V/V) .
- RT hour (s) (h or hr) ; minute (s) (min) ; retention time (Rt) ; gram (s) (g) ; milligram (s) (mg) ; milliliter (s) (mL) ; microliter (s) ( ⁇ L) ; millimole (mmol) ; volume: volume (V/V) .
- X or x may be used to express the number of times an action was repeated (e.g., washed with 2 x 200 mL 1N HCl) , or to convey a dimension (e.g., the dimension of a column is 30 x 250mm) .
- Step A (3-bromo-2-methylphenyl) methanol: To a solution of 3-bromo-2-methyl benzoic acid (35 g, 163 mmol) in THF (200 mL) was added borane THF complex (1.0 M, 212 mL, 212 mmol) . The mixture was allowed to stir for 24 h. TLC showed one single product spot. The reaction was quenched with water. The solvent THF was removed under reduced pressure. The resulting solid was dissolved in ethyl acetate (500 mL) , washed with 1N HCl, sodium carbonate, and brine.
- Step B 5-bromo-4-methyl-2-benzofuran-1 (3H) -one: To a flask charged with (3-bromo-2-methylphenyl) methanol (6.0 g, 30 mmol) was added a 1M TFA solution of thallium trifluoroacetate (16.2 g, 29.8 mmol) . The mixture was stirred at RT overnight. Analysis by TLC showed no starting material remaining. The solvent was removed under vacuum, and the residue was pumped under high vacuum for 30 min to ensure complete removal of TFA.
- Step A 3-hydroxymethyl-2-methyl phenol: To a 5 L 3-neck round bottomed flask equipped with overhead stirrer was charged NaBH 4 (87.0 g, 2.30 mol) and THF (3.0 L) and the resulting slurry was cooled to 10 °C. To the slurry was then added 3-hydroxy-2-methyl benzoic acid (175 g, 1.15 mol) portionwise over 20 min (T Max 17 °C) . A stirrable slurry formed, and was aged for an additional 45 min at 10-15 °C after which BF 3 -OEt 2 (321 mL, 2.53 mol) was added slowly over 1.5 hours.
- the slurry was aged at 10°C to 15 °C for 2 h then assayed for reaction completion (98.5% conversion) .
- the slurry was cooled to less than 10 °C and quenched with 931 mL MeOH slowly over 1.5 h (gas evolution) .
- the resulting slurry was aged overnight at RT.
- the batch was cooled to less than 10 °C then quenched with 1 N HCl (1.5 L) to get a homogeneous solution (pH solution ⁇ 1) , which was aged for 30 min and then the organic solvents were removed by rotary evaporation to approximately 1.8 L of total reaction volume (bath temperature was set to 50 °C; internal temperature of concentrate after rotary evaporation was ⁇ 40 °C) .
- Step B 4-Bromo-3-hydroxymethyl-2-methyl phenol: 3-Hydroxymethyl-2-methyl phenol (113.9 g, 824.0 mmol) was dissolved in a mixture of acetonitrile (850 mL) and trifluoroacetic acid (750.0 mL, 9, 735 mmol) in a 3-neck 5-L flask under nitrogen. The reaction mixture was cooled to -33 °C. N-bromosuccinimide (141 g, 791 mmol) was added over 15 minutes, with the temperature during addition in the range of-35 to -33 °C. The reaction mixture was allowed to stir for an additional 15 min during which time the temperature decreased to -40 °C.
- the cooling bath was removed, and potassium carbonate (741.0 g, 5, 358 mmol) diluted with water to a total of 1.0 L was added. Off-gassing was observed, and the temperature increased to 25 °C. MTBE (1.5 L) was added, and the reaction mixture was transferred to a separatory funnel. The layers were separated. The aqueous layer was diluted with water (500 mL) and extracted with MTBE (1 L) + EtOAc (500 mL) , and then MTBE (500 mL) + EtOAc (250 mL) . The combined organic layers were washed with water (240 mL) and dried over sodium sulfate.
- the sodium sulfate was removed by filtration, washed with additional MTBE and concentrated under reduced pressure.
- MTBE (684 mL, 2 volumes) was added, and the suspension was heated to 40 °C to produce a homogeneous solution. The solution was allowed to cool to room temperature.
- Six volumes of heptane were added, and the suspension was stirred overnight.
- the suspension was filtered, and the crystals were washed with 4: 1 heptane: MTBE (500 mL) , followed by heptane (500 mL) .
- the solid was dried under vacuum, providing 4-bromo-3-hydroxymethyl-2-methyl phenol.
- Step C 5-Hydroxy-4-methyl-3H-isobenzofuran-1-one: To a 2 L 3 neck flask equipped with overhead stirrer, N 2 inlet, and condenser were charged 4-bromo-3-hydroxymethyl-2-methyl phenol (100 g, 461 mmol) , CuCN (83.0 g, 921 mmol) , and DMF (500 mL) . The solution was sparged with N 2 for 15 min then heated to 145 °C to obtain a homogeneous solution. The solution was aged at 145 °C for 2h, then the reaction mixture was cooled to 95 °C. 41.5 mL water was added (sparged with N 2 ) , and the reaction aged for 20 h.
- the reaction was cooled to RT then the solids filtered through SOLKA- and the cake washed with 50 mL DMF.
- the DMF/EtOAc suspension was filtered through SOLKA- and the cake was washed with 250 mL EtOAc.
- the resulting filtrate was washed with 5% brine solution (3x500 mL) .
- the aqueous layers were extracted with 500 mL EtOAc and the combined organics were dried over MgSO 4 , fitered and evaporated.
- Step D 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate
- reaction mixture was quenched with water (200 mL) , then stirred with KB (activated carbon, 25 g) for 15 min.
- KB activated carbon, 25 g
- the biphasic mixture was filtered over SOLKA- washing with additional dichloromethane, and transferred to a separatory funnel, whereupon it was diluted with additional water (300 mL) .
- the layers were separated, and the organic layer was washed with water (500 mL) and 10%brine (200 mL) .
- the dichloromethane solution was dried over sodium sulfate, filtered and evaporated.
- the orange-red solid was adsorbed onto silica gel (27.5 g) and eluted through a pad of silica gel (271 g) with 25% ethyl acetate/hexanes.
- the resulting solution was concentrated under vacuum with the product crystallizing during concentration.
- the suspension was filtered, the solid washed with heptane and dried under vacuum and nitrogen, providing trifluoromethanesulfonic acid 4-methyl-1-oxo-1, 3-dihydro-isobenzofuran-5-yl ester.
- Racemic 4-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one (INTERMEDIATE 4) was resolved on a AD-H column (5x25cm) under supercritical fluid chromatography (SFC) conditions on a Berger MGIII preparative SFC instrument.
- the racemate was diluted to 50 mg/mL in 1:1 DCM:MeOH. The separation was accomplished using 10% EtOH/CO 2 , flow rate 200 mL/min, 100 bar, 25 °C. 500 ⁇ l injections were spaced every 2.12 mins.
- the resolution could also be achieved using a mobile phase of 8%MeOH /98% CO 2 with a flow rate of 100mL/min.
- the sample was prepared by dissolving in methanol, 20mg/mL, and using a 1 mL volume per injection. After separation, the fractions were dried off via rotary evaporator at bath temperature 40 °C.
- Step A 5- (1-Butoxy-vinyl) -4-methyl-3H-isobenzofuran-1-one: To a 1 L 3-neck flask was charged 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (63.0 g, 213 mmol) (INTERMEDIATE 2) , DMF (315 mL) , butyl vinyl ether (138 mL, 1063 mmol) ) then Et 3 N (35.6 mL, 255 mmol) . The solution was sparged with N 2 for 20 min.
- HBr (48%, 0.241 mL) was added and the reaction was aged at RT for approximately 1 h after which 236 mL water was then added to the batch. A water bath is used to maintain temp at 20 °C. Another 315 mL of water was added (solvent composition 1:2 THF:water) and the slurry was cooled to 15 °C. The resulting solids were filtered and washed with cold 1:2 THF:water (15 °C) : 150 mL displacement wash followed by 100 mL slurry wash. The solids were dried under vacuum at RT to provide 5- (2-bromo-acetyl) -4-methyl-3H-isobenzofuran-1-one.
- Step C 4-methyl-5- [ (2R) -oxiran-2-yl] -2-benzofuran-1 (3H) -one: 5- (2-Bromo-acetyl) -4-methyl-3H-isobenzofuran-1-one (48.8 g., 181 mmol) was charged to a 5 L 3 neck round bottom equipped with overhead stirrer, thermocouple, and heating mantle. 2-Propanol (1.22 L ) was added, followed by 610 mL of pH 7 0.1M potassium phosphate buffer. Buffer solution (610 mL) was charged to a 1.0L Erlenmeyer flask, and 2.44 g of NADP was added to the Erlenmeyer flask and swirled to dissolve.
- KRED MIF-20 (available from Codexis, Inc., 200 Penobscot Drive, Redwood City, CA 94063, www. codexis. com , tel. 1-650-421-8100) was added to the Erlenmeyer flask and the mixture was swirled to dissolve the solids. The resulting solution was added to the 5 L round bottom, which was then heated to 28 °C and aged for 6 hours, at which point the reaction was cooled to RT and triethylamine (50.2 mL, 360 mmol) was added. The resulting solution was aged at 40 °C for 1 h. The light slurry solution was cooled to RT, after which 122 g NaCl was added.
- the solution was aged at RT then extracted with 1.22 L IPAc.
- the aqueous layer was re-extracted with 400 mL IPAc and the combined organics were washed with 400 mL 20% brine solution, dried over MgSO 4 , filtered and concentrated by rotary evaporation.
- the resulting solids were taken up in 100 mL IPAc (thick slurry) .
- Hexanes were added (400 mL) and the suspension aged at RT then filtered and washed w/5: 1 Hexanes: IPAc solution (150 mL) .
- Step A 4-Methyl-5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) isobenzofuran-1 (3H) -one: A mixture of 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (INTERMEDIATE 4B, Step D, 5000 mg, 16.9 mmol) , KOAc (2000 mg, 20.3 mmol) , Pd (dppf) Cl 2 (618 mg, 0.844 mmol) and bis(pinacolato) diboron (5144 mg, 20.3 mmol) in dioxane (56 mL) was stirred at 75 °C overnight under N 2 .
- 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (INTERMEDIATE 4B, Step D, 5000 mg, 16.9 mmol) , KOAc
- Step B 4-Methyl-5-vinyl-d 3 -isobenzofuran-1 (3H) -one: A microwave vial was charged with 4-methyl-5-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) isobenzofuran-1 (3H) -one (770 mg, 2.81 mmol) , Pd(PPh 3 ) 2 Cl 2 (197 mg, 0.281 mmol) , toluene (9363 ⁇ l) , 20% Na 2 CO 3 /H 2 O (0.6 mL) , and vinyl-d 3 bromide (4.21 mL, 1 M in THF, 4.21 mmol) .
- Step C 4-Methyl-5- (oxiran-d 3 -2-yl) isobenzofuran-1 (3H) -one: To 4-methyl-5-vinyl-d 3 -isobenzofuran-1(3H) -one (300 mg, 1.69 mmol) in DCM (17 mL) was added mCPBA (584 mg, 3.39 mmol) at 0 °C. The reaction mixture was stirred at rt overnight, and washed with saturated NaHCO 3 . The organic layer was dried and evaporated to dryness.
- Step A (E) -4-Methyl-5- (prop-1-en-1-yl) isobenzofuran-1 (3H ) -one : To Pd (dppf) Cl 2 (0.220 g, 0.338 mmol) , K 3 PO 4 (6.75 mL, 1 M in water, 6.75 mmol) in THF (22 mL) was added potassium (E) -trifluoro (prop-1-en-1-yl) borate (0.749 g, 5.06 mmol) and 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (1.0 g, 3.38 mmol) .
- Step B 5- (1, 2-Dihydroxypropyl) -4-methylisobenzofuran-1 (3H) -one : To (E) -4-methyl-5- (prop-1-en-1-yl)isobenzofuran-1 (3H) -one (300 mg, 1.59 mmol) in acetonitrile/water (10/1, 18 mL) was added NMO (243 mg, 2.07 mmol) and potassium osmate (VI) dihydrate (29.4 mg, 0.080 mmol) at 0 °C. The reaction mixture was allowed to warm to rt and stirred at rt for 2 h. TLC showed the reaction completed.
- Step C 5- (2-hydroxyethyl) -6-iodo-2-benzofuran-1 (3H) -one: To a cooled (0 °C) solution of 5- (2-hydroxyethyl) -2-benzofuran-1 (3H) -one (9.00 g, 50.6 mmol) in 100 mL of TfOH was added NIS (12.5 g, 55.6 mmol) , then the mixture was stirred at 0 °C for 2 hrs and then poured into ice-water (500 mL) . The solution was extracted three times with 500 mL of EtOAc and the combined organic layers were washed with saturated NaHCO 3 and brine, dried over anhydrous sodium sulfate, filtered and concentrated.
- Step D 5- (2-hydroxyethyl) -6-methyl-2-benzofuran-1 (3H) -one: To a flask charged with 5- (2-hydroxyethyl) -6-iodo-2-benzofuran-1 (3H) -one (6.00 g, 19.7 mmol) and a stir bar was added Pd 2 (dba) 3 (452 mg, 0.493 mmol) , PPh 3 (1 g, 4 mmol) and NMP (50 mL) . The mixture was purged with N 2 and heated to 50 °C for 10 min, followed by addition of CuI (375 mg, 1.97 mmol) .
- Step E 2- (6-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl methanesulfonate: To a solution of 5-(2-hydroxyethyl) -6-methyl-2-benzofuran-1 (3H) -one (1.20 g, 6.25 mmol) and TEA (2.5 g, 25 mmol) in DCM (100 mL) was added MsCl (1.40 g, 12.5 mmol) at 0 °C. The mixture was stirred at ambient temperature overnight and then was was washed with water and brine. The organic layer was dried and concentrated to dryness. The collected title compound was used for the next step without any purification.
- Step F 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one: To a mixture of 2- (6-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl methanesulfonate (2.00 g, 7.41 mmol) and TEA (5 mL) in DCM (50 mL) was added DBU (5 mL) slowly at 0 °C. The mixture was stirred at rt overnight, and then was diluted with 50 mL of DCM, washed with 2 N HCl in three times and brine. The organic layer was dried and concentrated to dryness. The residue was purified by prep-TLC to give 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one.
- Step G 6-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one: To a solution of 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one (1.00 g, 5.75 mmol) in 50 mL of DCM was slowly added mCPBA (3.50 g, 17.4 mmol) in 50 mL of DCM at 0 °C. The mixture was warmed to room temperature, and stirred for 2 days. The mixture was washed with aqueous Na 2 SO 3 until KI indicator paper didn’t change color. The organic layer was washed with brine and then concentrated. The residue was purified via silica column to give 6-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one. LC-MS M+1 (calc. 191, found 191) .
- Step A 5-Bromo-2- (1H-tetrazol-1-yl) pyridine : To a solution of 5-bromopyridin-2-amine (5.0 g, 28.9 mmol) in acetic acid (40 ml, 699 mmol) was added (diethoxymethoxy) ethane (7.70 ml, 46.2 mmol) , followed by sodium azide (2.82 g, 43.3 mmol) . The mixture was heated at 80 °C for 1 h, cooled to room temperature and diluted with water. Precipitate was collected by filtration and dried under high vacuum to provide the title compound.
- Step B 5-Ethenyl-2- (1H-tetrazol-1-yl) pyridine: To a stirring solution of 5-bromo-2- (1H-tetrazol-1-yl) pyridine (1.0 g, 4.42 mmol) , in EtOH (70 mL) were added bis [ (diphenylphosphino) ferrocene] dichloropalladium (II) , complex with dichloromethane (0.361 g, 0.442 mmol) , potassium vinyl trifluoroborate (1.18 g, 8.85 mmol, 2 equiv.) , triethylamine (1.23 mL, 8.85 mmol, 2 equiv) , and water (0.5 mL) .
- Step C 5- (Oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine
- Step B 2- (1H-tetrazol-1-yl) -5-vinylpyrazine: A solution of 2-bromo-5- (1H-tetrazol-1-yl) pyrazine (11.2 g, 49.3 mmol) , potassium vinyltrifluoroborate (13.22 g, 99.0 mmol) , 1, 1'-bis (diphenylphosphino) ferrocene-palladium (ii) dichloride dichloromethane complex (2.01 g, 2.47 mmol) , and TEA (13.75 ml, 99.0 mmol) in ethanol (150 ml) was heated at reflux at 82 °C for 4 h.
- Step C 2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl) pyrazine: To a suspension of 2- (1H-tetrazol-1-yl) -5-vinylpyrazine (6.7 g, 38.5 mmol) in t-BuOH: water (96 ml: 190 ml) was added N-bromosuccinimide (7.53 g, 42.3 mmol) in portion at RT. The mixture was heated at 50 °C for 1 h, and cooled to 0 °C in an ice bath. NaOH (4.61 g in 30 mL water, 115 mmol) was added dropwise, and the resulting mixture was stirred at the same temperature for 20 min.
- Step B 1- (3-vinylphenyl) -1H-tetrazole: To a flask was charged 1- (3-bromophenyl) -1H-tetrazole (640 mg, 2.84 mmol) , potassium vinyltrifluoroborate (571 mg, 4.27 mmol) , PdCl2 (dppf) (104 mg, 0.142 mmol) . The flask was sealed, degassed, and filled with EtOH (14 mL) and Et 3 N (1.19 mL, 8.53 mmol) .
- Step C (S) -1- (3- (oxiran-2-yl) phenyl) -1H-tetrazole and (R) -1- (3- (oxiran-2-yl) phenyl) -1H-tetrazole: To 1-(3-vinylphenyl) -1H-tetrazole (444 mg, 2.58 mmol) in DCM (25 mL) was added mCPBA (1335 mg, 7.74 mmol) . The reaction mixture was stirred at rt overnight, and washed with NaHCO 3 , brine, dried and evaporated to give the crude product, which was purified by column chromatography (0-100% EtOAc/hexanes) to afford the racemic compound.
- Step A 2- (6- (1H-Tetrazol-1-yl) pyridin-3-yl) ethanol: To 5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine (INTERMEDIATE 7, 500 mg, 2.64 mmol) in ethanol (5.3 mL) was added 10 % Pd/C (101 mg, 0.952 mmol) and HCOONH 4 (500 mg, 7.93 mmol) . The reaction mixture was vigorously stirred for 1.5 h, and filtered through a pad of silica gel. The filtrate was evaporated to give 2- (6- (1H-tetrazol-1-yl) pyridin-3-yl)ethanol.
- Step B 2- (6- (1H-Tetrazol-1-yl) pyridin-3-yl) acetaldehyde
- Step A 2-Chloro-6- (1H-tetrazol-1-yl) pyridazine: To a solution of 6-chloropyridazin-3-amine (10.0 g, 77.0 mmol) in ethyl acetate (200 mL) was added trimethylsilyl 2, 2, 2-trifluoroacetate (22.7 mL, 131 mmol) . The mixture was stirred for 5 min, and triethoxymethane (22.8 ml, 137 mmol) was added. After the resulting mixture was stirred for another 5 min, azidotrimethylsilane (16.2 ml, 124 mmol) was added. Stirring continued at rt for 2 days, and the reaction mixture was filtered, and the solid was rinsed with ethyl acetate to afford the title compound.
- LCMS [M+1] + 183.
- Step B 3- (1H-tetrazol-1-yl) -6-vinylpyridazine: A solution of 2-chloro-6- (1H-tetrazol-1-yl) pyridazine (6.0 g, 32.9 mmol) , potassium vinyltrifluoroborate (6.6 g, 49.3 mmol) , 1, 1'-bis (di-tert-butylphosphino) ferrocene-palladium dichloride (2.14 g, 3.29 mmol) , and potassium phosphate aqueous solution (32.9 mL, 2 M, 65.7 mmol) in THF (160 ml) was heated at 80 °C overnight.
- Step A 5-Bromo-2-chloro-4-methoxypyridine: To a solution of 2-chloro-4-methoxypyridine (10.0 g, 69.7 mmol) in 50 mL of sulfuric acid at 0 °C was added NBS. The reaction mixture was allowed to stir and warm up to room temperature for 2 hour and then heated at 60 °C for 5 h. Then it was cooled to room temperature and neutralized with 1 N NaOH (pH ⁇ 7) , diluted with water (50 mL) and the aqueous layer was extracted with ethyl acetate (2 ⁇ 100 mL) . The organic layers were washed with water (2 ⁇ 50 mL) , sat.
- Step B 6-Chloro-4-methoxypyridine-3-carbonitrile: A solution of 5-bromo-2-chloro-4-methoxypyridine (5.0 g, 22.48 mmol) in DMF (80 mL) was purged with nitrogen for 15 min. At this point, Zn (CN) 2 (3.96 g, 33.7 mmol) and Pd (Ph 3 P) 4 (2.60 g, 2.25 mmol) were added, successively. The resulting suspension was stirred at 95 °C for 12 h under nitrogen atm. The reaction mixture was cooled to ambient temperature, filtered to remove inorganic solid.
- Step C 6-Ethenyl-4-methoxypyridine-3-carbonitrile: A 20 mL microwave tube was charged with 6-chloro-4-methoxypyridine-3-carbonitrile (200.0 mg, 1.2 mmol) , bis(diphenylphosphino) ferrocene] dichloropalladium (II) , complex with dichloromethane (97.0 mg, 0.12 mmol) , potassium vinyl trifluoroborate (318.0 mg, 2.37 mmol) , and triethylamine (0.33 mL, 2.37 mmol) , and EtOH (6 mL) . The microwave tube was evacuated and filled with nitrogen (two times) and heated to 140 °C.
- Step D 6- (2-Bromo-1-hydroxyethyl) -4-methoxypyridine-3-carbonitrile
- a solution of 6- (2-bromo-1-hydroxyethyl) -4-methoxypyridine-3-carbonitrile (74.0 mg, 0.288 mmol) in anhydrous methanol (7 mL) was treated with sodium carbonate (61.0 mg, 0.576 mmol, 2.0 equiv) , and allowed to stir at room temperature overnight. The solvent was evaporated. The residue was taken up in EtOAc (30 mL) and washed with water and brine.
- Absolute chemistry was determined by using VCD spectroscopy with high confidence. Analysis was done comparing experimental data to the calculated VCD and IR spectra of the (R) and (S) compounds.
- tert-Butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate is commercially available from a number of vendors, for example, Shanghai AQ BioPharma Co., Ltd, catalog #ABP1882. Alternatively, it may be prepared in various ways, including the procedure described below:
- Step B tert-Butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: A suspension of 1-tert-butyl 4-methyl 4-(cyanomethyl) piperidine-1, 4-dicarboxylate (70.0 g, 247.9 mmol) and Raney Ni (60 g) in MeOH (1500 mL) and NH 3 ⁇ H 2 O (80 mL) was stirred at 2 MPa of hydrogen at 50 °C for 18 h. The reaction mixture was filtered through a pad of and the filtrate was concentrated under vacuum to give a crude product, which was washed with ethyl acetate (200 mL) to give title compound.
- Step A tert-butyl 4- (2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate : Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a suspension of NaH (74.0 g, 2.16 mol 1.05 equiv, 70%) in tetrahydrofuran (2000 mL) at 0 °C, then added dropwise ethyl 2-(diethoxyphosphoryl) acetate (514 g, 2.06 mol, 1.05 equiv, 98%) with stirring at 0 °C.
- Step B tert-butyl 4- (2-ethoxy-2-oxoethyl) -4- (nitromethyl) piperidine-1-carboxylate: Into a 3000-mL 4-necked round-bottom flask were potassium carbonate (93.2 g, 662 mmol, 0.50 equiv) and DMSO (2000 mL). The resulting solution was heated to 80 °C. This was followed by the addition of tert-butyl 4- (2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate (368 g, 1.30 mol, 1.00 equiv, 95%) and CH 3 NO 2 (417 g, 6.70 mol, 5.00 equiv, 98%) slowly.
- the resulting solution was stirred for 120 min at 90 °C. After cooled to room temperature, the reaction mixture was adjusted to Ph 5 with HCl (0.5 mol/L) and diluted with 2000 mL of water. The resulting solution was extracted with 3x1500 mL of ether. The organic layers were combined, washed with 1x2000 mL of water and 1x2000 mL of saturated brine, dried and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:20 ⁇ 1:15 ⁇ 1:10) to afford the title compound.
- Step C 3-oxo-2, 8-diaza-spiro [4, 5] decane-8-carboxylic acid tert-butylester : A mixture of tert-butyl 4- (2-ethoxy-2-oxoethyl) -4- (nitromethyl) piperidine-1-carboxylate (330 g, 990 mmol, 1.00 equiv, 99%) and Ni (40 g, 0.15 equiv) in ethanol (1200 mL) was stirred for 24 h under a hydrogen atmosphere at room temperature. The solid was filtered out. The filtrate was concentrated under vacuum. The crude product was purified by re-crystallization from ether to afford the title compound.
- Step A 1-tert-Butyl 4-methyl 4- (2-methylallyl) piperidine-1, 4-dicarboxylate : A solution of N-Boc-piperidine-4-carboxylic acid methyl ester (2.00 g, 8.22 mmol) in THF (40 mL) was cooled to -78 °C . Under nitrogen, a 2.0 M THF solution of LDA (6.17 mL, 12.3 mmol) was added dropwise. The reaction mixture was stirred at -78 °C for 30 minutes before a solution of 3-bromo-2-methylpropene (1.60 g, 11.9 mmol) in THF (2 mL) was added.
- Step B 1-tert-Butyl 4-methyl 4- (2-oxopropyl) piperidine-1, 4-dicarboxylate : To a solution of 1-tert-butyl 4-methyl 4- (2-methylallyl) piperidine-1, 4-dicarboxylate (2.2 g, 7.4 mmol) in dioxane/water (60 mL, 1/1) under nitrogen was added osmium tetroxide (0.038g, 0.15 mmol) and sodium periodate (2.88 g, 13.5 mmol) . The mixture was stirred at room temperature for 3 hours. The mixture was then diluted with dichloromethane (50 mL) , washed with 20% Na 2 S 2 O 3 (20 mL) .
- dichloromethane 50 mL
- Step C tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate : 1-tert-Butyl 4-methyl 4- (2-oxopropyl) piperidine-1, 4-dicarboxylate (1.15 g, 3.84 mmol) in methanol (25 mL) was treated with ammonium acetate (3.85 g, 49.9 mmol) , sodium cyanoborohydride (0.681 g, 10.83 mmol) and magnesium sulfate (2.54 g, 21.1 mmol) . The mixture was heated at 80 °C in a sealed tube for 12 hours.
- the faster eluting isomer was determined to be (S) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate and the slower eluting isomer was (R) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate based on VCD spectroscopy analysis.
- LC-MS (IE, m/z) 291 (M+23) + .
- Step A tert-butyl 4- (2-ethoxy-2-oxoethyl) -4-hydroxypiperidine-1-carboxylate : To a solution of lithium bis(trimethylsilyl) amide (120 mL, 1.0 M solution in THF, 0.12 mol) in THF (120 mL) at -78 °C was added ethyl acetate (13 mL) ; then, a solution of tert-butyl 4-oxopiperidine-1-carboxylate (20 g, 0.1 mol) in THF (80 mL) was added at -78 °C. After the addition, the mixture was warmed up to 0 °C and stirred for another 2 h. The aqueous layer was extracted with ethyl acetate; the organic phase was washed with brine, dried over Na 2 SO 4 and concentrated to afford the crude title compound.
- Step B 2- (1- (tert-butoxycarbonyl) -4-hydroxypiperidin-4-yl) acetic acid: A solution of tert-butyl 4- (2-ethoxy-2-oxoethyl) -4-hydroxypiperidine-1-carboxylate (30.0 g, 0.105 mol) in methanol (130 mL) and 2N NaOH solution (100 mL, 0.2 mol) was stirred at 25 °C for 1.5 h, then the mixture was evaporated and the aqueous layer was extracted with ethyl acetate. The water phase was adjusted to pH 6 with 2N HCl, the aqueous layer was extracted with ethyl acetate and then the organic phase was washed with brine, dried over Na 2 SO 4 and concentrated to afford the crude title compound.
- Step C tert-butyl 2-oxo-1-oxa-3, 8-diazaspiro [4.5] decane-8-carboxylate: A mixture of 2- (1- (tert-butoxycarbonyl) -4-hydroxypiperidin-4-yl) acetic acid (22 g, 0.085 mol) , DPPA (30 g, 0.11 mol) , Et 3 N (150 mL) in Toluene (400 mL) was stirred at 105 °C under nitrogen for 12 h.
- Step A 1-tert-butyl 4-methyl 4- (allyloxy) piperidine-1, 4-dicarboxylate: NaH (0.92 g, 15.4 mol, 60%dispersion in mineral oil) was added the five portions to a stirred solution of compound 1-tert-butyl 4-methyl 4-hydroxypiperidine-1, 4-dicarboxylate (2 g, 7.7 mmol) being cooled to 0 °C in DMF (20 mL) . After the mixture was stirred at 0 °C, the 3-allyl bromide (1.2 g, 10 mmol) was added, dropwise. The mixture was stirred at rt for 16h.
- the reaction mixture was quenched by the addition of the saturated aqueous NH 4 Cl and evaporated to afford the crude product.
- the crude product was purified by column chromatography on silica gel eluted with (PE/EA 50:1 ⁇ 30:1 ⁇ 15:1) to give the title compound.
- Step B 1-tert-butyl 4-methyl 4- (2-oxoethoxy) piperidine-1, 4-dicarboxylate: To a solution of 1-tert-butyl 4-methyl 4- (allyloxy) piperidine-1, 4-dicarboxylate (1.2 g, 4 mmol) in MeOH (30 mL) was added osmium tetroxide (30 uL, 0.006 mmol, 0.81 g/mL H 2 O) and sodium periodate (16 ml, 16 mmol, 1M) . The mixture was allowed to stir at rt for 16 hours.
- osmium tetroxide 30 uL, 0.006 mmol, 0.81 g/mL H 2 O
- sodium periodate (16 ml, 16 mmol, 1M
- Step C 1-tert-butyl 4-methyl 4- (2- (dibenzylamino) ethoxy) piperidine-1, 4-dicarboxylate :
- Step D tert-butyl 5-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate:
- Step A tert-Butyl 4-oxopiperidine-1-carboxylate: To a solution of piperidin-4-one (1.0 mol, 100.0 g) and NaHCO 3 (1.6 mmol, 100 g) in H 2 O (1000 mL) was added (BOC) 2 O (1.2 mol, 191.6 g) , the reaction was stirred at 50 °C overnight. The residue was extracted with EtOAc (3 ⁇ 400 mL) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated to give tert-butyl 4-oxopiperidine-1-carboxylate.
- Step B tert-Butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate: To a mixture of tert-butyl 4-oxopiperidine-1-carboxylate (0.1 mol) and nitro-methane (0.1 mol) in methanol (200 mL) was added sodium methanolate (0.11 mol) at RT and the reaction was stirred for 1 h at room temperature. The solvent was evaporated. The residue was taken up into water, neutralized with acetic acid, extracted twice with EtOAc. The separated organic layer was washed with water, dried, filtered and evaporated to provide tert-butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate.
- Step C tert-Butyl 4- (aminomethyl) -4-hydroxypiperidine-1-carboxylate: The mixture of tert-butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate (15.0 g, 0.058 mol) and acetic acid (12 mL) in methanol (180 mL) was hydrogenated at rt with palladium-on-carbon (10%, 1.5 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated.
- Step D tert-Butyl 4- ( (2-chloroacetamido) methyl) -4-hydroxypiperidine-1-carboxylate: The mixture of tert-butyl 4- (aminomethyl) -4-hydroxypiperidine-1-carboxylate (10.0 g, 45 mmol) , chloroacetyl chloride (6 mL, 64 mmol) and K 2 CO 3 (14.0 g, 95 mmol) in EtOAc/H 2 O (100 mL/100 mL) was stirred for 1 h at 0 °C. The crude mixture was extracted with EtOAc (2 ⁇ 300 mL) .
- Step E tert-Butyl 3-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate: To a mixture of potassium tert-butoxide (31.8 g, 283 mmol) and tert-butanol (500 mL) was added tert-butyl 4- ( (2-chloroacetamido) methyl) -4-hydroxypiperidine-1-carboxylate (41.9 g, 141 mmol) in THF (300 mL) over 40 minutes and the resulting mixture was continued to stir for 1 h at room temperature before it was concentrated.
- Step F tert-Butyl 1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate: To a solution of tert-butyl 3-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate (16.0 g, 60 mmol) in THF (70 mL) was added tetrahydrofuran-borane (250 mL, 250 mmol) at room temperature. The reaction mixture was refluxed for 2 h and the solvent was removed under the reduced presure.
- Step A methyl piperidine-4-carboxylate: To a solution of piperidine-4-carboxylic acid (400 g, 3.10 mol) in MeOH (3.5 L) was added SOCl 2 (550g, 4.65mol) dropwise at RT. The reaction mixture was then heated to 40-50°C overnight. The next day, after TLC confirmed that the starting material was no longer present, the solvent was removed on a rotary evaporator to provide the title compound.
- Step C tert-butyl 4-cyanopiperidine-1-carboxylate
- POCl 3 400 mL
- piperidine-4-carboxamide 100 g, 0.78 mol
- the reaction mixture was then heated to reflux for 3 h, cooled to RT, and filtered.
- the filtrate was evaporated on a vacuum distillation plant, and the residue was diluted with 250 mL CH 2 Cl 2 , and poured into 200 mL ice-water, stirred for 30 min and pH was adjusted to 9-10 by 40% NaOH (175 g) .
- Step D tert-butyl 4-cyano-4- ( (tosyloxy) methyl) piperidine-1-carboxylate: Diisopropylamine (58 g) was added to anhydrous THF (600 mL) under N 2 protection, n-BuLi (2.5 M, 230 mL, 1.2 eq) was added at -40°C ⁇ -50 °C in 1 , then the mixture was stirred at -30°C ⁇ -40 °C for 30 min.
- tert-Butyl 4-cyanopiperidine-1-carboxylate (100 g, 476 mmol, 1 eq.) in 400 mL anhydrous THF was added to the reaction mixture at about -60°C to about -70 °C in 1 h, then stirred at about -50°C ⁇ to about 60 °C for 30 min.
- (HCHO) n (58 g, 4eq ) was heated to get HCHO gas to pass through 1600 mL anhydrous THF to get a milky solution.
- the milky solution was added to the reaction mixture at about -40°C to about -50 °C in 30 min and then warmed to -5°C slowly.
- reaction mixture was quenched with 50 mL H 2 O.
- TsCl 109 g, 571 mmol, 1.2 eq.
- Et 3 N 96 g, 952 mmol, 2 eq.
- Step E tert-butyl 2, 7-diazaspiro [3.5] nonane-7-carboxylate oxalate
- tert-butyl 4-cyano-4- ( (tosyloxy) methyl) piperidine-1-carboxylate (41 g, 104 mmol, 1 eq.) in anhydrous THF (600 mL)
- LiAlH 4 (4.7 g, 12 5mmol, 1.2 eq.) in portion at 5-7 °C
- TLC confirmed that the raw material disappeared, then 4.7 g H 2 O, 4.7 g 15% NaOH, and 14.1 g H 2 O was added to quench the reaction.
- Step A 2, 8-diazaspiro [4.5] decan-1-one hydrochloride: To a solution of tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (92 g, 0.36 mol) in CH 2 Cl 2 (1 L) was slowly added a 4 M HCl solution (500 mL) . The mixture was stirred for 8 h at RT. The mixture was concentrated under vacuum to afford the title compound.
- Step B (R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8- diazaspiro [4.5] decan-1-one: To a solution of 2, 8-diazaspiro [4.5] decan-1-one hydrochloride (68 g, 0.35 mol) in ethanol (1.5 L) was added Et 3 N (55 mL) . The mixture was stirred for 2 hours. Then (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (65 g, 0.34 mol) was added. The mixture was heated to reflux for 40 h.
- Step B (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one: To (R) -tert-butyl 8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8-diazaspiro [4.5] decane-2-carboxylate (500 mg, 1.16 mmol) in DCM (5.8 mL) was added TFA (1.8 mL, 23.2 mmol) at 0 °C. The reaction mixture was stirred at RT for 1 h.
- Step B (S) -6- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methoxynicotinonitrile: To a solution of tert-butyl 8- (2- (5-cyano-4-methoxypyridin-2-yl) -2-hydroxyethyl) -2, 8-diazaspiro [4.5] decane-2-carboxylate (0.500 mg, 1.20 mmol) in dichloromethane (4.0 mL) at 0 °C was added trifluoromethylacetic acid (2.0 mL) . The reaction was stirred at room temperature for 30 min. The mixture was concentrated in vacuo and dried under high vacuum.
- Step B 3-methoxy-5- (2, 8-diazaspiro [4.5] decan-2-yl) -1, 2, 4-thiadiazole: tert-Butyl 2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate (150.9 mg, 0.426 mmol) was dissolved in DCM (2 mL) , and TFA (0.984 mL, 12.8 mmol) was added to free Boc protection and yield the TFA salt. After evaporation of the solvents, the residue was dissolved in CHCl 3 : IPA (3:1) .
- Step A tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxa-4, 9-diazaspiro [5.5] undecane-9- carboxylate:
- RuPhos Indoline Precatalyst 0.058 g, 0.079 mmol
- sodium tert-butoxide 0.305 g, 3.17 mmol
- 6-bromo-2-methylpyridazin-3 (2H) -one (0.300 g, 1.587 mmol
- tert-butyl 1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate 0.88 g, 1.905 mmol
- Step B 2-methyl-6- (1-oxa-4, 9-diazaspiro [5.5] undecan-4-yl) pyridazin-3 (2H) -one:
- the title compound was prepared in a similar fashion to that described for INTERMEDIATE 27 above using TFA.
- LC-MS (IE, m/z) 265 (M+1) + .
- Step A tert-butyl 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8- carboxylate: To a reaction flask was charged tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (2.00 g, 7.86 mmol) , 6-bromo-2-methylpyridazin-3 (2H) -one (1.64 mg, 8.65 mmol) , Pd 2 (dba) 3 (180 mg, 0.197 mmol) , Xantphos (341 mg, 0.590 mmol) , and Cs 2 CO 3 (5.12 g, 15.7 mmol) .
- the flask was sealed, degased, and filled with anhydrous dioxane (26 mL) .
- the reaction mixture was heated at 90 °C overnight, diluted with EtOAc and DCM, then filtered through After solvent evaporation, the crude product was purified by silica gel column chromatography (0-10% MeOH/DCM as eluent) to afford the title compound.
- Step B 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one: tert-Butyl 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (2.55 g, 7.04 mmol) in DCM (12 mL) was treated with TFA (8.1 mL, 106 mmol) at 0 °C to free Boc protection and give TFA salt.
- 6-Bromo-3-pyridazinol 200 mg, 1.14 mmol
- potassium carbonate 316 mg, 2.29 mmol
- anhydrous acetonitrile 5.7 mL
- Ethyl iodide 102 ⁇ L, 1.26 mmol
- the flask was then equipped with a reflux condenser, then heated at reflux for 3 h.
- the flask was cooled to room temperature and then monitored by TLC and LCMS.
- the reaction mixture was filtered through and the flask was rinsed with methanol.
- 6-Bromopyridazin-3 (2H) -one (100 mg, 0.571 mmol) , cyclopropylboronic acid (73.6 mg, 0.857 mmol) , diacetoxycopper (208 mg, 1.14 mmol) , pyridine (368 ⁇ L, 4.57 mmol) , triethylamine (399 ⁇ L, 2.86 mmol) and anhydrous THF (2.8 mL) were charged to a microwave vial equipped with a rubber septum and magnetic stirbar. Under air, the reaction mixture was microwaved at 140 °C for 10 min. The flask was cooled to room temperature and then monitored by TLC and LCMS.
- Step A 5-bromopyridin-2-ol: Into a 10 L round-bottom flask, was placed a solution of H 2 SO 4 (480 ml) in H 2 O (6000 ml) . 5-Bromopyridin-2-amine (400 g, 2.31 mol, 1.00 equiv) was added to the mixture. The reaction mixture was allowed to react with stirring for 10 minutes and it was cooled to –10 °C. A solution of NaNO 2 (180 g, 2.61 mol, 1.09 equiv) in H 2 O (1200 ml) was added drop-wise to the mixture with stirring, while cooling the reaction mixture to a temperature of 0-5 °C.
- Step B 5-bromo-1- (difluoromethyl) pyridin-2 (1H) -one: A solution of 5-bromopyridin-2-ol (200 g, 1.15 mol, 1.00 equiv) in DMSO (2 L) was placed into a 3 L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen. To this mixture was added 60% NaH (50 g) and the mixture was allowed to react for 15 minutes.
- 6-Chloro-2, 4-dimethylpyridazin-3 (2H) -one was prepared with the same condition as INTERMEDIATE 40 using 6-chloro-4-methylpyridazin-3 (2H) -one.
- Step A 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate: At 0 °C to a dioxane (10 mL) and water (5 mL) solution of commercially available (ChemBridge Building Block Library catalog # 4042448; Aldrich catalog # CDS019358) tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-9-carboxylate (1.00 g, 3.71 mmol) was added sodium bicarbonate (0.624 g, 7.43 mmol) , followed by 9-fluorenylmethyl chloroformate (0.960 g, 3.71 mmol, drop wise over 30 min period with syringe pump) .
- Step B 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo- 1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate:
- the title compounds was prepared in an analogous fashion to INTERMEDIATE 34 (Step A) starting from 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate and and 6-bromo-2-methylpyridazin-3 (2H) -one.
- LC/MS (M+1) + : 600.28.
- Step C (9H-fluoren-9-yl) methyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo-1, 4, 9- triazaspiro [5.5] undecane-1-carboxylate: To a solution of 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate (33 mg, 0.055 mmol) in MeOH (10 mL) was added HCl (0.069 mL, 4 M in dioxane, 0.275 mmol) . After 4 h, the reaction mixture was evaporated to afford the HCl salt of the title compound. LC/MS: (M+1) + : 500.07.
- Step B 2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one: The title compounds was prepared in an analogous fashion to INTERMEDIATE 34 (Step B) starting from tert-butyl 1-oxo-2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate.
- LC/MS (M+1) + : 232.05.
- Step B tert-butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: To tert-butyl 2- (isothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (65 mg, 0.193 mmol) in DCM (1.9 mL) was added NBS (41.1 mg, 0.231 mmol) . The reaction mixture was heated at 40 °C for 2 h, and diluted with water, extracted with EtOAc.
- Step C 2- (4-bromoisothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one: tert-Butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (65 mg, 0.156 mmol) in DCM (1.6 mL) was treated with TFA (0.36 mL, 4.68 mmol) at 0 °C to free Boc protection and give TFA salt. The reaction mixture was concentrated, and treated with 0.1N NaOH aqeous solution, and extracted with IPA/CHCl 3 (1/3) to give the title compound as a free base after concentration. LC/MS: (M+1) + : 317.22.
- Step A tert-butyl 2- (4-methylisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: To a microwave vial was charged with tert-butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (product of Step B of INTERMEDIATE 77, 50 mg, 0.120 mmol) , 2, 4, 6-trimethyl-1, 3, 5, 2, 4, 6-trioxatriborinane (60.3 mg, 0.240 mmol) , Pd (dtbpf) Cl 2 (3.91 mg, 6.00 ⁇ mol) , and potassium phosphate (102 mg, 0.480 mmol) .
- Step B 2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one: The title compound was prepared in an analogous fashion to Step C of INTERMEDIATE 77 starting from tert-butyl 2- (4-methylisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate.
- Step A 9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] undecane-1, 5-dicarbonitrile:
- a mixture of 1-benzylpiperidin-4-one (1 kg) and ethyl cyanoacetate (1.195 kg) in a saturated ethanolic ammonia solution (3 L) was stirred for 12 h at about 0-2 °C.
- the reaction mixture was filtered and the solid was dried in vacuo to afford the title compound which was used for next step directly without further purification.
- Step B diethyl 2, 2'- (1-benzylpiperidine-4, 4-diyl) diacetate: The crude 9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] undecane-1, 5-dicarbonitrile in con H 2 SO 4 (1.2 L) and water (1 L) was refluxed for 3 days until the starting material was consumed. The reaction mixture was neutralized by sodium carbonate (1.9 kg) and extracted with ethyl acetate. The combined organic layer was washed with brine, dried and concentrated in vacuo to afford the title compound.
- Step C diethyl 2, 2'- (1- (tert-butoxycarbonyl) piperidine-4, 4-diyl) diacetate: A mixture of diethyl 2, 2'- (1-benzylpiperidine-4, 4-diyl) diacetate (500 g, 1.44 mol) , Boc 2 O (380 g) and Pd (OH) 2 /C (50 g) in methanol (500 mL) under H 2 atmosphere (50 psi) was stirred for 24 hours at RT. The mixture was filtered and the filtrate was concentrated in vacuo to afford the title compound.
- Step D tert-butyl 4, 4-bis (2-hydroxyethyl) piperidine-1-carboxylate: To a suspension of LiAlH 4 (81.9 g, 2.15 mol) in dry THF (6 L) at -40 °C was added a solution of diethyl 2, 2'- (1- (tert-butoxycarbonyl) piperidine-4, 4-diyl) diacetate (478 g, 1.34 mol) in dry THF (2 L) for 2 hours, the reaction mixture was stirred for 0.5h at this same temperature and warmed to RT slowly.
- Step E tert-butyl 4, 4-bis (2- ( (methylsulfonyl) oxy) ethyl) piperidine-1-carboxylate: To a solution of tert-butyl 4, 4-bis (2-hydroxyethyl) piperidine-1-carboxylate (329 g, 1.21 mol) in dry DCM (3.5 L) at -25 °C was added TEA (505 mL, 3.62 mol) followed by addition of DMAP (32.9 g, 0.27 mol) and MsCl (310 g) . The reaction mixture was stirred for 0.5 h at the same temperature. Then a solution of 10% citric acid was added, the organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried and concentrated in vacuo to afford the title compound.
- Step F tert-butyl 9-benzyl-3, 9-diazaspiro [5.5] undecane-3-carboxylate
- Step G tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate: A mixture of tert-butyl 9-benzyl-3, 9-diazaspiro [5.5] undecane-3-carboxylate (240 g, 0.7 mol) and Pd (OH) 2 /C (24 g) in methanol (1.5 L) under hydrogen atmosphere (60 psi) at 40 °C for 24h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was treated with 1N HCl/methanol and filtered to afford compound the title compound as the HCl salt.
- Step A (R) -tert-butyl 9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9- diazaspiro [5.5] undecane-3-carboxylate: To a solution of tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate hydrochloride (114 g, 0.39 mol) in ethanol (1 L) was added Et 3 N (60 mL) . The mixture was stirred for 2 hours.
- Step B (R) -5- (1-hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one: To a solution of (R) -tert-butyl 9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (83 g, 0.19 mol) in CH 2 Cl 2 (1 L) was slowly added a 4 M HCl solution (300 mL) . The mixture was stirred for 8 h. The mixture was filtered.
- Step A (R) -tert-butyl 9- (2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2-hydroxyethyl) -3, 9- diazaspiro [5.5] undecane-3-carboxylate: To a solution of tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (11.6 g, 0.04 mol) in EtOH (104 mL) was added TEA (6 mL) . The mixture was stirred for 3h at 25 degree.
- Step B (R) -1- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethanol: To a solution of (R) -tert-butyl 9- (2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2-hydroxyethyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (15 g, 0.032 mol) in CH 2 Cl 2 (187 mL) was slowly added a 4 M HCl solution (57 mL) . The mixture was stirred for 3 h. The mixture was filtered.
- Step B tert-butyl 9- (1-methyl-6-oxo-1, 6-dihydropyridazin-4-yl) -3, 9-diazaspiro [5.5] undecane-3- carboxylate: To a MW vial was charged tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (220 mg, 0.756 mmol) , 5-iodo-2-methylpyridazin-3 (2H) -one (196 mg, 0.832 mmol) , Pd 2 (dba) 3 (17.32 mg, 0.019 mmol) , Xantphos (32.8 mg, 0.057 mmol) , and Cs 2 CO 3 (493 mg, 1.513 mmol) .
- Step C 2-methyl-5- (3, 9-diazaspiro [5.5] undecan-3-yl) pyridazin-3 (2H) -one
- Step C was conducted in a similar fashion to Step C of INTERMEDIATE 77.
- LC/MS: [ (M+1) ] + 263.
- the vial was fitted with a stir bar, capped and placed in a heating block at 95°C with stirring for 16 hours. After 16 hours, the solvents were removed (Genevac) , and the product was dissolved in 1.5 mL of DMSO, the solution was filtered and the product was purified by semi-preparative HPLC (gradient of 0-40% acetonitrile over 12 min.) .
- the vial was purged with nitrogen gas, sealed and placed on a heating/stir block at 85 °C for 16 hours.
- the solutions from the reaction was filtered and the product purified by semi-preparative HPLC (gradient of 0-40% acetonitrile over 12 min) .
- the MW vial was sealed, degassed, and heated at 145 °C for 60 h.
- the reaction mixture was diluted with DCM, dry-loaded to silica gel column, purified by silica gel column (0-10%MeOH/DCM as eluent) to give the syn and anti products, which were then respectively resolved by SFC-HPLC using a AS-H column to provide the title compounds.
- LC-MS (IE, m/z) 466.88 (M+1) + .
- Example 110 was prepared in an analog fashion to Example 56 using Intermediates 4A and 83.
- LC/MS [(M+1) ] + 453.
- hROMK hROMK ir 1.1
- Dulbecco's Modified Eagle Medium supplemented with non-essential amino acids, Penicillin/Streptomycin/Glutamine, G418 and FBS.
- the media was aspirated from the flask and rinsed with 10 mL calcium/magnesium-free PBS.
- 5 mL of 1X trypsin (prepared in Ca/Mg Free PBS) was added to T-225 flask and flask was returned to 37°C/CO 2 incubator for 2-3 minutes.
- the side of the flask was gently banged with one’s hand.
- the cells completely titrated and then the cells were transferred to 25 mL complete media, centrifuged at 1,500 rpm for 6 min followed by resuspension in complete growth media and determine cell concentration.
- 4E6 cells/T-225 flask will attain >80% confluency in 4 days. Under ideal growth conditions and appropriate tissue culture practices, this cell line is stable for 40-45 passages.
- ⁇ 1000X FluxOR TM Reagent Reconstitute a vial of component A in 100 ⁇ l DMSO; Mix well; Store 10 ⁇ l aliquots at -20°C
- ⁇ Probenecid/Assay Buffer 100 mL of 1X FluxOR TM Assay Buffer; 1 mL of reconstituted component D; Store at 4°C
- ⁇ Loading Buffer 10 ⁇ l 1000X FluxOR TM Reagent; 100 ⁇ l component C; 10 mL Probenecid/Assay Buffer
- ⁇ Stimulant Buffer (prepared at 5X final concentration in 1X FluxOR TM Chloride-Free Buffer) : 7.5 mM thallium sulfate and 0.75 mM potassium sulfate (to give a final assay concentration of 3 mM Thallium/0.3 mM potassium) . Store at 4°C when not in use. If kept sterile, this solution is good for months.
- Assay protocol The ROMK channel functional thallium flux assay was performed in 384 wells, using the FLIPR-Tetra instrument. HEK-hKir1.1 cells were seeded in Poly-D-Lysine microplates and kept in a 37°C-10%CO 2 incubator overnight. On the day of the experiment, the growth media was replaced with the FluxOR TM reagent loading buffer and incubated, protected from light, at ambient temperature (23-25°C) for 90 min. The loading buffer was replaced with assay buffer ⁇ test compound followed by 30 min incubation at ambient temperature, where the thallium/potassium stimulant was added to the microplate.
- control compound is included to support that the assay is giving consistent results compared to previous measurements, although the control is not required to obtain the results for the test compounds.
- the control can be any compound of Formula I of the present invention, preferably with an IC50 potency of less than 1 ⁇ M in this assay.
- the control could be another compound (outside the scope of Formula I) that has an IC 50 potency in this assay of less than 1 ⁇ M.
Abstract
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Description
The Renal Outer Medullary Postassium (ROMK) channel Kir 1.1) (see e.g., Ho, K., et al., Cloning and expression of an inwardly rectifying ATP-regulated potassium channel, Nature, 1993, 362 (6415) : p. 31-8.1, 2; and Shuck, M.E., et al., Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel, J Biol Chem, 1994, 269 (39) : p. 24261-70) is a member of the inward rectifier family of potassium channels expressed in two regions of the kidney: thick ascending loop of Henle (TALH) and cortical collecting duct (CCD) (see Hebert, S.C., et al., Molecular diversity and regulation of renal potassium channels, Physiol Rev, 2005, 85 (1) : p. 319-713). At the TALH, ROMK participates in potassium recycling across the luminal membrane which is critical for the function of the Na+/K+/2Cl-co-transporter, the rate-determining step for salt reuptake in this part of the nephron. At the CCD, ROMK provides a pathway for potassium secretion that is tightly coupled to sodium uptake through the amiloride-sensitive sodium channel (see Reinalter, S.C., et al., Pharmacotyping of hypokalaemic salt-losing tubular disorders, Acta Physiol Scand, 2004, 181 (4) : p. 513-21; and Wang, W., Renal potassium channels: recent developments, Curr Opin Nephrol Hypertens, 2004, 13 (5) : p. 549-55). Selective inhibitors of the ROMK channel (also referred to herein as inhibitors of ROMK or ROMK inhibitors) are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo-or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.P., A.G. Gharavi, and D.S. Geller, Molecular mechanisms of human hypertension, Cell, 2001, 104 (4) : p. 545-56) . Human genetics (Ji, W., et al., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat Genet, 2008, 40 (5) : p. 592-9; and Tobin, M.D., et al., Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population, Hypertension, 2008, 51 (6) : p. 1658-64) and genetic ablation of ROMK in rodents (see Lorenz, J.N., et al., Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome, J Biol Chem, 2002, 277 (40) : p. 37871-80 and Lu, M., et al., Absence of small conductance K+ channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter's) knockout mice, J Biol Chem, 2002, 277 (40) : p. 37881-7) support these expectations. To our knowledge, the first publicly disclosed small molecule selective inhibitors of ROMK, including VU590, were reported from work done at Vanderbilt University as described in Lewis, L.M., et al., High-Throughput Screening Reveals a Small-Molecule Inhibitor of the Renal Outer Medullary Potassium Channel and Kir7.1, Mol Pharmacol, 2009, 76 (5) : p. 1094–1103. The compound VU591 was later reported in Bhave, G. et al., Development of a Selective Small-Molecule Inhibitor of Kir1.1, the Renal Outer Medullary Potassium Channel, Mol Pharmacol, 2011, 79 (1) , p. 42–50, the text of which states that "ROMK (Kir1.1) , is a putative drug target for a novel class of loop diuretics that would lower blood pressure without causing hypokalemia. "
Patent application publication number WO2010/129379, published November 11, 2010 having common representative Merck Sharp & Dohme Corp., (also published as US2010/0286123 on same date) , describes ROMK inhibitors having the generic formula:
wherein R5 and R6 are independently-H, -C1-6 alkyl, -C3-6 cycloalkyl, -CF3, -CHF2, -CH2F or -CH2OH; X is-H,-OH, -OC1-3alkyl, -F, oxo, NH2 or-CH3; and X1 is -H or -CH3.
Patent application publication number WO2012/058134, published May 3, 2012, having common representative Merck Sharp & Dohme Corp., describes ROMK inhibitors having the generic formula:
wherein A and B are mono and/or bicyclic aromatic groups; R2 is -H,
-C1-6 alkyl, -C3-6 cycloalkyl, CF3, -CH2OH, or -CO2R, or R2 can be joined to R1 or R10a to form a ring; R3 is -H, -C1-6 alkyl, -C3-6 cycloalkyl, -OH, -F, -OC1-3 alkyl, or -CH2OH, or R3 can be joined to R10a to form a ring.
Patent application publication number WO2012/058116, published May 3, 2012, having common representative Merck Sharp & Dohme Corp., describes ROMK inhibitors having the generic formula:
wherein R5 and R6 are independently -H, -C1-6 alkyl or–C (O) OC1-3alkyl; and X, X1, Y and Y1 are independently–H or-C1-6alkyl; or Y1 can be joined together with Z2 to form a fused ring system. Additional published patent applications to Merck Sharp and Dohme Corp., which describe ROMK inhibitors, include: WO2013/028474; WO2013/039802; WO2013/062892; WO2013/066714; WO2013/066717; WO2013/066718; and WO2013/090271.
However, continuing discovery of selective small molecule inhibitors of ROMK is still needed for the development of new treatments for hypertension, heart failure, edematous states and related disorders. The compounds of Formula I and salts thereof of this invention are selective inhibitors of the ROMK channel and could be used for the treatment of hypertension, heart failure and other conditions where treatment with a diuretic or natriuretic would be beneficial.
SUMMARY OF THE INVENTION
The present invention provides for compounds of the Formula of the formula
or a pharmaceutically acceptable salt thereof,
wherein:
X is
Y is–O-, -NH-or a bond;
Z is
R is independently H, alkyl (e.g., methyl or ethyl) or haloalkyl (e.g., -CHF2 or-CF3) ;
R1 is H, D or-OH;
R2 is H or D;
R3 is H or D;
R4 is H, D, or alkyl (e.g., methyl or ethyl) ;
R5 is independently oxo or alkyl optionally substituted by 1-5 fluorine atoms;
R6 is H or alkyl (e.g., methyl or ethyl) ;
R7 is H or alkyl (e.g., methyl or ethyl) ;
R8 is H; halo; alkyl (e.g., methyl or ethyl) optionally substituted by–OR, –C (O) OR12, -OC (O) -R12, or 1-5 halogen atoms (e.g., -CHF2 or-CF3) ; -OR (e.g., methoxy or ethoxy) ; phenyl; -C (O) OR13; -N(R14) (R15) ; furanyl; or–OCD3;
R9 is H, alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., -CHF2 or-CF3) or cycloalkyl e.g. (cyclopropyl) ;
R10 is H, halo, or alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., -CHF2 or-CF3) ;
R11 is H, alkyl (e.g., methyl or ethyl) optionally substituted by 1-5 halogen atoms (e.g., methyl or ethyl) or–OR (e.g., methoxy or ethoxy) ;
R12 is H or alkyl (e.g., methyl or ethyl) ;
R13 is H or alkyl (e.g., methyl or ethyl) ;
R14 is H, alkyl (e.g., methyl or ethyl) ;
R15 is H or alkyl (e.g., methyl or ethyl) ;
n is 0, 1 or 2;
o is 1, 2 or 3; and
p is 1 or 2.
The compound of Formula I are inhibitors of the ROMK (Kir1.1) channel. As a result, the compounds of Formula I could be used in methods of treatment, inhibition or amelioration of one or more disease states that could benefit from inhibition of ROMK. The compounds of this invention could be used in methods of treatment which comprise administering a therapeutically or prophylactically effective
amount of a compound of Formula I to a patient in need of a diuretic and/or natriuretic agent. Therefore, the compounds of Formula I could be valuable pharmaceutically active compounds for the therapy, prophylaxis or both of medical conditions, including, but not limited to, cardiovascular diseases such as hypertension and heart failure as well as chronic kidney disease, and conditions associated with excessive salt and water retention. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs which are useful for the treatment of hypertension, heart failure and conditions associated with excessive salt and water retention. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I. These and other aspects of the invention will be evident from the description contained herein.
An embodiment of this invention is compounds of Formula I or pharmaceutically acceptable salts thereof.
Another embodiment of this invention is a compound of Formula I having the structural formula
or a pharmaceutically acceptable salt thereof.
wherein R1, R3, R4, R5, R6, R7, Z, and n are as defined in Formula I.
Another embodiment of this invention is a compound of Formula II having the structural formula:
wherein:
Z is
R1, R3, R4, R6, R7, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula II having the structural formula:
wherein
Z is
R1, R3, R4, R6, R7, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is compound of Formula II having the structural formula:
wherein:
Ra is H or alkyl;
Z is
R1, R3, R4, R6, R7, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
Z is
R1, R3, R4, R6, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
Ra is H or oxo;
Y is–O-or–NH-;
Z is
R1, R3, R4, R6, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
Ra is H or oxo;
Y is –O-or–NH-;
Z is
R1, R3, R4, R6, R7, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is
R1, R3, R4, R6, R7, and R8 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
Z is
R1, R7, R9 and R10 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is
R1, R7, R9 and R10 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
Z is
R1, R3, R4, R6, R8, R9, and R10 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Ra is H or oxo; and
Z is
R, R1, R8, and R10 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
X is
R1 and R9 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof,
wherein:
R1, R7, R8, R9, R10, and R11 are as defined in Formula I.
Another embodiment of this invention is a compound of Formula I having the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
R1 is H or–OH
Z is
R8 is as defined in Formula I.
Another embodiment of the present invention is compounds of Formulae I, II, IIa, IIb, IIc, V, and VI above or their pharmaceutically acceptable salts wherein R1 is–OH, R3 is H and R4 is H, R6 is methyl and R7 is H.
Another embodiment of the present invention is compounds of Formulae I, X, XI, or XII or their pharmaceutically acceptable salts wherein R1 is H.
Another embodiment of the present invention is compounds of Formula I, II, IIa, IIb, IIc, III, IV, V.VII, VIII, IX and XII wherein Z is:
Another embodiment is a compound which is:
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (isothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methylisothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methyl-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (isothiazol-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-3-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one (methoxy-d3) ;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-(methylamino) pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (1-methyl-6-oxo-1,6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl-d3) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- ( (1R, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;
(R) -8- ( (1S, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one; or
(R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -4- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-oneor a pharmaceutically acceptable salt thereof.
All structural formulae, embodiments and classes thereof described herein include the pharmaceutically acceptable salts of the compounds defined therein.
As used herein except if noted otherwise, “D refers to deuterium and when it is used with respect to a specific position in a formula or structure, it means that the dueterium in this position is enriched with deuterium that is above the level of naturally distribution of deuterium.
"Alkyl" is intended to include both branched-and straight-chain saturated aliphatic hydrocarbon groups having , e.g., 1-12, 1-6 or 1-4 carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification. For example the term “C1-6 alkyl” (or “C1-C6 alkyl” ) , means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms and includes all of the hexyl and pentyl isomers as well as n-, iso-, sec-and tert-butyl (butyl, s-butyl, i-butyl, t-butyl; Bu = butyl) , n-and i-propyl (Pr = propyl) , ethyl (Et) and methyl (Me) .
“Halogen” means a fluorine, chlorine, bromine or iodine atom. "Halo" means –F, -Cl, -Br, or –I. A non-limiting example includes fluorine or fluoro.
“Haloalkyl” means a halo-alkyl group in which the halo and alkyl groups are as previously defined. The bond to the parent moiety is through the alkyl group. Non-limiting examples include–CH2CF3 and-CF3.
“Cycloalkyl” is a cyclized alkyl ring having 3-12 or 3-6 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
"Oxo" is a " C= (O) " functional group, that is a carbonyl group.
Unless expressly depicted or described otherwise, variables depicted in a structural formula with a "floating" bond, such as R5 and R8, are permitted on any available carbon atom in the ring to which the variable is attached.
In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. R1, R2, etc., are to be chosen in conformity with well-known principles of chemical structure connectivity and stability.
The term "substituted" shall be deemed to include multiple degrees of substitution by a named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
Where a substituent or variable has multiple definitions, it is understood that the substituent or variable is defined as being selected from the group consisting of the indicated definitions.
The compounds of Formula I may have one or more chiral (asymmetric) centers. The present invention encompasses all stereoisomeric forms of the compounds of Formula I. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have (R) or (S) configuration. When bonds to a chiral carbon are depicted as straight lines in the structural Formulas of the invention, or when a compound name is recited without an (R) or (S) chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of each such chiral carbon, and hence each enantiomer or diastereomer and mixtures thereof, are embraced within the Formula or by the name. The production of specific stereoisomers or mixtures thereof may be identified in the Examples where such stereoisomers or mixtures were obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof from being within the scope of this invention.
The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, enantiomers
are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios. In the case of a cis/trans isomerism the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or it can be done on a final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Alternatively, absolute stereochemistry may be determined by Vibrational Circular Dichroism (VCD) spectroscopy analysis. Where compounds of this invention are capable of tautomerization, all individual tautomers as well as mixtures thereof are included in the scope of this invention. The present invention includes all such isomers, as well as salts, solvates (which includes hydrates) and solvated salts of such racemates, enantiomers, diastereomers and tautomers and mixtures thereof.
Reference to the compounds of Formula I herein encompasses the compounds of Formulae I-XIII and all embodiments and classes thereof. Reference to the compounds of this invention as those of a specific formula or embodiment, e.g., Formulae I –XIII or embodiments thereof, or any other generic structural formula or specific compound described or claimed herein, is intended to encompass the specific compound or compounds falling within the scope of the Formula or embodiment, including salts thereof, particularly pharmaceutically acceptable salts, solvates (including hydrates) of such compounds and solvated salt forms thereof, where such forms are possible, unless specified otherwise.
In the compounds of Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of Formula I. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H) . Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
When the compounds of Formula I contain one or more acidic or basic groups the invention also includes the corresponding pharmaceutically acceptable salts. Thus, the compounds of Formula I which contain acidic groups can be used according to the invention as, for example but not limited to, alkali metal salts, alkaline earth metal salts or as ammonium salts. Examples of such salts include but are not
limited to sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of Formula I which contain one or more basic groups, i.e. groups which can be protonated, can be used according to the invention in the form of their acid addition salts with inorganic or organic acids as, for example but not limited to, salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, benzenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid,
naphthalenedisulfonic acids, oxalic acid, acetic acid, trifluoroacetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, etc. If the compounds of Formula I simultaneously contain acidic and basic groups in the molecule the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions) . Salts can be obtained from the compounds of Formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts. The present invention also includes all salts of the compounds of Formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
Furthermore, compounds of the present invention may exist in amorphous form and/or one or more crystalline forms, and as such all amorphous and crystalline forms and mixtures thereof of the compounds of Formula I are intended to be included within the scope of the present invention. In addition, some of the compounds of the instant invention may form solvates with water (i.e., a hydrate) or common organic solvents. Such solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the instant compounds are likewise encompassed within the scope of this invention, along with un-solvated and anhydrous forms.
Any pharmaceutically acceptable pro-drug modification of a compound of this invention which results in conversion in vivo to a compound within the scope of this invention is also within the scope of this invention. For example, esters can optionally be made by esterification of an available carboxylic acid group or by formation of an ester on an available hydroxy group in a compound. Similarly, labile amides can be made. Pharmaceutically acceptable esters or amides of the compounds of this invention may be prepared to act as pro-drugs which can be hydrolyzed back to an acid (or -COO-depending on the pH of the fluid or tissue where conversion takes place) or hydroxy form particularly in vivo and as such are encompassed within the scope of this invention. Examples of pharmaceutically acceptable pro-drug modifications include, but are not limited to, -C1-6alkyl esters and -C1-6alkyl substituted with phenyl esters.
Accordingly, the compounds within the generic structural formulas, embodiments and specific compounds described and claimed herein encompass salts, all possible stereoisomers and tautomers, physical forms (e.g., amorphous and crystalline forms) , solvate and hydrate forms thereof and any
combination of these forms, as well as the salts thereof, pro-drug forms thereof, and salts of pro-drug forms thereof, where such forms are possible unless specified otherwise.
The compounds of Formula I according to the invention are inhibitors of ROMK, and therefore could be used as diuretic and/or natriuretic agents. ROMK inhibitors may be used to help to increase urination and increase urine volume and also to prevent or reduce reabsorption of sodium in the kidneys leading to increased excretion of sodium and water. Therefore, the compounds could be used for treatment or prophylaxis or both of disorders that benefit from increased excretion of water and sodium from the body. Accordingly, the compounds of this invention could be used in a method for inhibiting ROMK comprising administering a compound of Formula I in a ROMK-inhibitory effective amount to a patient in need thereof. This also encompasses the use of the compounds for inhibiting ROMK in a patient comprising administering a compound of claim 1 in a therapeutically effective amount to a patient in need of diueresis, natriuresis or both. The inhibition of ROMK by the compounds of Formula I can be examined, for example, in the Thallium Flux Assay described below. Moreover, this invention also relates to the use of the compounds of Formula I or salts thereof to validate in vitro assays, for example but not limited to the Thallium Flux Assay described herein.
The compounds of this invention could be used in a method for causing diuresis, natriuresis or both, comprising administering a compound of Formula I in a therapeutically effective amount to a patient in need thereof. Therefore, the compounds of Formula I of this invention could be used in methods for treatment of, prevention of or reduction of risk for developing medical conditions that benefit from increased excretion of water and sodium, such as but not limited to one or more of hypertension, such as essential hypertension (also known as primary or idiopathic hypertension) which is a form of hypertension for which no cause can be found, heart failure (which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure) and/or other conditions associated with excessive salt and water retention. The compounds could also be used to treat hypertension which is associated with any of several primary diseases, such as renal, pulmonary, endocrine, and vascular diseases, including treatment of patients with medical conditions such as heart failure and/or chronic kidney disease. Furthermore, the compounds of Formula I could be used in methods for treatment of, prevention of or reduction of risk for developing one or more disorders such as pulmonary hypertension, particularly pulmonary arterial hypertension (PAH) , cardiovascular disease, edematous states, diabetes mellitus, diabetes insipidus, post-operative volume overload, endothelial dysfunction, diastolic dysfunction, systolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eclampsia, cerebral edema, nephropathy, glomerulonephritis, nephrotic syndrome, acute kidney insufficiency, chronic kidney insufficiency (also referred to as chronic kidney disease, or more generally as renal impairment) , acute tubular necrosis, hypercalcemia, idiopathic edema, Dent's disease, Meniere's disease, glaucoma, benign intracranial hypertension, and other conditions for which a diuretic or natriuretic or both would have therapeutic or prophylactic benefit. The compounds of the invention may be administered to a patient having, or at risk of having, one or more conditions for which a diuretic or natriuretic or both would have therapeutic or prophylactic benefit such as those described herein.
The compounds of Formula I may potentially have reduced liabilities (for example, hypo-or hyperkalemia, new onset of diabetes, dyslipidemia, etc. ) over currently used clinical agents. Also the compounds may have reduced risk for diuretic tolerance, which can be a problem with long-term use of loop diuretics.
In general, compounds that are ROMK inhibitors can be identified as those compounds which, when tested, have an IC50 of 5 μM or less, preferably 1 μM or less, and more preferably 0.25 μM or less, in the Thallium Flux Assay, described in more detail further below.
The dosage amount of the compound to be administered depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of Formula I. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is expected that the compound will be administered chronically on a daily basis for a length of time appropriate to treat or prevent the medical condition relevant to the patient, including a course of therapy lasting days, months, years or the life of the patient.
In general, a daily dose of approximately 0.001 to 100 mg/kg, preferably 0.001 to 30 mg/kg, in particular 0.001 to 10 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results. The daily dose is preferably administered in a single dose or can be divided into several, for example two, three or four individual doses, and may be, for example but not limited to, 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, etc., on a daily basis. In some cases, depending on the potency of the compound or the individual response, it may be necessary to deviate upwards or downwards from the given daily dose. Furthermore, the compound may be formulated for immediate or modified release such as extended or controlled release.
The term “patient” includes animals, preferably mammals and especially humans, who use the instant active agents for the prophylaxis or treatment of a medical condition. Administering of the drug to the patient includes both self-administration and administration to the patient by another person. The patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for developing said disease or medical condition or developing long-term complications from a disease or medical condition.
The term” therapeutically effective amount” is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. A prophylactically effective amount is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
The terms “preventing, ” “prevention, ” "prophylactic" and derivatives of these terms as used herein refer to administering a compound to a patient before the onset of clinical symptoms of a condition not yet present in the patient. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention or reduction of risk of myocardial infarction or prevention or reduction of risk for complications related to hypertension.
In the methods of treatment of this invention, the ROMK inhibitors may be administered via any suitable route of administration such as, for example, orally, parenterally, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous (IV) , intramuscular, intrasternal injection or infusion techniques. Oral formulations are preferred for treatment of chronic indications such as hypertension or chronic heart failure, particularly solid oral dosage units such as pills, tablets or capsules, and more particularly tablets. IV dosing is preferred for acute treatment, for example for the treatment of acute heart failure.
This invention also provides pharmaceutical compositions comprised of a compound of Formula I and a pharmaceutically acceptable carrier which is comprised of one or more excipients or additives. An excipient or additive is an inert substance used to formulate the active drug ingredient. For oral use, the pharmaceutical compositions of this invention containing the active ingredient may be in forms such as pills, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. The excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, mannitol, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
Pharmaceutical compositions may also contain other customary additives, for example but not limited to, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. Oral immediate-release and time-controlled release dosage forms may be employed, as well as enterically coated oral dosage forms. Tablets may be uncoated or they may be coated by known techniques for aesthetic purposes, to mask taste or for other reasons. Coatings can also be used to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents
such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
The instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining a compound of Formula I with a pharmaceutically acceptable carrier. Also encompassed is the pharmaceutical composition which is made by combining a compound of Formula I with a pharmaceutically acceptable carrier. Furthermore, a therapeutically effective amount of a compound of this invention can be used for the preparation of a medicament useful for inhibiting ROMK, for causing diuresis and/or natriuresis, and/or for treating, preventing or reducing the risk for any of the medical conditions described herein, in dosage amounts described herein.
The amount of active compound of Formula I and/or its pharmaceutically acceptable salts in the pharmaceutical composition may be, for example but not limited to, from about 0.1 mg to 1 g, particularly 0.1 mg to about 200 mg, more particularly from about 0.1 mg to about 100 mg, and even more particularly from about 0.1 to about 50 mg, per dose on a free acid/free base weight basis, but depending on the type of the pharmaceutical composition, potency of the active ingredient and/or the medical condition being treated, it could also be lower or higher. Pharmaceutical compositions usually comprise about 0.5 to about 90 percent by weight of the active compound on a free acid/free base weight basis.
The compounds of Formula I inhibit ROMK. Due to this property, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on ROMK is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples. The compounds of Formula I can also be employed as intermediates for the preparation of other pharmaceutically active compounds.
One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I. The additional active agent (or agents) is intended to mean a medicinal compound that is different from the compound of Formula I, and which is a pharmaceutically active agent (or agents) that is active in the body, including pro-drugs, for example esterified forms, that convert to pharmaceutically active form after administration, and also includes free-acid, free-base and pharmaceutically acceptable salts of said additional active agents when such forms are sold commercially or are otherwise chemically possible. Generally, any suitable additional active agent or agents, including but not limited to anti-hypertensive agents, additional diuretics, anti-atherosclerotic agents such as a lipid
modifying compound, anti-diabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I in a single dosage formulation (a fixed dose drug combination) , or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents) . Examples of the one or more additional active agents which may be employed include but are not limited to thiazide-like diuretics, e.g., hydrochlorothiazide (HCTZ or HCT) ; angiotensin converting enzyme inhibitors (e.g, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril) ; dual inhibitors of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) such as omapatrilat, sampatrilat and fasidotril; angiotensin II receptor antagonists, also known as angiotensin receptor blockers or ARBs, which may be in free-base, free-acid, salt or pro-drug form, such as azilsartan, e.g., azilsartan medoxomil potassiumcandesartan, e.g., candesartan cilexetil eprosartan, e.g., eprosartan mesylateirbesartanlosartan, e.g., losartan potassiumolmesartan, e.g, olmesartan medoximiltelmisartan valsartanand any of these drugs used in combination with a thiazide-like diuretic such as hydrochlorothiazide (e.g., ) , etc. ) ; potassium sparing diuretics such as amiloride HCl, spironolactone, epleranone, triamterene, each with or without HCTZ; carbonic anhydrase inhibitors, such as acetazolamide; neutral endopeptidase inhibitors (e.g., thiorphan and phosphoramidon) ; aldosterone antagonists; aldosterone synthase inhibitors; renin inhibitors (e.g enalkrein; RO 42-5892; A 65317; CP 80794; ES 1005; ES 8891; SQ 34017; aliskiren (2(S) , 4 (S) , 5 (S) , 7 (S) -N- (2-carbamoyl-2-methylpropyl) -5-amino-4-hydroxy-2, 7-diisopropyl-8- [4-methoxy-3-(3-methoxypropoxy) -phenyl] -octanamid hemifumarate) SPP600, SPP630 and SPP635) ; endothelin receptor antagonists; vasodilators (e.g. nitroprusside) ; calcium channel blockers (e.g., amlodipine, nifedipine, verapamil, diltiazem, felodipine, gallopamil, niludipine, nimodipine, nicardipine, bepridil, nisoldipine) ; potassium channel activators (e.g., nicorandil, pinacidil, cromakalim, minoxidil, aprilkalim, loprazolam) ; sympatholitics; beta-adrenergic blocking drugs (e.g., acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, metoprolol tartate, nadolol, propranolol, sotalol, timolol) ; alpha adrenergic blocking drugs (e.g., doxazocin, prazocin or alpha methyldopa) ; central alpha adrenergic agonists; peripheral vasodilators (e.g. hydralazine) ; nitrates or nitric oxide donating compounds, e.g. isosorbide mononitrate; lipid lowering agents, e.g., HMG-CoA reductase inhibitors such as simvastatin and lovastatin which are marketed asandin lactone pro-drug form and function as inhibitors after administration, and pharmaceutically acceptable salts of dihydroxy open ring acid HMG-CoA reductase inhibitors such as atorvastatin (particularly the calcium salt sold in) , rosuvastatin (particularly the calcium salt sold in) , pravastatin (particularly the sodium salt sold in) , and fluvastatin (particularly the sodium salt sold in) ; a cholesterol absorption inhibitor such as ezetimibeand ezetimibe in combination with any other lipid lowering agents such as the HMG-CoA reductase inhibitors noted above and particularly with simvastatin or with atorvastatin calcium; ) and/or with an HMG-CoA reductase inhibitor; niacin in immediate-release or controlled release forms, and particularly niacin in combination with a DP
antagonist such as laropiprant and/or with an HMG-CoA reductase inhibitor; niacin receptor agonists such as acipimox and acifran, as well as niacin receptor partial agonists; metabolic altering agents including insulin sensitizing agents and related compounds for the treatment of diabetes such as biguanides (e.g., metformin) , meglitinides (e.g., repaglinide, nateglinide) , sulfonylureas (e.g., chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide) , thiazolidinediones also referred to as glitazones (e.g., pioglitazone, rosiglitazone) , alpha glucosidase inhibitors (e.g., acarbose, miglitol) , dipeptidyl peptidase inhibitors, (e.g., sitagliptinalogliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin) , ergot alkaloids (e.g., bromocriptine) , combination medications such as (sitagliptin with metformin) , and injectable diabetes medications such as exenatide and pramlintide acetate; phosphodiesterase-5 (PDE5) inhibitors such as sildenafil (Revatio, Viagra) , tadalafil (Cialis, Adcirca) vardenafil HCl (Levitra) ; or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including but not limited to diazoxide; and including the free-acid, free-base, and pharmaceutically acceptable salt forms, pro-drug forms (including but not limited to esters) , and salts of pro-drugs of the above medicinal agents where chemically possible. Trademark names of pharmaceutical drugs noted above are provided for exemplification of the marketed form of the active agent (s) ; such pharmaceutical drugs could be used in a separate dosage form for concurrent or sequential administration with a compound of Formula I, or the active agent (s) therein could be used in a fixed dose drug combination including a compound of Formula I.
Several methods for preparing the compounds of this invention are described in the following Schemes and Examples. Starting materials and intermediates are purchased, made from known procedures, or as otherwise illustrated. Some frequently applied routes to the compounds of Formula I are also described by the Schemes as follows. In some cases the order of carrying out the the steps of reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The "R" substituents in the Schemes correspond to the substituents defined in Formula I at the same positions on the structures. The structures:
where X is tetrazole, lactone or nitrile, correspond to X and Z respectively in Formula I.
Several methods for preparing the compounds of this invention are described in the examples. Starting materials and intermediates are purchased, made from known procedures, or as otherwise illustrated. Some frequently applied routes to the compounds of Formula I are also described by the Schemes as follows. In some cases the order of carrying out the steps of reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.
Compounds of Formula IA, which is substituted at the benzylic position with an OH group, can be prepared following the sequence outlined in Scheme 1. Coupling of epoxide 1 to spirocyclic amines 2 at elevated temperatures leads to the formation of alcohols IA (Nomura, Y. et al. Chemical & Pharmaceutical Bulletin, 1995, 43 (2) , 241-6) . The reaction can be carried out with conventional heating
or by heating using a microwave apparatus. A number of solvents can be used in this reaction; for example, ethanol and 2-propanol. Spirocyclic amines may be free bases, or they may be salts, in which case a base such as triethylamine or N, N’ -diisopropylethylamine may be added. When enantiopure chiral epoxides are employed (such as (R) -1 in Scheme 1) epoxide opening occurs with retention of stereochemistry in the benzylic position and individual isomer (R) -IA may be obtained (and if the (S) -epoxide is employed the alcohol produced will have the opposite stereochemistry to that shown) . Alternatively, chiral HPLC separation of enantiomers or diastereomers of IA may be performed to provide single enantiomers or diastereomers.
SCHEME 1
Compounds of Formula IB, which has no OH group at the benzylic position, can be prepared by the sequences detailed in Scheme 2. Aldehydes 3 may be used in reductive alkylation reactions of spirocyclic amines 2 to afford compounds of the invention corresponding to formula IB by using various reductive amination conditions (for example using sodium cyanoborohydride, sodium triacetoxy borohydride, or titanium tetra-isopropoxide, followed by sodium borohydride or sodium cyanoborohydride) . Compounds of Formula IB can also be prepared by hydroamination between styrene 4 and spirocyclic amines 2 catalyzed by bis (1, 5-cyclooctadiene) rhodium (I) tetrafluoroborate and bis (2-diphenylphosphino-phenyl) ether.
SCHEME 2
Alternatively, compounds of the Formula IA may be prepared by coupling of the NH in spirocycles 5 to an aromatic or heterocyclic coupling partner 6 (where A represents chloride, bromide, iodide, fluoride, boronic acid) . This coupling reaction may be accomplished in a variety of ways, depending upon the nature of of 4 and the coupling partner. For example, in some cases this coupling can be achieved by thermal or microwave heating in one of a variety of potential solvents, such as DMF or dioxane, in the presence or absence of a base such as triethylamine or potassium carbonate, or cesium carbonate. Alternatively, the coupling can be accomplished using a catalyst-ligand system, for example heating with Xantphos and Pd2 (dba) 3 in the presence of a base such as cesium carbonate in a solvent such as dioxane (Buchwald, S.L.; Yin, J. J. Am. Chem. Soc. 2002, 124, 6043) . Numerous other C-N coupling conditions, known from the literature such as Pd-catalyzed (Review: Buchwald, S. L. Chem. Sci. 2011, 2, 27) and Cu (I) -catalyzed reactions (Buchwald, S.L. et al. J. Am. Chem. Soc. 2002, 124, 7421) , may be applied.
SCHEME 3
The epoxides 1 (and single enatiomers (R) -1 and (S) -1) can be prepared following the method detailed in Scheme 4. Treatment of 7 (where halide is chloride, bromide, iodide, or trifluoromethane sulfonate) with commercially available potassium vinyl trifluoroborate (Molander, G.; Luciana, A. Journal of Organic Chemistry, 2005, 70, 3950-3956) under palladium catalyzed coupling conditions with an appropriate phosphine ligand gives rise to styrene 4 (Molander, G.; Brown, A. Journal of Organic
Chemistry, 2006, 71, 9681-9686) . Alternatively, other methods may be employed, for example, using vinylstannane reagents and palladium catalysis. The resulting styrenes 4 is the coupling partner used in Scheme 2. It can be converted to the corresponding epoxides 1 under various epoxidation conditions, for example, with mCPBA (Fringuelli, F. et al. Organic Preparations and Procedures International, 1989, 21, 757-761). The racemic epoxide 1 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers, which can be used in place of 1 according to Scheme 1.
SCHEME 4
Alternatively, enantiopure epoxides (R) -1 or (S) -1 can be prepared as shown in Scheme 5. Treatment of 7 (where halide is bromide, iodide, or trifluoromethane sulfonate) with commercial available vinyl butylether 7 under palladium catalyzed conditions with a suitable ligand and base (for example Pd(OAc) 2, DPPP, Et3N) can provide the enol ethers 9. Enol ethers may be prepared using other methods known to the chemist. Treatment of the resulting enol ethers 9 with NBS or other similar reagents affords the corresponding bromomethyl ketones 10. These can be subjected to a variety of asymmetric ketone reduction conditions, for example with an enzyme that can affect such a transformation with high enantioselectivity. Subsequent treatment with a base such as triethylamine leads to cyclization, affording the enantioenriched epoxides (R) -1 or (S) -1 (depending upon the asymmetric reducing agent) .
SCHEME 5
As shown in Scheme 6, aldehyde 3 can be prepared by hydrogenation of intermediate epoxides (1, from Scheme 4) followed by oxidation with Dess-Martine periodinane.
SCHEME 6
Amine 5 can be prepared in sequences described in Scheme 7. Treatment of epoxide (R) -1 with commercially available or unavailable amines 12 (commercially unavailable amines 12 are prepared as described in the experimental section below) under conventional or microwave heating conditions leads to form 13, which was then deprotected by TFA or HCl to give free amine 5 after treatment with ion-exchange column.
SCHEME 7
When spirolactams (where R represents a carbonyl group) are involved, amine 5 can be prepared through Scheme 8. Boc deprotection of spirolactams 14 with TFA or HCl, followed by treatment with
ion-exchange column affords free amines 15. Epoxide opening reaction of (R) -1 by 15 under conventional or microwave heating conditions leads to amine 5.
SCHEME 8
Spirocyclic amines 2 can be prepared as described in Scheme 9. Spirocyclic diamines or amino lactams (where R represents a carbonyl group) 14, protected with Boc group, can be coupled to electrophiles 6 (where A represents I, Cl, Br or OTf) in a variety of ways, depending upon the nature of coupling partners. For example, in some cases this coupling can be achieved by thermal or microwave heating in the presence or absence of a base, such as DIPEA. Sometime the coupling can be achieved using a catalyst-ligand system, for example Pd2 (dba) 3 and Xantphos. Some spirocyclic diamines or amino lactams 14 described herein are commercially available; others can prepared as described in the experimental section below. Some halides 6 are commercially available; some can be prepared as described in the examples below. Intermediates 16 are converted to spirocyclic amines 2 by removal of the protective group; for example, tert-butoxycarbonyl can be removed with TFA or HCl.
SCHEME 9
General Procedures:
Reactions sensitive to moisture or air were performed under nitrogen or argon using anhydrous solvents and reagents. The progress of reactions was determined by either analytical thin layer chromatography (TLC) usually performed with E. Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm or liquid chromatography-mass spectrometry (LC-MS).
Typically the analytical LC-MS system used consisted of a Waters ZQTM platform with electrospray ionization in positive ion detection mode with an Agilent 1100 series HPLC with autosampler. The column was usually a Water Xterra MS C18, 3.0 × 50 mm, 5 μm. The flow rate was 1 mL/min, and the injection volume was 10 μL. UV detection was in the range 210–400 nm. The mobile phase consisted of solvent A (water plus 0.06% TFA) and solvent B (acetonitrile plus 0.05% TFA) with a gradient of 100%solvent A for 0.7 min changing to 100% solvent B over 3.75 min, maintained for 1.1 min, then reverting to 100% solvent A over 0.2 min.
Preparative HPLC purifications were usually performed using a mass spectrometry directed system. Usually they were performed on a Waters Chromatography Workstation configured with LC-MS System Consisting of: Waters ZQTM single quad MS system with Electrospray Ionization, Waters 2525 Gradient Pump, Waters 2767 Injecto /Collector, Waters 996 PDA Detector, the MS Conditions of: 150-750 amu, Positive Electrospray, Collection Triggered by MS, and a WatersC-18 5 micron, 30 mm (id) x 100 mm column. The mobile phases consisted of mixtures of acetonitrile (10-100%) in water containing 0.1% TFA. Flow rates were maintained at 50 mL/min, the injection volume was 1800 μL, and the UV detection range was 210–400 nm. Mobile phase gradients were optimized for the individual compounds. Reactions performed using microwave irradiation were normally carried out using an Emrys Optimizer manufactured by Personal Chemistry, or an Initiator manufactured by Biotage. Concentration of solutions was carried out on a rotary evaporator under reduced pressure. Flash chromatography was usually performed using aFlash Chromatography apparatus (Dyax Corp. ) on silica gel (32-63 mM, 60 pore size) in pre-packed cartridges of the size noted. 1H NMR spectra were acquired at 500 MHz spectrometers in CDCl3 solutions unless otherwise noted. Chemical shifts were reported in parts per million (ppm) . Tetramethylsilane (TMS) was used as internal reference in CD3Cl solutions, and residual CH3OH peak or TMS was used as internal reference in CD3OD solutions. Coupling constants (J) were reported in hertz (Hz) . Chiral analytical chromatography was performed on one ofAS, AD, OD, IA, orOJ columns (250x4.6 mm) (Daicel Chemical Industries, Ltd. ) with noted percentage of either ethanol in hexane (%Et/Hex) or isopropanol in heptane (%IPA/Hep) as isocratic solvent systems. Chiral preparative chromatography was conducted on one of of CHIRALPAK AS, of CHIRALPAK AD, OD, IA, OJ columns (20x250 mm) (Daicel Chemical Industries, Ltd. ) with desired isocratic solvent systems identified on chiral analytical chromatography or by supercritical fluid (SFC) conditions.
Abbreviations and acronyms that may be used herein include: -C (O) CH3 (Ac) ; -OC (O) CH3 (OAc) ; acetic acid (AcOH; HOAc) ; 1-chloroethylchloroformate (ACE-Cl) ; 2, 2'-bis (diphenylphosphino) -1, 1'-binaphthyl (BINAP) ; benzyl (Bn) ; t-butyloxycarbonyl (Boc or BOC) ; di-t-butyl dicarbonate ((BOC) 2O, Boc2O) ; benzyloxycarbonyl (Cbz) ; n-butyl (Bu) ; tert-butyl (t-butyl) ; cyclopentyl methyl ether (CPME) ; carbonyldiimidazole (CDI) ; diethylaminosulfur trifluoride (DAST) ; dibenzylideneacetone
(dba) ; 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) ; 1, 2-dichloroethane (DCE) ; dichloromethane (DCM) ; diethyl amine (DEA) ; dimethoxyethane (DME) ; diisobutylaluminium hydride (DIBAL-H ) ; N, N-diisopropylethylamine (DIEA, DIPEA, Hunig's base) ; dioxane is 1, 4-dioxane; di-isopropylamine (DIPA) ; 1, 1’ -bis (diphenylphosphino) ferrocene (dppf , DPPF) ; Dess-Martin Periodinane (DMP; 1, 1, 1-triacetoxy-1, 1-dihydro-1, 2-benziodoxol-3 (1H) -one) ; dimethylsulfide (DMS) ; dimethylsulfoxide (DMSO) ; N; N-dimethylformamide (DMF) ; 4-dimethylaminopyridine (DMAP) ; dimethylacetamide (DMA; DMAC) ; 1, 3-bis (diphenylphosphino) propane (DPPP) ; (Oxydi-2, 1-phenylene) bis (diphenylphosphine) (DPEPhos) ; eithyl (ET) ; ethyl acetate (EtOAc or EA) ; ethanol (EtOH) ; diethyl ether (ether or Et2O) ; 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC, EDAC or EDCI) ; 2- (7-Aza-1H-benzotriazole-1-yl) -1, 1, 3, 3-tetramethyluronium hexafluorophosphate (HATU) ; hexane (Hex) ; hexamethylphosphoramide (HMPA) ; 1-hydroxybenzotriazole hydrate (HOBt) ; isopropanol (IPA or iPrOH) ; isopropyl acetate (IPAc) ; potassium bis (trimethylsilyl) amide (KHMDS) ; lithium aluminum hydride (LAH) ; lithium diisopropylamide (LDA) ; 3-chloroperoxybenzoic acid (mCPBA) ; methanol (MeOH) ; CH3SO2- (mesyl or Ms); methane sulfonyl chloride or mesyl chloride (MsCl) ; methanesulfonic acid (MsOH) ; methyl (Me) ; methyl tert-butyl ether (MTBE) ; nicotinamide adenine dinucleotide phosphate (NADP) ; N-bromo succinimide (NBS) ; N-chlorosuccinimide (NCS) ; N-iodosuccinimide (NIS) ; N-methylmorpholine-N-oxide (NMO) ; N-methyl morpholine (NMP) ; sodium hexamethyldisilazide (NaHMDS) ; sodium triacetoxyborohydride (NaBH (OAc) 3) ; pyridinium chlorochromate (PCC) ; phenyl (Ph) ; petroleum ether (PE or petrol ether) ; tetrakis (triphenylphosphine) palladium (Pd (PPh3) 4) ;
tris (dibenzylidineacetone) dipalladium (Pd2 (dba) 3) ; Pd (dppf) Cl2 or PdCl2 (dppf) is 1, 1′-Bis(diphenylphosphino) ferrocene] -dichloropalladium (II) which may be complexed with CH2Cl2; tetra-n-butylammonium fluoride (TBAF) ; tert-butyldimethylsilyl chloride (TBS-Cl) ; triethylamine (TEA) ; trifluoroacetic acid (TFA) ; -SO2CF3 (Tf) ; trifluoromethanesulfonic acid (triflic acid, TfOH) ; trifluoromethanesulfonic anhydride (triflic anhydride, (Tf) 2O) ; 2-tetrahydrofuran (THF) ; N, N, N′, N′-tetramethylethylenediamine (TMEDA) ; p-toluenesulfonic acid (TsOH or PTSA) ; dicyclohexylphosphino-2', 4', 6'-triisopropylbiphenyl (X-Phos) ; diethylaminodifluorosulfinium tetrafluoroborate (XtalFluor- ) ; 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (Xantphos) . Additional abbreviations and acronyms are: racemic or racemate (rac. ) ; starting material (SM) ; round-bottom flask (RB or RBF) ; aqueous (aq) ; saturated aqueous (sat’ d) ; saturated aqueous sodium chloride solution (brine) ; maximum temperature (Tmax) ; medium pressure liquid chromatography (MPLC) ; high pressure liquid chromatography (HPLC) ; preparative HPLC (prep-HPLC) ; flash chromatography (FC) ; liquid chromatography (LC) ; supercritical fluid chromatography (SFC) ; 2-dicyclohexylphosphino-2', 6'-dimethoxybiphenyl (SPhos) ; thin layer chromatography (TLC) ; preparative TLC (prep-TLC) ; mass spectrum (ms or MS) ; liquid chromatography-mass spectrometry (LC-MS, LCMS or LC/MS) ; column volume (CV) ; room temperature (rt, r.t. or RT) ; hour (s) (h or hr) ; minute (s) (min) ; retention time (Rt) ; gram (s) (g) ; milligram (s) (mg) ; milliliter (s) (mL) ; microliter (s) (μL) ; millimole (mmol) ; volume: volume (V/V) . is a trademark name for diatomaceous earth, andis a trademark name for powdered cellulose. X or x may be used to express the number of times an action was repeated (e.g., washed with 2 x 200 mL 1N HCl) , or to convey a dimension (e.g., the dimension of a column is 30 x 250mm) .
The following are representative procedures for the preparation of the compounds used in the following Examples, or which can be substituted for the compounds used in the following Examples which may not be commercially available.
INTERMEDIATE 1
Step A: (3-bromo-2-methylphenyl) methanol: To a solution of 3-bromo-2-methyl benzoic acid (35 g, 163 mmol) in THF (200 mL) was added borane THF complex (1.0 M, 212 mL, 212 mmol) . The mixture was allowed to stir for 24 h. TLC showed one single product spot. The reaction was quenched with water. The solvent THF was removed under reduced pressure. The resulting solid was dissolved in ethyl acetate (500 mL) , washed with 1N HCl, sodium carbonate, and brine. The organic layer was dried over sodium sulfate and concentrated to afford (3-bromo-2-methylphenyl) methanol. 1H NMR (500 MHz, CDCl3) δ7.76 (d, J = 8.0 Hz, 1H) , 7.63 (d, J = 8.0 Hz, 1H) , 5.30 (s, 2H) , 2.42 (s, 3H) .
Step B: 5-bromo-4-methyl-2-benzofuran-1 (3H) -one: To a flask charged with (3-bromo-2-methylphenyl) methanol (6.0 g, 30 mmol) was added a 1M TFA solution of thallium trifluoroacetate (16.2 g, 29.8 mmol) . The mixture was stirred at RT overnight. Analysis by TLC showed no starting material remaining. The solvent was removed under vacuum, and the residue was pumped under high vacuum for 30 min to ensure complete removal of TFA. To the residue was then added palladium (II) chloride (529 mg, 2.98 mmol) , lithium chloride (2.53 g, 59.7 mmol) , magnesium oxide (2.41 g, 59.7 mmol) , and MeOH (150 mL) . The reaction was flushed with CO twice, and kept under CO at room temperature. Analysis by LC showed a big product spot within 2 hours. To this solution was added ethyl acetate to precipitate the salts. The black solution was filtered through apad, washed with EtOAc, adsorbed onto silica and purified by silica gel chromatography to afford 5-bromo-4-methyl-2-benzofuran-1 (3H) -one. 1H NMR (500 MHz, CDCl3) δ ppm 7.71 (d, J = 8.0 Hz, 1H) , 7.58 (d, J = 8.0 Hz, 1H) , 5.25 (s, 2H) , 2.37 (s, 3H).
INTERMEDIATE 2
Step A: 3-hydroxymethyl-2-methyl phenol: To a 5 L 3-neck round bottomed flask equipped with overhead stirrer was charged NaBH4 (87.0 g, 2.30 mol) and THF (3.0 L) and the resulting slurry was cooled to 10 ℃. To the slurry was then added 3-hydroxy-2-methyl benzoic acid (175 g, 1.15 mol) portionwise over 20 min (TMax 17 ℃) . A stirrable slurry formed, and was aged for an additional 45 min at 10-15 ℃ after which BF3-OEt2 (321 mL, 2.53 mol) was added slowly over 1.5 hours. The slurry was aged at 10℃ to 15 ℃ for 2 h then assayed for reaction completion (98.5% conversion) . The slurry was
cooled to less than 10 ℃ and quenched with 931 mL MeOH slowly over 1.5 h (gas evolution) . The resulting slurry was aged overnight at RT. The batch was cooled to less than 10 ℃ then quenched with 1 N HCl (1.5 L) to get a homogeneous solution (pH solution~1) , which was aged for 30 min and then the organic solvents were removed by rotary evaporation to approximately 1.8 L of total reaction volume (bath temperature was set to 50 ℃; internal temperature of concentrate after rotary evaporation was~40 ℃) . The slurry was held at 45 ℃ for 30 min then cooled slowly to 15 ℃. The solids were filtered and washed with cold (15 ℃) water (2 x 300 mL) , providing 3-hydroxymethyl-2-methyl phenol. 1H-NMR (400 MHz, DMSO-d6 ) : δ 9.11 (s, 1H) , 6.95 (t, J = 7.8 Hz, 1H) , 6.82 (d, J = 7.4 Hz, 1H) , 6.71 (d, J = 7.8 Hz, 1H) , 4.93 (t, J = 5.5 Hz, 1H) , 4.44 (d, J = 5.5 Hz, 2H) , 2.06 (s, 3H) .
Step B: 4-Bromo-3-hydroxymethyl-2-methyl phenol: 3-Hydroxymethyl-2-methyl phenol (113.9 g, 824.0 mmol) was dissolved in a mixture of acetonitrile (850 mL) and trifluoroacetic acid (750.0 mL, 9, 735 mmol) in a 3-neck 5-L flask under nitrogen. The reaction mixture was cooled to -33 ℃. N-bromosuccinimide (141 g, 791 mmol) was added over 15 minutes, with the temperature during addition in the range of-35 to -33 ℃. The reaction mixture was allowed to stir for an additional 15 min during which time the temperature decreased to -40 ℃. The cooling bath was removed, and potassium carbonate (741.0 g, 5, 358 mmol) diluted with water to a total of 1.0 L was added. Off-gassing was observed, and the temperature increased to 25 ℃. MTBE (1.5 L) was added, and the reaction mixture was transferred to a separatory funnel. The layers were separated. The aqueous layer was diluted with water (500 mL) and extracted with MTBE (1 L) + EtOAc (500 mL) , and then MTBE (500 mL) + EtOAc (250 mL) . The combined organic layers were washed with water (240 mL) and dried over sodium sulfate. The sodium sulfate was removed by filtration, washed with additional MTBE and concentrated under reduced pressure. MTBE (684 mL, 2 volumes) was added, and the suspension was heated to 40 ℃ to produce a homogeneous solution. The solution was allowed to cool to room temperature. Six volumes of heptane were added, and the suspension was stirred overnight. The suspension was filtered, and the crystals were washed with 4: 1 heptane: MTBE (500 mL) , followed by heptane (500 mL) . The solid was dried under vacuum, providing 4-bromo-3-hydroxymethyl-2-methyl phenol. 1H NMR (400 MHz, DMSO-d6) : δ 9.52 (s, 1H) , 7.21 (d, J = 8.6 Hz, 1H) , 6.71 (d, J = 8.6 Hz, 1H) , 4.88 (t, J = 5.1 Hz, 1H) , 4.59 (d, J = 5.1 Hz, 2H), 2.23 (s, 3H) .
Step C: 5-Hydroxy-4-methyl-3H-isobenzofuran-1-one: To a 2 L 3 neck flask equipped with overhead stirrer, N2 inlet, and condenser were charged 4-bromo-3-hydroxymethyl-2-methyl phenol (100 g, 461 mmol) , CuCN (83.0 g, 921 mmol) , and DMF (500 mL) . The solution was sparged with N2 for 15 min then heated to 145 ℃ to obtain a homogeneous solution. The solution was aged at 145 ℃ for 2h, then the reaction mixture was cooled to 95 ℃. 41.5 mL water was added (sparged with N2) , and the reaction aged for 20 h. The reaction was cooled to RT then the solids filtered through SOLKA-and the cake washed with 50 mL DMF. To a 3 L flask containing 1 L EtOAc was added the DMF filtrate. A precipitate coating formed in bottom of flask. The DMF/EtOAc suspension was filtered through SOLKA-and the cake was washed with 250 mL EtOAc. The resulting filtrate was washed with 5% brine solution (3x500 mL) . The aqueous layers were extracted with 500 mL EtOAc and the combined organics were dried over MgSO4, fitered and evaporated. The solids were slurried in 250 mL MTBE at RT then
filtered and washed with 100 mL MTBE. The solids were dried under vacuum at RT, providing 5-hydroxy-4-methyl-3H-isobenzofuran-1-one. 1H NMR (400 MHz, DMSO-d6 ) : δ 10.52 (s, 1H) , 7.51 (d, J = 8.3 Hz, 1H) , 6.99 (d, J = 8.3 Hz, 1H) , 5.28 (s, 2H) , 2.07 (s, 3H) .
Step D: 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate
5-Hydroxy-4-methyl-3H-isobenzofuran-1-one (46.8 g, 285 mmol) was suspended in dichloromethane (935 mL) in 2-L roundbottom flask equipped with overhead stirrer under nitrogen. Triethylamine (59.5 mL, 427 mmol) was added, and the reaction mixture was cooled in an ice bath to 3.8 ℃. Trifluoromethanesulfonic anhydride (67.4 mL, 399 mmol) was added via addition funnel over 50 min, keeping the temperature < 10 ℃. After stirring the reaction mixture for an additional 15 min, the reaction mixture was quenched with water (200 mL) , then stirred withKB (activated carbon, 25 g) for 15 min. The biphasic mixture was filtered over SOLKA-washing with additional dichloromethane, and transferred to a separatory funnel, whereupon it was diluted with additional water (300 mL) . The layers were separated, and the organic layer was washed with water (500 mL) and 10%brine (200 mL) . The dichloromethane solution was dried over sodium sulfate, filtered and evaporated. The orange-red solid was adsorbed onto silica gel (27.5 g) and eluted through a pad of silica gel (271 g) with 25% ethyl acetate/hexanes. The resulting solution was concentrated under vacuum with the product crystallizing during concentration. The suspension was filtered, the solid washed with heptane and dried under vacuum and nitrogen, providing trifluoromethanesulfonic acid 4-methyl-1-oxo-1, 3-dihydro-isobenzofuran-5-yl ester. 1H NMR (400 MHz, CDCl3) : δ 7.87 (d, J = 8.4 Hz, 1H) , 7.47 (d, J = 8.4 Hz, 1H), 5.32 (s, 2H) , 2.41 (s, 3H) .
INTERMEDIATE 3
5-Bromo-4-methyl-2-benzofuran-1 (3H) -one (598 mg, 4.47 mmol) (INTERMEDIATE 1) , potassium vinyl trifluoroborate (507 mg, 2.23 mmmol) , PdCl2 (dppf) -CH2Cl2 adduct (182 mg, 0.223 mmmol) , and TEA (0.622 mL, 4.47 mmol) were added to 10 mL ethanol in a 20 mL microwave tube. The tube was sealed and degassed, then heated to 140 ℃ for 20 min. Analysis by LC-MS showed product peak. The reaction mixture was diluted with ethyl acetate, washed with brine twice, dried and evaporated to dryness. The crude product was purified by MPLC chromatography using a 120gcolumn and 0-80% EtOAc/hexane solvent system to yield 5-ethenyl-4-methyl-2-benzofuran-1 (3H) -one. 1H NMR (500 MHz, CDCl3) : δ ppm 7.76 (d, J = 8Hz, 1H) , 7.03 (dd, J= 11, 17 Hz, 1H) , 5.84 (d, J= 17 Hz, 1H) , 5.55 (d, J = 11 Hz, 1H) , 5.29 (s, 2H) , 2.34 (s, 3H) ; LC-MS: M+1 = 175.
INTERMEDIATE 4
5-Ethenyl-4-methyl-2-benzofuran-1 (3H) -one (1.46g, 8.38 mmol) (INTERMEDIATE 30) was added to DCM (25 mL) at 0 ℃ then mCPBA (2.89 g, 16.8 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was washed once each with saturated aqueous Na2S2O3, NaHCO3, and brine. The organic layer was dried over Na2SO4, filtered, and evaporated to dryness. The crude material was purified by MPLC chromatography through 120g REDI-column eluting with 0-80%EtOAc/hexane solvent system to yield target 4-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one. 1H NMR (500 MHz, CDCl3) : δ ppm 7.77 (d, J = 8 Hz, 1H) , 7.43 (d, J = 8 Hz, 1H) , 5.30 (s, 2 H) , 4.12 (s, 1 H) , 3.27 (t, J = 4Hz, 1 H) , 2.735 (dd, J = 2.2, 5.5 Hz, 1H) , 2.43 (s, 3H) . LC-MS: M+1 = 191.
INTERMEDIATES 4A AND 4B (Method 1)
4A: 4-methyl-5- [ (2R) -oxiran-2-yl] -2-benzofuran-1 (3H) -one
4B: 4-methyl-5- [ (2S) -oxiran-2-yl] -2-benzofuran-1 (3H) -one
Racemic 4-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one (INTERMEDIATE 4) was resolved on aAD-H column (5x25cm) under supercritical fluid chromatography (SFC) conditions on a Berger MGIII preparative SFC instrument. The racemate was diluted to 50 mg/mL in 1:1 DCM:MeOH. The separation was accomplished using 10% EtOH/CO2 , flow rate 200 mL/min, 100 bar, 25 ℃. 500 μl injections were spaced every 2.12 mins. The fast epoxide (4-methyl-5- [ (2R) -oxiran-2-yl] -2-benzofuran-1(3H) -one, 4B) eluted first, and the slow epoxide (4-methyl-5- [ (2S) -oxiran-2-yl] -2-benzofuran-1 (3H) -one, 4A) eluted second.
Alternatively, the resolution could also be achieved using a mobile phase of 8%MeOH /98% CO2 with a flow rate of 100mL/min. In that case the sample was prepared by dissolving in methanol, 20mg/mL, and using a 1 mL volume per injection. After separation, the fractions were dried off via rotary evaporator at bath temperature 40 ℃.
The absolute stereochemistry of each enantiomer was inferred based on the X-ray crystal structure determination of a final compound made with 4B and by Mosher ester and Trost ester H NMR analysis of esters made starting from 4B. Both epoxide isomers find utility in the present invention.
INTERMEDIATE 4A (Method 2)
4-methyl-5- [ (2R) -oxiran-2-yl] -2-benzofuran-1 (3H) -one
Step A: 5- (1-Butoxy-vinyl) -4-methyl-3H-isobenzofuran-1-one: To a 1 L 3-neck flask was charged 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (63.0 g, 213 mmol) (INTERMEDIATE 2) , DMF (315 mL) , butyl vinyl ether (138 mL, 1063 mmol) ) then Et3N (35.6 mL, 255 mmol) . The solution was sparged with N2 for 20 min. To the solution was added Pd (OAc) 2 (1.19 g., 5.32 mmol) and DPPP (2.41 g., 5.85 mmol) and sparged for an additional 10 min then heated to 80 ℃. After aging for a 1 hr, the solution was cooled to less than 10 ℃ then quenched with 630 mL EtOAc and washed with 5% NH4Cl (2 x 315 mL) , 10% brine (2 x 315 mL) , dried over MgSO4, filtered, concentrated by rotary evaporation and flushed with EtOAc (3 x 100 mL) to remove excess butyl vinyl ether, providing crude 5- (1-butoxy-vinyl) -4-methyl-3H-isobenzofuran-1-one. 1H NMR (400 MHz, DMSO-d6 ) : δ 7.67 (d, J = 7.7 Hz, 1H) , 7.48 (d, J = 7.7 Hz, 1H) , 5.42 (s, 2H) , 4.54 (d, J = 2.3 Hz, 1H) , 4.27 (d, J = 2.3 Hz, 1H) , 3.85 (t, J = 6.4 Hz, 2H) , 2.27 (s, 3H) , 1.71-1.64 (m, 2H) , 1.46-1.37 (m, 2H) , 0.92 (t, J = 7.4 Hz, 3H) .
Step B: 5- (2-Bromo-acetyl) -4-methyl-3H-isobenzofuran-1-one: To a 1 L 3-neck flask equipped with overhead stirrer was added crude 5- (1-butoxy-vinyl) -4-methyl-3H-isobenzofuran-1-one (55.8 g) and THF (315 mL) . The solution was cooled to less than 5 ℃ after which water (79 mL) was added and the solution was maintained at less than 5 ℃. NBS (41.6 g) was then added portion-wise while maintaining Tmax = 19 ℃. The solution was then warmed to RT for 30 minutes. HBr (48%, 0.241 mL) was added and the reaction was aged at RT for approximately 1 h after which 236 mL water was then added to the batch. A water bath is used to maintain temp at 20 ℃. Another 315 mL of water was added (solvent composition 1:2 THF:water) and the slurry was cooled to 15 ℃. The resulting solids were filtered and washed with cold 1:2 THF:water (15 ℃) : 150 mL displacement wash followed by 100 mL slurry wash. The solids were dried under vacuum at RT to provide 5- (2-bromo-acetyl) -4-methyl-3H-isobenzofuran-1-one. 1H NMR (400 MHz, DMSO-d6 ) : δ 7.99 (d, J = 7.8 Hz, 1H) , 7.82 (d, J = 7.8 Hz, 1H) , 5.49 (s, 2H) , 4.92 (s, 2H) , 2.33 (s, 3H) .
Step C: 4-methyl-5- [ (2R) -oxiran-2-yl] -2-benzofuran-1 (3H) -one: 5- (2-Bromo-acetyl) -4-methyl-3H-isobenzofuran-1-one (48.8 g., 181 mmol) was charged to a 5 L 3 neck round bottom equipped with overhead stirrer, thermocouple, and heating mantle. 2-Propanol (1.22 L ) was added, followed by 610 mL of pH 7 0.1M potassium phosphate buffer. Buffer solution (610 mL) was charged to a 1.0L Erlenmeyer flask, and 2.44 g of NADP was added to the Erlenmeyer flask and swirled to dissolve. A reducing enzyme, KRED MIF-20 (2.44 g) (available from Codexis, Inc., 200 Penobscot Drive, Redwood City, CA 94063, www. codexis. com, tel. 1-650-421-8100) was added to the Erlenmeyer flask and the mixture was swirled to dissolve the solids. The resulting solution was added to the 5 L round bottom, which was then heated to 28 ℃ and aged for 6 hours, at which point the reaction was cooled to RT and triethylamine
(50.2 mL, 360 mmol) was added. The resulting solution was aged at 40 ℃ for 1 h. The light slurry solution was cooled to RT, after which 122 g NaCl was added. The solution was aged at RT then extracted with 1.22 L IPAc. The aqueous layer was re-extracted with 400 mL IPAc and the combined organics were washed with 400 mL 20% brine solution, dried over MgSO4, filtered and concentrated by rotary evaporation. The resulting solids were taken up in 100 mL IPAc (thick slurry) . Hexanes were added (400 mL) and the suspension aged at RT then filtered and washed w/5: 1 Hexanes: IPAc solution (150 mL) . The crystalline solids were dried under vacuum at RT to provide 4-methyl-5- [ (2R) -oxiran-2-yl]-2-benzofuran-1 (3H) -one. 1H NMR (400 MHz, CDCl3 ) : δ 7.75 (d, J = 8.1 Hz, 1H) , 7.42 (d, J = 8.1 Hz, 1H) , 5.28 (s, 2H) , 4.10 (dd, J = 4.0, 2.8, 1H) , 3.26 (dd, J = 5.6, 4.0, 1H) , 2.72 (dd, J = 5.6, 2.8, 1H) , 2.42 (s, 3H) .
INTERMEDIATE 4C
Step A: 4-Methyl-5- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) isobenzofuran-1 (3H) -one: A mixture of 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (INTERMEDIATE 4B, Step D, 5000 mg, 16.9 mmol) , KOAc (2000 mg, 20.3 mmol) , Pd (dppf) Cl2 (618 mg, 0.844 mmol) and bis(pinacolato) diboron (5144 mg, 20.3 mmol) in dioxane (56 mL) was stirred at 75 ℃ overnight under N2. The reaction solution was concentrated, and the residue was dissolved in EtOAc (100 mL) and filtered. The filtrate was washed with water (50 mL) . The organic layer was separated and concentrated, and the residue was purified by column chromatography (0-100% EtOAc/hex) to give the title compound. LC/MS: [ (M+1) ] + = 275; 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.7 Hz, 1H) , 7.74 (d, J = 7.5 Hz, 1H), 5.28 (s, 2H) , 2.54 (s, 3H) , 1.40 (s, 12H) .
Step B: 4-Methyl-5-vinyl-d3-isobenzofuran-1 (3H) -one: A microwave vial was charged with 4-methyl-5-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) isobenzofuran-1 (3H) -one (770 mg, 2.81 mmol) , Pd(PPh3) 2Cl2 (197 mg, 0.281 mmol) , toluene (9363 μl) , 20% Na2CO3/H2O (0.6 mL) , and vinyl-d3 bromide (4.21 mL, 1 M in THF, 4.21 mmol) . The reaction mixture was stirred at 90 ℃ for overnight under N2. The reaction solution was concentrated, and the residue was purified by column chromatography (EtOAc/hex 0-50%) to give 4-methyl-5-vinyl-d3-isobenzofuran-1 (3H) -one. LC/MS: [(M+1) ] + = 178; 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.5 Hz, 1H) , 7.75 (d, J = 7.5 Hz, 1H) , 5.29 (s, 2H), 2.54 (s, 3H) .
Step C: 4-Methyl-5- (oxiran-d3-2-yl) isobenzofuran-1 (3H) -one: To 4-methyl-5-vinyl-d3-isobenzofuran-1(3H) -one (300 mg, 1.69 mmol) in DCM (17 mL) was added mCPBA (584 mg, 3.39 mmol) at 0 ℃. The reaction mixture was stirred at rt overnight, and washed with saturated NaHCO3. The organic layer was dried and evaporated to dryness. The crude product was purified by column chromatograph (0-100%EtOAc/hex) to give 4-methyl-5- (oxiran-d3-2-yl) isobenzofuran-1 (3H) -one. LC/MS: [ (M+1) ] + = 194; 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.9 Hz, 1H) , 7.31 (d, J = 7.9 Hz, 1H) , 5.20 (s, 2H) , 2.35 (s, 3H) .
INTERMEDIATE 5
Step A: (E) -4-Methyl-5- (prop-1-en-1-yl) isobenzofuran-1 (3H ) -one: To Pd (dppf) Cl2 (0.220 g, 0.338 mmol) , K3PO4 (6.75 mL, 1 M in water, 6.75 mmol) in THF (22 mL) was added potassium (E) -trifluoro (prop-1-en-1-yl) borate (0.749 g, 5.06 mmol) and 4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (1.0 g, 3.38 mmol) . The reaction mixture was de-gassed for 10 min and the resulting mixture was stirred overnight at 70 ℃. The reaction mixture was cooled to room temperature and diluted with EtOAc and water. After separation of layers, the aqueous layer was extracted with EtOAc, and combined organic layers were washed with brine, dried over anhydrous MgSO4, filtered, concentrated and purified by silica gel column chromatography using (0-50%) acetone-hexanes as mobile phase to give the title compound. LC/MS: [ (M+1) ] + = 189.
Step B: 5- (1, 2-Dihydroxypropyl) -4-methylisobenzofuran-1 (3H) -one: To (E) -4-methyl-5- (prop-1-en-1-yl)isobenzofuran-1 (3H) -one (300 mg, 1.59 mmol) in acetonitrile/water (10/1, 18 mL) was added NMO (243 mg, 2.07 mmol) and potassium osmate (VI) dihydrate (29.4 mg, 0.080 mmol) at 0 ℃. The reaction mixture was allowed to warm to rt and stirred at rt for 2 h. TLC showed the reaction completed. The reaction mixture was filtered through a pad of silica gel, rinsed with 10% MeOH/DCM. The crude product was purified with column chromatography (0-10% MeOH/DCM) to give 5- (1, 2-dihydroxypropyl) -4-methylisobenzofuran-1 (3H) -one. LC/MS: [ (M+1) ] + = 223.
INTERMEDIATE 6
Step A: 5-prop-2-en-1-yl-2-benzofuran-1 (3H) -one: A mixture of 5-bromo-2-benzofuran-1 (3H) -one (15.0 g, 70.4 mmol) , allyl-tributyl-stannane (25.6 g, 77.5 mmol) , LiCl (11.8 g, 282 mmol) and Pd (PPh3) 4 (1.2 g, 1.0 mmol) in 100 mL toluene was heated under N2 between about 90 to about 100 ℃ overnight. After cooling to rt , the mixture was diluted with 250 mL EtOAc and filtered. The filtrate was washed with water and brine, dried over anhydrous Na2SO4 and concentrated to dryness. The residue was purified via column (DCM/PE = 1: 5) to give title compound.
Step B: 5- (2-hydroxyethyl) -2-benzofuran-1 (3H) -one: To a solution of 5-prop-2-en-1-yl-2-benzofuran-1(3H) -one (13.5 g, 45.2 mmol) in 200 mL DCM/MeOH (V/V = 1:1) was bubbled O3 at -78 ℃ for 30 min, and N2 was bubbled for another 15 min at -78 ℃. Then 20 mL of Me2S were added, and the mixture was stirred at r.t. overnight before concentrating to dryness. The residue was dissolved in MeOH (100 mL) and then cooled to 0 ℃. NaBH4 (5.90 g, 155 mmol) was added in portions. The resulting mixture was stirred at 0 ℃ for 1 h, then quenched with citric acid (aq.) and extracted three times with EtOAc. The
combined organic layers were washed with NaHCO3 (aq.) and brine, dried over anhydrous Na2SO4 and concentrated to dryness. The residue was purified via column chromatography (EtOAc/Petrol Ether = 1:5) to give title compound. 1H-NMR (400 MHz, CDCl3) δ ppm 7.86 (d, J = 7.8 Hz, 1H) , 7.41 (d, J = 7.8 Hz, 1H), 7.38 (s, 1H) , 5.29 (s, 2H) , 3.92~3.98 (m, 2H) , 3.01 (t, J = 6.4 Hz, 2H) .
Step C: 5- (2-hydroxyethyl) -6-iodo-2-benzofuran-1 (3H) -one: To a cooled (0 ℃) solution of 5- (2-hydroxyethyl) -2-benzofuran-1 (3H) -one (9.00 g, 50.6 mmol) in 100 mL of TfOH was added NIS (12.5 g, 55.6 mmol) , then the mixture was stirred at 0 ℃ for 2 hrs and then poured into ice-water (500 mL) . The solution was extracted three times with 500 mL of EtOAc and the combined organic layers were washed with saturated NaHCO3 and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (EtOAc/PE = 1:5) to give the desired 5- (2-hydroxyethyl) -6-iodo-2-benzofuran-1 (3H) -one and isomeric by-product 5- (2-hydroxyethyl) -4-iodo-2-benzofuran-1 (3H) -one. 1H-NMR (400 MHz, CDCl3) δ ppm 7.84 (d, J = 7.8 Hz, 1H) , 7.46 (d, J = 7.8 Hz, 1H), 5.09 (s, 2H) , 3.93 (q, J = 6.3 Hz, 2H) , 3.16 (t, J = 6.3 Hz, 2H) , 1.45 (t, J = 5.5 Hz, 1H) .
Step D: 5- (2-hydroxyethyl) -6-methyl-2-benzofuran-1 (3H) -one: To a flask charged with 5- (2-hydroxyethyl) -6-iodo-2-benzofuran-1 (3H) -one (6.00 g, 19.7 mmol) and a stir bar was added Pd2 (dba) 3 (452 mg, 0.493 mmol) , PPh3 (1 g, 4 mmol) and NMP (50 mL) . The mixture was purged with N2 and heated to 50 ℃ for 10 min, followed by addition of CuI (375 mg, 1.97 mmol) . After the mixture was heated for another10 min, Sn (CH3) 4 (5.30 g, 29.6 mmol) was added into the reaction, and it was heated to 120 ℃ for 2 h. After cooled to room temperature, the mixture was diluted with saturated NH4Cl (200 mL) and extracted with EtOAc (3 times 200 mL) . The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by prep-HPLC to give title compound. 1H-NMR (400 MHz, CDCl3) δ ppm 7.72 (s, 1H) , 7.33 (s, 1H) , 5.27 (s, 2H) , 3.93 (t, J = 6.3 Hz, 2H) , 3.01 (t, J = 6.3 Hz, 2H) , 2.44 (s, 3H) .
Step E: 2- (6-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl methanesulfonate: To a solution of 5-(2-hydroxyethyl) -6-methyl-2-benzofuran-1 (3H) -one (1.20 g, 6.25 mmol) and TEA (2.5 g, 25 mmol) in DCM (100 mL) was added MsCl (1.40 g, 12.5 mmol) at 0 ℃. The mixture was stirred at ambient temperature overnight and then was washed with water and brine. The organic layer was dried and concentrated to dryness. The collected title compound was used for the next step without any purification.
Step F: 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one: To a mixture of 2- (6-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl methanesulfonate (2.00 g, 7.41 mmol) and TEA (5 mL) in DCM (50 mL) was added DBU (5 mL) slowly at 0 ℃. The mixture was stirred at rt overnight, and then was diluted with 50 mL of DCM, washed with 2 N HCl in three times and brine. The organic layer was dried and concentrated to dryness. The residue was purified by prep-TLC to give 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one.
Step G: 6-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one: To a solution of 5-ethenyl-6-methyl-2-benzofuran-1 (3H) -one (1.00 g, 5.75 mmol) in 50 mL of DCM was slowly added mCPBA (3.50 g, 17.4 mmol) in 50 mL of DCM at 0 ℃. The mixture was warmed to room temperature, and stirred for 2 days. The mixture was washed with aqueous Na2SO3 until KI indicator paper didn’t change color. The organic
layer was washed with brine and then concentrated. The residue was purified via silica column to give 6-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one. LC-MS M+1 (calc. 191, found 191) .
INTERMEDIATES 6A and 6B
6A: (R) -6-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one and (S)-6-methyl-5- (oxiran-2-
yl)isobenzofuran-1 (3H) -one
6B: (S) -6-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one and (S) -6-methyl-5- (oxiran-2-
yl)isobenzofuran-1 (3H) -one
The title compounds were obtained by chiral SFC separation of the racemic 6-methyl-5-oxiran-2-yl-2-benzofuran-1 (3H) -one (INTERMEDIATE 6) using aAD column (250mmX50mm, 10um) ; mobile phase: A: supercritical CO2 , B: MeOH, A:B = 85:15 at 250ml/min. First peak to elute (6A) : HNMR 400 MHz CDCl3 δ 7.68 (s, 1H) , 7.36 (s, 1H) , 5.24 (d, J = 3.6 Hz, 2H) , 4.05 (dd, J = 2.8 Hz, 3.6 Hz, 1H) , 3.24 (dd, J = 4.0 Hz, 6.4 Hz, 1H) , 2.63 (dd, J = 2.8 Hz, 6.4 Hz, 1H) , 2.50 (s, 3H); second peak to elute (7B) : 400 MHz CDCl3 δ 7.68 (s, 1H) , 7.35 (s, 1H) , 5.24 (d, J = 3.6 Hz, 2H) , 4.05 (dd, J = 2.8 Hz, 3.6 Hz, 1H) , 3.24 (dd, J = 4.0 Hz, 6.4 Hz, 1H) , 2.63 (dd, J = 2.8 Hz, 6.4 Hz, 1H) , 2.50 (s, 3H) .
INTERMEDIATE 7
7A: (R) -5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine
7B: (S) -5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine
Step A: 5-Bromo-2- (1H-tetrazol-1-yl) pyridine: To a solution of 5-bromopyridin-2-amine (5.0 g, 28.9 mmol) in acetic acid (40 ml, 699 mmol) was added (diethoxymethoxy) ethane (7.70 ml, 46.2 mmol) , followed by sodium azide (2.82 g, 43.3 mmol) . The mixture was heated at 80 ℃ for 1 h, cooled to room temperature and diluted with water. Precipitate was collected by filtration and dried under high vacuum to provide the title compound.
Step B: 5-Ethenyl-2- (1H-tetrazol-1-yl) pyridine: To a stirring solution of 5-bromo-2- (1H-tetrazol-1-yl) pyridine (1.0 g, 4.42 mmol) , in EtOH (70 mL) were added bis [ (diphenylphosphino) ferrocene] dichloropalladium (II) , complex with dichloromethane (0.361 g, 0.442 mmol) , potassium vinyl trifluoroborate (1.18 g, 8.85 mmol, 2 equiv.) , triethylamine (1.23 mL, 8.85 mmol, 2 equiv) , and water (0.5 mL) . The reaction mixture was heated at reflux (90 ℃, oil bath) under N2. Upon
completion (1-2 h) as determined by reverse phase HPLC-MS and TLC (eluent: 10% ethyl acetate in hexane) , the mixture was cooled to room temperature, diluted with water. The organic layer was separated, and the aqueous was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, and concentrated. The crude material was chromatographed over a column of SiO2 (0-20%EtOAc in hexane as eluent) . Evaporation of the solvent yielded the title compound. LCMS [M+1] + =174.03.
Step C: 5- (Oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine
To a solution of 5-ethenyl-2- (1H-tetrazol-1-yl) pyridine (0.664 g, 3.83 mmol) in a 2:1 ratio of H2O: t-BuOH (30 mL) was added N-bromosuccinimide (0.751 g, 4.22 mmol) in portions over 5 min. The mixture was heated at 40 ℃ for 1 h, cooled to 5 ℃, made basic with sodium hydroxide aqueous solution (0.46 g in 5 mL of H2O, 11.50 mmol) , stirred for another 1 h at the same temperature, and poured into H2O (10 mL) . The product was precipitated out as white solid. The solid was collected by filtration, washed with water, and dried in vacuum. 1H NMR (500 MHz, DMSO-d6) , δ 10.17 (s, 1H) , 8.60 (d, J =1.4 Hz, 1H) , 8.04-7.99 (m, 2H) , 4.14 (dd, J = 2.7 Hz, J = 2.8 Hz, 1H) , 3.23 (t, J = 4.6 Hz, 1H) , 3.02 (dd, J = 25 Hz, 1H) ; LCMS [M+1] + = 190. Further chiral separation (AD-H 30x250mm, 50% MeOH/CO2, 70 mL/min, 100bar, 46 mg in MeOH/DCM) conducted by the separation and purification group afforded fast eluted 7A (R) -5- (oxiran-2-yl) -2-1H-tetrazol-1-yl) pyridine and slow eluted 7B (S) -5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine. Absolute chemistry was determined by using vibrational VCD spectroscopy with high confidence. Analysis was done comparing experimental data to the calculated VCD and IR spectra of the (R) and (S) compounds.
INTERMEDIATE 8
8A: (R) -2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl) pyrazine
8B: (S) -2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl) pyrazine
Step A: 2-Bromo-5- (1H-tetrazol-1-yl) pyrazine
To a solution of 5-bromopyrazin-2-amine (10.75 g, 57.5 mmol) in ethyl acetate (150 ml) was added trimethylsilyl 2, 2, 2-trifluoroacetate (16.88 ml, 98 mmol) . After the mixture was stirred for 5 min, triethoxymethane (17.21 ml, 103 mmol) was added. The resulting mixture was stirred for another five min, and this was followed by addition of zidotrimethylsilane (12.09 ml, 92 mmol) . Stirring continued at rt for 2 days, and the mixture was concentrated under reduced pressure. Recrystallization of the residue from ethyl acetate afforded 2-bromo-5- (1H-tetrazol-1-yl) pyrazine. LCMS [M+2+1] + = 228.98.
Step B: 2- (1H-tetrazol-1-yl) -5-vinylpyrazine: A solution of 2-bromo-5- (1H-tetrazol-1-yl) pyrazine (11.2 g, 49.3 mmol) , potassium vinyltrifluoroborate (13.22 g, 99.0 mmol) , 1, 1'-bis (diphenylphosphino) ferrocene-palladium (ii) dichloride dichloromethane complex (2.01 g, 2.47 mmol) , and TEA (13.75 ml, 99.0 mmol)
in ethanol (150 ml) was heated at reflux at 82 ℃ for 4 h. The reaction mixture was cooled to rt, and the precipitation was filtered off. The filtrate was concentrated, and the residue was purified by flash chromatography (Si , ethyl acetate in hexane: 35 to 45%) affording 2- (1H-tetrazol-1-yl) -5-vinylpyrazine LCMS [M+1] + = 175.10. The filter cake was stirred in DCM (50 mL) , and the solid was filtered off. The filtrate was concentrated to afford more 2- (1H-tetrazol-1-yl) -5-vinylpyrazine.
Step C: 2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl) pyrazine: To a suspension of 2- (1H-tetrazol-1-yl) -5-vinylpyrazine (6.7 g, 38.5 mmol) in t-BuOH: water (96 ml: 190 ml) was added N-bromosuccinimide (7.53 g, 42.3 mmol) in portion at RT. The mixture was heated at 50 ℃ for 1 h, and cooled to 0 ℃ in an ice bath. NaOH (4.61 g in 30 mL water, 115 mmol) was added dropwise, and the resulting mixture was stirred at the same temperature for 20 min. The white solid product was collected by filtration, washed with water, dried under vacuum to give 2- (1H-tetrazol-1-yl) -5-vinylpyrazine LCMS [M+1] + = 191.07. Chiral separation (AD-H 30x250mm, 50% MeOH/CO2, 70 mL/min, 100 bar, MeOH/DCM) conducted by the separation and purification group afforded fast eluted isomer 8A (S) -2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl)pyrazine and slow eluted isomer 8B (R) -2- (oxiran-2-yl) -5- (1H-tetrazol-1-yl) pyrazine. LCMS [M+1] + =191.10.
INTERMEDIATE 9
9A: (R) -1- (3- (oxiran-2-yl) phenyl)-1H-tetrazole
9B: (S) -1- (3- (oxiran-2-yl) phenyl) -1H-tetrazole
Step A: 1- (3-bromophenyl) -1H-tetrazole: A 10-20 mL Biotage InitiatorTM microwave reactor vessels equipped with magnetic stir bars and septum cap was charged with 3-bromoaniline (0.633 mL, 5.81 mmol) , AcOH (10 mL) , triethyl orthoformate (2.90 mL, 17.44 mmol) and NaN3 (1.134 g, 17.44 mmol) . The reaction mixtures were placed into a pre-heated 80 ℃ metal reaction block and stirred for 3 h. LCMS indicates complete conversion to the desired tetrazole. The reaction mixture was cooled to room temperature and diluted with deonized H2O. The aqueous medium was extracted with EtOAc, the organic layer was separated and washed with saturated aq. NaCl -dried (Na2SO4) , filtered, concentrated under reduced pressure and dried in vacuo to afford the title compound. LC/MS: [ (M+2) ] + = 227.
Step B: 1- (3-vinylphenyl) -1H-tetrazole: To a flask was charged 1- (3-bromophenyl) -1H-tetrazole (640 mg, 2.84 mmol) , potassium vinyltrifluoroborate (571 mg, 4.27 mmol) , PdCl2 (dppf) (104 mg, 0.142 mmol) . The flask was sealed, degassed, and filled with EtOH (14 mL) and Et3N (1.19 mL, 8.53 mmol) . The reaction mixture was heated at 85 ℃ for 3 h, and filtered to give the crude product, which was purified by column chromatography (0-100% EtOAc/hexanes) to give the title compound. LC/MS: [ (M+1) ] + = 173.
Step C: (S) -1- (3- (oxiran-2-yl) phenyl) -1H-tetrazole and (R) -1- (3- (oxiran-2-yl) phenyl) -1H-tetrazole: To 1-(3-vinylphenyl) -1H-tetrazole (444 mg, 2.58 mmol) in DCM (25 mL) was added mCPBA (1335 mg, 7.74 mmol) . The reaction mixture was stirred at rt overnight, and washed with NaHCO3, brine, dried and evaporated to give the crude product, which was purified by column chromatography (0-100%
EtOAc/hexanes) to afford the racemic compound. The racemate was submitted for SFC chiral separation with methodIC, 20% (2:1 MeOH:MeCN) /CO2 to give the Fast and Slow eluting enantiomers. 1H NMR (500 MHz, CDCl3) δ 9.05 (s, 1H) , 7.70-7.50 (m, 3H) , 4.01 (dd, J = 4.0, 2.6 Hz, 1H), 3.25 (dd, J = 5.5, 4.0 Hz, 1H) , 2.85 (dd, J = 5.5, 2.6 Hz, 1H) .
The following epoxides in Table 1 were prepared according to the method described for INTERMEDIATES 7 to 9.
Table 1
INTERMEDIATE 12
Step A: 2- (6- (1H-Tetrazol-1-yl) pyridin-3-yl) ethanol: To 5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine (INTERMEDIATE 7, 500 mg, 2.64 mmol) in ethanol (5.3 mL) was added 10 % Pd/C (101 mg, 0.952 mmol) and HCOONH4 (500 mg, 7.93 mmol) . The reaction mixture was vigorously stirred for 1.5 h, and filtered through a pad of silica gel. The filtrate was evaporated to give 2- (6- (1H-tetrazol-1-yl) pyridin-3-yl)ethanol. 1H NMR (500 MHz, CDCl3) δ 9.54 (s, 1H) , 8.43 (d, J = 2.0 Hz, 1H) , 8.02 (d, J = 8.3 Hz, 1H) , 7.90 (dd, J = 8.3, 2.0 Hz, 1H) , 3.91 (t, J = 6.3 Hz, 2H) , 2.96 (t, J = 6.3 Hz, 2H) .
Step B: 2- (6- (1H-Tetrazol-1-yl) pyridin-3-yl) acetaldehyde
To 2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) ethanol (100 mg, 0.523 mmol) in DCM (2.6 mL) was added Dess-Martin periodinane (333 mg, 0.785 mmol) . The mixture was vigorously stirred for 1.5 h, and diluted with 10% Na2S2O2, NaHCO3, and stirred for 20 min. The aqueous layer was extracted with DCM, and the
organic layers were washed with brine, dried, and concentrated to give 2- (6- (1H-tetrazol-1-yl) pyridin-3-yl)acetaldehyde. LC/MS: [ (M+1) ] + = 190.
INTERMEDIATE 13
Step A: 2-Chloro-6- (1H-tetrazol-1-yl) pyridazine: To a solution of 6-chloropyridazin-3-amine (10.0 g, 77.0 mmol) in ethyl acetate (200 mL) was added trimethylsilyl 2, 2, 2-trifluoroacetate (22.7 mL, 131 mmol) . The mixture was stirred for 5 min, and triethoxymethane (22.8 ml, 137 mmol) was added. After the resulting mixture was stirred for another 5 min, azidotrimethylsilane (16.2 ml, 124 mmol) was added. Stirring continued at rt for 2 days, and the reaction mixture was filtered, and the solid was rinsed with ethyl acetate to afford the title compound. LCMS [M+1] + = 183.
Step B: 3- (1H-tetrazol-1-yl) -6-vinylpyridazine: A solution of 2-chloro-6- (1H-tetrazol-1-yl) pyridazine (6.0 g, 32.9 mmol) , potassium vinyltrifluoroborate (6.6 g, 49.3 mmol) , 1, 1'-bis (di-tert-butylphosphino) ferrocene-palladium dichloride (2.14 g, 3.29 mmol) , and potassium phosphate aqueous solution (32.9 mL, 2 M, 65.7 mmol) in THF (160 ml) was heated at 80 ℃ overnight. The reaction mixture was allowed to cool to rt and separated. The aqueous phase was extracted with EtOAc, and the organic layers were dried over MgSO4, and concentrated, and the residue was purified by silica gel chromatography (EtOAc in hexane: 0 to 100%) to afford the title compound. LCMS [M+1-28] + = 147.
INTERMEDIATE 14
14A: (S) -4-Methoxy-6- (oxiran-2-yl)pyridine-3-carbonitrile
14B: (R) -4-Methoxy-6- (oxiran-2-yl) pyridine-3-carbonitrile
Step A: 5-Bromo-2-chloro-4-methoxypyridine: To a solution of 2-chloro-4-methoxypyridine (10.0 g, 69.7 mmol) in 50 mL of sulfuric acid at 0 ℃ was added NBS. The reaction mixture was allowed to stir and warm up to room temperature for 2 hour and then heated at 60 ℃ for 5 h. Then it was cooled to room temperature and neutralized with 1 N NaOH (pH~7) , diluted with water (50 mL) and the aqueous layer was extracted with ethyl acetate (2 × 100 mL) . The organic layers were washed with water (2 × 50 mL) , sat. NaHCO3, brine, dried over Mg2SO4 and concentrated to provide an oil, which was chromatographed. On elution with 0-25% EtOAc /hexanes the final product was obtained. 1H NMR (500 MHz, DMSO-d6) , δ 8.4 (s, 1H) , 7.29 (s, 1H) , 3.97 (s, 3H) ; LC/MS (M+1) + = 223.
Step B: 6-Chloro-4-methoxypyridine-3-carbonitrile: A solution of 5-bromo-2-chloro-4-methoxypyridine (5.0 g, 22.48 mmol) in DMF (80 mL) was purged with nitrogen for 15 min. At this point, Zn (CN) 2 (3.96 g, 33.7 mmol) and Pd (Ph3P) 4 (2.60 g, 2.25 mmol) were added, successively. The resulting suspension was stirred at 95 ℃ for 12 h under nitrogen atm. The reaction mixture was cooled to ambient temperature,
filtered to remove inorganic solid. The solvent (DMF) was evaporated to provide the crude residue as an oil, which was purified on silica gel and eluted with 0-30% ethyl acetate/hexanes to afford the product. 1H NMR (500 MHz, DMSO-d6) , δ 8.69 (s, 1H) , 7.50 (s, 1H) , 4.04 (s, 3H) ; LC/MS (M+1) + = 169.
Step C: 6-Ethenyl-4-methoxypyridine-3-carbonitrile: A 20 mL microwave tube was charged with 6-chloro-4-methoxypyridine-3-carbonitrile (200.0 mg, 1.2 mmol) , bis(diphenylphosphino) ferrocene] dichloropalladium (II) , complex with dichloromethane (97.0 mg, 0.12 mmol) , potassium vinyl trifluoroborate (318.0 mg, 2.37 mmol) , and triethylamine (0.33 mL, 2.37 mmol) , and EtOH (6 mL) . The microwave tube was evacuated and filled with nitrogen (two times) and heated to 140 ℃. After 1 h, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over Na2SO4. The extracts were concentrated and chromatographed over a column of SiO2 (0-30% EtOAc /hexanes as eluent) . Evaporation of the solvent yielded the title compound.
1H NMR (500 MHz, DMSO-d6) , δ 8.65 (s, 1H) , 6.89 (s, 1H) , 6.83 (dd, J = 10.7 Hz, 1H) , 6.42 (d, J = 7.3 Hz, 1H) , 5.70 (d, J = 10.6 Hz, 1H) 4.05 (s, 3H) ; LC/MS (M+1) + = 161.
Step D: 6- (2-Bromo-1-hydroxyethyl) -4-methoxypyridine-3-carbonitrile
A solution of 6-ethenyl-4-methoxypyridine-3-carbonitrile (80.0 mg, 0.499 mmol) in 1, 4-dioxane (8 mL) and H2O (4 mL) was treated with N-bromosuccinimide (89.0 mg, 0.499 mmol, 1.0 equiv) . The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was poured into H2O (8 mL) and extracted with EtOAc (3 × 30 mL) . The combined organic layers were washed with saturated aqueous NaCl (1 × 30 mL) , dried over Na2SO4. Evaporation of the solvent gave an oil that was purified over SiO2 (0-30 % EtOAc /hexanes as eluent) yielding 6- (2-bromo-1-hydroxyethyl) -4-methoxypyridine-3-carbonitrile. 1H NMR (500 MHz, DMSO-d6) , δ 8.65 (s, 1H) , 7.19 (s, 1H) , 5.05 (t, J = 5.4 Hz, 1H) , 4.05 (s, 3H) , 3.85 (dd, J = 4.5 Hz, 1H) , 3.75 (dd, J = 6.1 Hz, 1H) ; LC/MS (M+1) + = 241.
Step E: 14B: (R) -4-methoxy-6- (oxiran-2-yl) pyridine-3-carbonitrile and 14A: (S) -4-methoxy-6- (oxiran-2- yl)pyridine-3-carbonitrile:A solution of 6- (2-bromo-1-hydroxyethyl) -4-methoxypyridine-3-carbonitrile (74.0 mg, 0.288 mmol) in anhydrous methanol (7 mL) was treated with sodium carbonate (61.0 mg, 0.576 mmol, 2.0 equiv) , and allowed to stir at room temperature overnight. The solvent was evaporated. The residue was taken up in EtOAc (30 mL) and washed with water and brine. After drying over Na2SO4, the organic layer was removed and the residue was purified over SiO2 (10-45% EtOAc/hexanes as eluent) to yield 4-methoxy-6- (oxiran-2-yl) pyridine-3-carbonitrile. 1H NMR (500 MHz, DMSO-d6) , δ 8.64 (s, 1H) , 6.87 (s, 1H) , 4.08 (dd, J = 2.6 Hz, J = 2.3 Hz, 1H) , 4.03 (s, 3H) , 3.26 (dd, J = 4.6 Hz, J = 5.4 Hz, 1H) , 2.87 (dd, J = 2.2 Hz, J = 2.4 Hz, 1H) ; LC/MS (M+1) + = 177.
Resolution of the epoxides was carried out (preparative SFC, 160 mL/min., 10% MeOH in SC CO2, AD-H) to provide:
Fast Eluting Isomer 14A: (M+1) + = 177.
Slow Eluting Isomer 14B: (M+1) + = 177.
Absolute chemistry was determined by using VCD spectroscopy with high confidence. Analysis was done comparing experimental data to the calculated VCD and IR spectra of the (R) and (S) compounds.
INTERMEDIATE 15
tert-Butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate is commercially available from a number of vendors, for example, Shanghai AQ BioPharma Co., Ltd, catalog #ABP1882. Alternatively, it may be prepared in various ways, including the procedure described below:
Step A: 1-tert-Butyl 4-methyl 4- (cyanomethyl) piperidine-1, 4-dicarboxylate: To a solution of commercially available 1-tert-butyl 4-methyl piperidine-1, 4-dicarboxylate (200 g, 0.82 mol) in anhydrous THF (2 L) was added LDA (2M in THF, 575 mL, 1.15 mol) drop-wise at -65 ℃ under N2. The mixture was stirred at -65 ℃ for 1.5 h. To the mixture was added bromoacetonitrile (148 g, 1.23 mol) in anhydrous THF (500 mL) at -65 ℃. The mixture was stirred at -65 ℃ for 1 h, then warmed up to room temperature and stirred overnight. The reaction was quenched with water (800 mL) at 0 ℃ and the combined reaction mixture was concentrated in vacuum to give a crude product, which was extracted with ethyl acetate (1 L x 3) . The combined organic phases were washed with brine (1 L) and dried over Na2SO4. The organic layer was filtered and the filtrate was concentrated in vacuum to give a crude product, which was purified by column chromatography on silica gel eluting with petroleum ether/ethyl acetate (from petroleum ether to 2/1 ) to give title compound. 1H-NMR (400 MHz, CDCl3) δ 3.900-3.750 (m, 5H) , 3.120-3.000 (m, 2H) , 2.612-2.562 (m, 2H) , 2.190-2.111 (m, 2H) , 1.590-1.502 (m, 2H) , 1.402 (s, 9H).
Step B: tert-Butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: A suspension of 1-tert-butyl 4-methyl 4-(cyanomethyl) piperidine-1, 4-dicarboxylate (70.0 g, 247.9 mmol) and Raney Ni (60 g) in MeOH (1500 mL) and NH3·H2O (80 mL) was stirred at 2 MPa of hydrogen at 50 ℃ for 18 h. The reaction mixture was filtered through a pad ofand the filtrate was concentrated under vacuum to give a crude product, which was washed with ethyl acetate (200 mL) to give title compound. 1H-NMR (400 MHz, CDCl3) δ 6.05 (s, 1H) , 4.0 (s, 2H) , 3.37-3.34 (m, 2H) , 3.02-2.96 (m, 2H) , 2.08-2.05 (m, 2H) , 1.88-1.87 (m, 2H), 1.51-1.41 (m, 11H) .
INTERMEDIATE 16
Step A: tert-butyl 4- (2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate: Into a 10-L 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a suspension of NaH (74.0 g, 2.16 mol 1.05 equiv, 70%) in tetrahydrofuran (2000 mL) at 0 ℃, then added dropwise ethyl 2-(diethoxyphosphoryl) acetate (514 g, 2.06 mol, 1.05 equiv, 98%) with stirring at 0 ℃. This was followed by the addition of a solution of tert-butyl 4-oxopiperidine-1-carboxylate (400 g, 1.97 mol, 1.00 equiv, 98%) in tetrahydrofuran (1200 mL) dropwise with stirring at 0℃. The resulting solution was stirred for 60 min at room temperature and then quenched by the addition of 2000 mL of water. The resulting
solution was extracted with 2x1000 mL of ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate and concentrated under vacuum. The residue was washed with 1x1000 mL of hexane and dried. This resulted in tert-butyl 4- (2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate.
Step B: tert-butyl 4- (2-ethoxy-2-oxoethyl) -4- (nitromethyl) piperidine-1-carboxylate: Into a 3000-mL 4-necked round-bottom flask were potassium carbonate (93.2 g, 662 mmol, 0.50 equiv) and DMSO (2000 mL). The resulting solution was heated to 80 ℃. This was followed by the addition of tert-butyl 4- (2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate (368 g, 1.30 mol, 1.00 equiv, 95%) and CH3 NO2 (417 g, 6.70 mol, 5.00 equiv, 98%) slowly. The resulting solution was stirred for 120 min at 90 ℃. After cooled to room temperature, the reaction mixture was adjusted to Ph 5 with HCl (0.5 mol/L) and diluted with 2000 mL of water. The resulting solution was extracted with 3x1500 mL of ether. The organic layers were combined, washed with 1x2000 mL of water and 1x2000 mL of saturated brine, dried and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:20~1:15~1:10) to afford the title compound.
Step C: 3-oxo-2, 8-diaza-spiro [4, 5] decane-8-carboxylic acid tert-butylester: A mixture of tert-butyl 4- (2-ethoxy-2-oxoethyl) -4- (nitromethyl) piperidine-1-carboxylate (330 g, 990 mmol, 1.00 equiv, 99%) and Ni (40 g, 0.15 equiv) in ethanol (1200 mL) was stirred for 24 h under a hydrogen atmosphere at room temperature. The solid was filtered out. The filtrate was concentrated under vacuum. The crude product was purified by re-crystallization from ether to afford the title compound. LC-MS (ES, m/z) : 199 [M+H] +; H-NMR (400MHz, CDCl3, ppm) : 1.447-1.476 (9H, s) , 1.597-1.673 (4H, m, J = 30.4Hz) , 2.235 (2H, s) , 3.226 (2H, s) , 3.284-3.348 (2H, m, J = 25.6 Hz) , 3.507-3.567 (2H, m, J = 24 Hz) , 6.048 (1H, s) .
INTERMEDIATE 17
Step A: 1-tert-Butyl 4-methyl 4- (2-methylallyl) piperidine-1, 4-dicarboxylate: A solution of N-Boc-piperidine-4-carboxylic acid methyl ester (2.00 g, 8.22 mmol) in THF (40 mL) was cooled to -78 ℃ . Under nitrogen, a 2.0 M THF solution of LDA (6.17 mL, 12.3 mmol) was added dropwise. The reaction mixture was stirred at -78 ℃ for 30 minutes before a solution of 3-bromo-2-methylpropene (1.60 g, 11.9 mmol) in THF (2 mL) was added. After the reaction was stirred for 1 hour at this temperature, a sample was taken for LC-MS analysis and it showed that the reaction was completed. The reaction was quenched by adding saturated ammonium chloride solution (5 mL) and the mixture was allowed to warm up to room temperature. The mixture was then extracted with EtOAc (50 mL twice) . The combined organic layers were washed with brine (30 mL) , dried over anhydrous sodium sulfate and filtered. The filtrates were concentrated and the crude product was purified by column chromatography eluting with 0-30%ethyl acetate/hexane to give title compound. LC-MS (IE, m/z) : 242.21 [M-56+1] +.
Step B: 1-tert-Butyl 4-methyl 4- (2-oxopropyl) piperidine-1, 4-dicarboxylate: To a solution of 1-tert-butyl 4-methyl 4- (2-methylallyl) piperidine-1, 4-dicarboxylate (2.2 g, 7.4 mmol) in dioxane/water (60 mL, 1/1) under nitrogen was added osmium tetroxide (0.038g, 0.15 mmol) and sodium periodate (2.88 g, 13.5
mmol) . The mixture was stirred at room temperature for 3 hours. The mixture was then diluted with dichloromethane (50 mL) , washed with 20% Na2S2O3 (20 mL) . The organic layers were combined and washed with brine (20 mL) , dried over anhydrous sodium sulfate, and filtered. The filtrates were concentrated and the residue was purified by column chromatography eluting with 0-60% ethyl acetate/hexane to afford 1-tert-butyl 4-methyl 4- (2-oxopropyl) piperidine-1, 4-dicarboxylate. LC-MS (IE, m/z) : 322.26 (M+23) +.
Step C: tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: 1-tert-Butyl 4-methyl 4- (2-oxopropyl) piperidine-1, 4-dicarboxylate (1.15 g, 3.84 mmol) in methanol (25 mL) was treated with ammonium acetate (3.85 g, 49.9 mmol) , sodium cyanoborohydride (0.681 g, 10.83 mmol) and magnesium sulfate (2.54 g, 21.1 mmol) . The mixture was heated at 80 ℃ in a sealed tube for 12 hours. The reaction mixture was filtered through a pad of and the filter cake was washed with methanol. The filtrates were then concentrated and the residue was purified by column chromatography eluting with 0-10% methanol/ethyl acetate to afford the title compound. LC-MS (IE, m/z) : 291.27 (M+23) +.
INTERMEDIATE 17A and 17B
Fast eluting 17A: (S) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate; (R) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate
Slow eluting 17B: (R) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate; (R) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate
tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate was subjected to SFC purification. The two enantiomers were resolved onIA column eluting with 30%MeOH: MeCN (2: 1) /CO2 (100 bar, 35℃) . The faster eluting isomer was determined to be (S) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate and the slower eluting isomer was (R) -tert-Butyl 3-methyl-1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate based on VCD spectroscopy analysis. LC-MS (IE, m/z) : 291 (M+23) +.
INTERMEDIATE 18
Step A: tert-butyl 4- (2-ethoxy-2-oxoethyl) -4-hydroxypiperidine-1-carboxylate: To a solution of lithium bis(trimethylsilyl) amide (120 mL, 1.0 M solution in THF, 0.12 mol) in THF (120 mL) at -78 ℃ was added ethyl acetate (13 mL) ; then, a solution of tert-butyl 4-oxopiperidine-1-carboxylate (20 g, 0.1 mol)
in THF (80 mL) was added at -78 ℃. After the addition, the mixture was warmed up to 0 ℃ and stirred for another 2 h. The aqueous layer was extracted with ethyl acetate; the organic phase was washed with brine, dried over Na2SO4 and concentrated to afford the crude title compound.
Step B: 2- (1- (tert-butoxycarbonyl) -4-hydroxypiperidin-4-yl) acetic acid: A solution of tert-butyl 4- (2-ethoxy-2-oxoethyl) -4-hydroxypiperidine-1-carboxylate (30.0 g, 0.105 mol) in methanol (130 mL) and 2N NaOH solution (100 mL, 0.2 mol) was stirred at 25 ℃ for 1.5 h, then the mixture was evaporated and the aqueous layer was extracted with ethyl acetate. The water phase was adjusted to pH 6 with 2N HCl, the aqueous layer was extracted with ethyl acetate and then the organic phase was washed with brine, dried over Na2SO4 and concentrated to afford the crude title compound.
Step C: tert-butyl 2-oxo-1-oxa-3, 8-diazaspiro [4.5] decane-8-carboxylate: A mixture of 2- (1- (tert-butoxycarbonyl) -4-hydroxypiperidin-4-yl) acetic acid (22 g, 0.085 mol) , DPPA (30 g, 0.11 mol) , Et3N (150 mL) in Toluene (400 mL) was stirred at 105 ℃ under nitrogen for 12 h. The reaction mixture was quenched by the addition of the saturated aqueous NaHCO3, the organic phase was washed with brine, dried over Na2SO4, the mixture was concentrated to remove most of toluene, then ether was added and filtered. The filter cake was washed with ether and the solid was dried under vacuum to afford the pure title compound. 1H NMR (300 MHz, CDCl3) δ : 5.35 (brs, 1H) , 3.83-3.85 (m, 2H) , 3.26-3.35 (m, 4H) , 1.93-1.97 (m, 2H) , 1.68-1.75 (m, 2H) , 1.46 (s, 9H) .
INTERMEDIATE 19
Step A: 1-tert-butyl 4-methyl 4- (allyloxy) piperidine-1, 4-dicarboxylate: NaH (0.92 g, 15.4 mol, 60%dispersion in mineral oil) was added the five portions to a stirred solution of compound 1-tert-butyl 4-methyl 4-hydroxypiperidine-1, 4-dicarboxylate (2 g, 7.7 mmol) being cooled to 0 ℃ in DMF (20 mL) . After the mixture was stirred at 0 ℃, the 3-allyl bromide (1.2 g, 10 mmol) was added, dropwise. The mixture was stirred at rt for 16h. The reaction mixture was quenched by the addition of the saturated aqueous NH4Cl and evaporated to afford the crude product. The crude product was purified by column chromatography on silica gel eluted with (PE/EA 50:1→30:1→15:1) to give the title compound.
Step B: 1-tert-butyl 4-methyl 4- (2-oxoethoxy) piperidine-1, 4-dicarboxylate: To a solution of 1-tert-butyl 4-methyl 4- (allyloxy) piperidine-1, 4-dicarboxylate (1.2 g, 4 mmol) in MeOH (30 mL) was added osmium tetroxide (30 uL, 0.006 mmol, 0.81 g/mL H2O) and sodium periodate (16 ml, 16 mmol, 1M) . The mixture was allowed to stir at rt for 16 hours. The mixture was quenched with Na2S2O3 (50 mg ) , extracted with ethyl acetate (20 mL X 3) , dried over Na2SO4 and concentrated to afford the crude product, which was further purified by column chromatography on silica gel eluted with (PE /EA 20:1→10:1→5:1→1:1) to give the title compound.
Step C: 1-tert-butyl 4-methyl 4- (2- (dibenzylamino) ethoxy) piperidine-1, 4-dicarboxylate:
To a stirred solution of 1-tert-butyl 4-methyl 4- (2-oxoethoxy) piperidine-1, 4-dicarboxylate (0.3 g, 1 mmol) in DCE (5 mL) was added dibenzyl amine (0.3 g, 1.5 mmol) , the resulted mixture was stirred at room
temperature for 1h. Then sodium triacetoxyborohydride (0.42 g, 2 mmol) was added to the reaction mixture, the reaction mixture was stirred for further 4h at room temperature. The mixture was quenched with water (5 mL) , extracted with DCM (5 mL x 3) , the combined organic portions were concentrated and purified by column chromatography gel eluted with (PE /EA 5:1→2:1→1:1) to give the title compound.
Step D: tert-butyl 5-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate:
A mixture of 1-tert-butyl 4-methyl 4- (2- (dibenzylamino) ethoxy) piperidine-1, 4-dicarboxylate (290 mg, 0.6 mmol) and 10% palladium hydroxide on carbon (20%, w/w, 30 mg) in MeOH (10 mL) was hydrogenated under 40 psi of hydrogen at 30 ℃ overnight. Then the mixture was cooled to roomtemperature and the catalyst was filtered off. The filtrate was concentrated in vacuo to give title compound.
INTERMEDIATE 20
Step A: tert-Butyl 4-oxopiperidine-1-carboxylate: To a solution of piperidin-4-one (1.0 mol, 100.0 g) and NaHCO3 (1.6 mmol, 100 g) in H2O (1000 mL) was added (BOC) 2O (1.2 mol, 191.6 g) , the reaction was stirred at 50 ℃ overnight. The residue was extracted with EtOAc (3×400 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to give tert-butyl 4-oxopiperidine-1-carboxylate. 1H NMR (300 MHz, CDCl3) δ : 1.49 (s, 9H) , 2.43 (t, J1 = 6.0 Hz, J2 = 6.0 Hz, 4H), 3.71 (t, J1 = 6.0 Hz, J2 = 6.0 Hz, 4H) .
Step B: tert-Butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate: To a mixture of tert-butyl 4-oxopiperidine-1-carboxylate (0.1 mol) and nitro-methane (0.1 mol) in methanol (200 mL) was added sodium methanolate (0.11 mol) at RT and the reaction was stirred for 1 h at room temperature. The solvent was evaporated. The residue was taken up into water, neutralized with acetic acid, extracted twice with EtOAc. The separated organic layer was washed with water, dried, filtered and evaporated to provide tert-butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate. 1H NMR (300 MHz, CDCl3) δ : 1.46 (s, 9H) , 1.61 (t, J1 = 5.4 Hz, J2 = 5.4 Hz, 4H) , 2.92 (s, 1H) , 3.19 (t, J1 = 12.0 Hz, J2 = 12.0 Hz, 2H), 3.94 (t, J1 = 6.9 Hz, J2 = 6.9 Hz, 2H) , 4.43 (s, 2H) .
Step C: tert-Butyl 4- (aminomethyl) -4-hydroxypiperidine-1-carboxylate: The mixture of tert-butyl 4-hydroxy-4- (nitromethyl) piperidine-1-carboxylate (15.0 g, 0.058 mol) and acetic acid (12 mL) in methanol (180 mL) was hydrogenated at rt with palladium-on-carbon (10%, 1.5 g) as a catalyst. After uptake of hydrogen, the catalyst was filtered off and the filtrate was evaporated. The residue was taken up into ice water, alkalized with potassium hydroxide, extracted twice with EtOAc, dried over Na2SO4, filtered and concentrated to give tert-butyl 4- (aminomethyl) -4-hydroxypiperidine-1-carboxylate.
Step D: tert-Butyl 4- ( (2-chloroacetamido) methyl) -4-hydroxypiperidine-1-carboxylate: The mixture of tert-butyl 4- (aminomethyl) -4-hydroxypiperidine-1-carboxylate (10.0 g, 45 mmol) , chloroacetyl chloride (6 mL, 64 mmol) and K2CO3 (14.0 g, 95 mmol) in EtOAc/H2O (100 mL/100 mL) was stirred for 1 h at 0 ℃. The crude mixture was extracted with EtOAc (2×300 mL) . The combined organics were dried over Na2SO4, filtered and concentrated in vacuo to give tert-butyl 4- ( (2-chloroacetamido) methyl) -4-
hydroxypiperidine-1-carboxylate. 1H NMR (300 MHz, CDCl3) δ : 1.45 (s, 9H) , 1.53 (d, 4H) , 2.59 (s, 1H), 3.21 (s, 2H) , 3.35 (s, 2H) , 3.78 (d, J = 18.0 Hz, 2H) , 4.13 (s, 2H) , 6.99 (s, 1H) .
Step E: tert-Butyl 3-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate: To a mixture of potassium tert-butoxide (31.8 g, 283 mmol) and tert-butanol (500 mL) was added tert-butyl 4- ( (2-chloroacetamido) methyl) -4-hydroxypiperidine-1-carboxylate (41.9 g, 141 mmol) in THF (300 mL) over 40 minutes and the resulting mixture was continued to stir for 1 h at room temperature before it was concentrated. The residue was diluted with EtOAc and water, the organic layer was separated, washed with brine, and concentrated to provide tert-butyl 3-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate. 1H NMR (300 MHz, CDCl3) δ : 1.41 (s, 9H) , 1.52 (s, 2H) , 1.90 (d, J = 12.0 Hz, 2H) , 2.59 (s, 1H) , 3.12 (m, 2H), 3.25 (s, 2H) , 3.84 (d, J = 6.4 Hz, 2H) , 4.17 (s, 2H) , 6.12 (s, 1H) .
Step F: tert-Butyl 1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate: To a solution of tert-butyl 3-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate (16.0 g, 60 mmol) in THF (70 mL) was added tetrahydrofuran-borane (250 mL, 250 mmol) at room temperature. The reaction mixture was refluxed for 2 h and the solvent was removed under the reduced presure. To the resulting mixture was added MeOH and N1, N1, N2, N2-tetramethylethane-1, 2-diamine and the reaction was stirred at 78 ℃ overnight. The reaction was concentrated and the residue was diluted with EtOAc and water. The organic layer was separated, washed with brine, and concentrated in vacuo to give tert-butyl 1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate. 1H NMR (300 MHz, CDCl3) δ : 1.45 (s, 9H) , 1.61 (s, 2H) , 1.93 (d, J = 12.0 Hz, 2H) , 2.67 (s, 2H) , 2.83 (m, 2H) , 3.16 (t, J1 = 9.0 Hz, J2 = 12.0 Hz, 2H) , 3.65 (m, 4H) .
INTERMEDIATE 21
Step A: methyl piperidine-4-carboxylate: To a solution of piperidine-4-carboxylic acid (400 g, 3.10 mol) in MeOH (3.5 L) was added SOCl2 (550g, 4.65mol) dropwise at RT. The reaction mixture was then heated to 40-50℃ overnight. The next day, after TLC confirmed that the starting material was no longer present, the solvent was removed on a rotary evaporator to provide the title compound.
Step B: piperidine-4-carboxamide To a mixture of methyl piperidine-4-carboxylate (590g, 3.10mol) in NH3/MeOH (4.5L, V/V = 40%) was added K2CO3 (5.0g, 36mmol) . The resulting reaction mixture was heated to 140-150℃ overnight. The next day the solvent was removed on the rotary evaporator, and the crude product recrystallized by CH3OH/EtOAc to afford the title compound.
Step C: tert-butyl 4-cyanopiperidine-1-carboxylate To POCl3 (400 mL) was added piperidine-4-carboxamide (100 g, 0.78 mol) in portion. The reaction mixture was then heated to reflux for 3 h, cooled to RT, and filtered. The filtrate was evaporated on a vacuum distillation plant, and the residue was diluted with 250 mL CH2Cl2, and poured into 200 mL ice-water, stirred for 30 min and pH was adjusted to 9-10 by 40% NaOH (175 g) . Then 300 mL acetone was added to make the reaction mixture homogeneous, and (Boc) 2O (202 g, 0.938mol) was added (control pH = 9-10) . After addition the reaction mixture was stirred at rt for 1 h. H2O (1 L) was added to make the salt dissolve, and the organic phase was separated. The aqueous phase was extracted by EtOAc (500mL x 2) . The organic phases were combined, dried by
Na2SO4, and evaporated on a rotary evaporator to get the crude product, which was passed through a silica gel column to provide the title compound. 1H NMR (300 MHz, CDCl3) δ 3.69-3.61 (m, 2H) , 3.37-3.29 (m, 2H) , 2.81-2.78 (m, 1H) . 1.88-1.77 (m, 1H) , 1.45 (s, 9H) .
Step D: tert-butyl 4-cyano-4- ( (tosyloxy) methyl) piperidine-1-carboxylate: Diisopropylamine (58 g) was added to anhydrous THF (600 mL) under N2 protection, n-BuLi (2.5 M, 230 mL, 1.2 eq) was added at -40℃~-50 ℃ in 1 , then the mixture was stirred at -30℃~-40 ℃ for 30 min. tert-Butyl 4-cyanopiperidine-1-carboxylate (100 g, 476 mmol, 1 eq.) in 400 mL anhydrous THF was added to the reaction mixture at about -60℃ to about -70 ℃ in 1 h, then stirred at about -50℃~to about 60 ℃ for 30 min. In another 2 L three-neck flask, (HCHO) n (58 g, 4eq ) was heated to get HCHO gas to pass through 1600 mL anhydrous THF to get a milky solution. The milky solution was added to the reaction mixture at about -40℃ to about -50 ℃ in 30 min and then warmed to -5℃ slowly. The reaction mixture was quenched with 50 mL H2O. TsCl (109 g, 571 mmol, 1.2 eq.) was added to the reaction mixture, followed by Et3N (96 g, 952 mmol, 2 eq.) within 30 min. The mixture was stirred overnight at rt. The next day the solvent was removed on the rotary evaporator, and the residue was passed through a silica gel column to yield the title compound. 1H NMR (300 MHz, CDCl3) δ 7.84-7.81 (m, 2H) , 7.40-7.37 (m, 2H) , 4.14 (m, 2H) , 3.99 (m, 2H), 3.01 (m, 2H) , 2.48 (s, 3H) , 1.92-1.88 (m, 2H) , 1.53-1.47 (m, 2H) , 1.45 (s, 9H) .
Step E: tert-butyl 2, 7-diazaspiro [3.5] nonane-7-carboxylate oxalate To a solution of tert-butyl 4-cyano-4- ( (tosyloxy) methyl) piperidine-1-carboxylate (41 g, 104 mmol, 1 eq.) in anhydrous THF (600 mL) was added LiAlH4 (4.7 g, 12 5mmol, 1.2 eq.) in portion at 5-7 ℃, then it was stirred at 5-7 ℃ for 10 min. TLC confirmed that the raw material disappeared, then 4.7 g H2O, 4.7 g 15% NaOH, and 14.1 g H2O was added to quench the reaction. The mixture was filtered and the filtrate was washed by EtOAc (250 mL x 6) . The solvent was removed on the rotary evaporator to get the crude product, which was then dissolved in 45 mL CH3OH, added the oxalic acid solution (13g in 26 mL CH3OH) , and stirred for 30 min. Anhydrous ether (500 mL) was added, and white solid appeared, which was filtered, washed by ether (100 mL x 3) to get the title compound. 1H NMR (300 MHz, D2O-d6) δ 3.92 (s, 4H) , 3.39-3.36 (t, 4H) , 1.84-1.80 (q, 4H) , 1.42 (s, 9H) .
INTERMEDIATE 22
Step A: 2, 8-diazaspiro [4.5] decan-1-one hydrochloride: To a solution of tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (92 g, 0.36 mol) in CH2Cl2 (1 L) was slowly added a 4 M HCl solution (500 mL) . The mixture was stirred for 8 h at RT. The mixture was concentrated under vacuum to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H) , 9.02 (s, 1H) , 7.72 (s, 1H) , 3.30-3.20 (m, 2H) , 3.16 (m, J = 6.8Hz, 2H) , 2.98-2.85 (m, 2H) , 1.96 (m, J = 6.8Hz, 2H) , 1.90-1.80 (m, 2H), 1.55 (d, J = 14 Hz, 2H) .
Step B: (R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8- diazaspiro [4.5] decan-1-one: To a solution of 2, 8-diazaspiro [4.5] decan-1-one hydrochloride (68 g, 0.35 mol) in ethanol (1.5 L) was added Et3N (55 mL) . The mixture was stirred for 2 hours. Then (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (65 g, 0.34 mol) was added. The mixture was heated to reflux for 40 h. After filtration, the solid was collected to provide the title compound. The filtrate was concentrated and purified by SFC separation to provide additional title compound. 1H NMR (400 Hz, CDCl3) δ 7.82-7.75 (m, 2H) , 6.00 (s, 1H) , 5.24 (s, 2H) , 5.08 (dd, J = 2.1 Hz and 10.4 Hz, 1H) , 4.21 (s, 1H), 3.35 (t, J = 6.8 Hz, 2H) , 3.17-3.14 (m, 1H) , 2.85-2.82 (m, 1H) , 2.57 (dd, J = 2.1 Hz and 10.4 Hz, 1H), 2.49 (t, J = 8.8 Hz, 1H) , 2.37 (t, J = 10.8 Hz, 1H) , 2.27 (s, 3H) , 2.23 (J = 6.8 Hz, 1H) , 2.09-1.98 (m, 4H), 1.52 (t, J = 12.8 Hz, 2H) .
INTERMEDIATE 23
Step A: 1-oxa-4, 9-diazaspiro [5.5] undecan-5-one: The mixture of tert-butyl 5-oxo-1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate (1.00 g, 3.70 mmol) in DCM/TFA (1: 1, 30 mL) was stirred at room temperature for 1 hour. The mixture was concentrated to afford the title compound as a TFA salt.
Step B: (R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -1-oxa-4, 9- diazaspiro [5.5] undecan-5-one: The mixture of 1-oxa-4, 9-diazaspiro [5.5] undecan-5-one (1.00 g, 3.52 mmol) and TEA (1.07 g, 10.6 mmol) , (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (736 mg, 3.87 mmol) in EtOH (35 mL) was stirred at 90 ℃ for 20 h. The mixture was concentrated and the residue was purified by chromatography on silica gel (DCM /MeOH = 10/1) to afford the title compound. LC-MS (ESI, m/z) : 361.2 [M+1] +.
The following intermediates in Table 2 were prepared according to the method described for INTERMEDIATE 23 using (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (INTERMEDIATE 4A) and the spirocycles specified below.
Table 2
INTERMEDIATE 26
Step A: (R) -tert-butyl 8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8- diazaspiro [4.5] decane-2-carboxylate: To (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (3.8 g, 20 mmol) in EtOH (42 mL) was added tert-butyl 2, 8-diazaspiro [4.5] decane-2-carboxylate (4.0 g, 16.6 mmol) . The reaction mixture was heated at 90 ℃ overnight. The reaction mixture was concentrated, and purified by silica gel column chromatography (0-10% MeOH/EtOAc) to give the title compound. LC/MS: [ (M+1) ] + = 431.
Step B: (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one: To (R) -tert-butyl 8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8-diazaspiro [4.5] decane-2-carboxylate (500 mg, 1.16 mmol) in DCM (5.8 mL) was added TFA (1.8 mL, 23.2 mmol) at 0 ℃. The reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated, and azeotroped with DCM/MeOH/PhMe to remove as much TFA as possible. Then a 10 g Bond Elut SCX was first rinsed with MeOH, load sample with MeOH, washed with MeOH dropwise to remove TFA, finally rinsed with 2N NH3/MeOH to get the title compound as free amine. LC/MS: [ (M+1) ] + = 331.
INTERMEDIATE 27
Step A: tert-Butyl 8- (2- (5-cyano-4-methoxypyridin-2-yl) -2-hydroxyethyl) -2, 8-diazaspiro [4.5] decane-2- carboxylate: A microwave tube was charged with tert-butyl 2, 8-diazaspiro [4.5] decane-2-carboxylate (0.500 g, 2.08 mmol) , 4-methoxy-6- (oxiran-2-yl) pyridine-3-carbonitrile (Intermediate 14 slow eluting isomer B, 0.367 g, 2.08 mmol) , and ethanol (4.0 mL) . The solution was degassed and filled with
nitrogen (3x) , then sealed and heated in a microwave reactor to 140 ℃ for 1 hr. The reaction was cooled to RT and concentrated in vacuo. The resulting residue was purified by prep TLC (2% MeOH: DCM) to provide tert-butyl 8- (2- (5-cyano-4-methoxypyridin-2-yl) -2-hydroxyethyl) -2, 8-diazaspiro [4.5] decane-2-carboxylate.
1H NMR (500 MHz, CDCl3) , δ 8.44 (s, 1H) , 7.21 (s, 1H) , 4.71 (m, 1H) , 3.95 (s, 3H) , 3.28 (m, , 2H) , 3.09 (m, 2H) , 2.78 (m, 1H) , 2.65 (m, 1H) , 2.48 (m, 1H) , 2.37 (m, 3H) , 1.58 (m, 4H) , 1.38 (s, 9H) ; LC-MS (IE, m/z) : 417 [M+1] +.
Step B: (S) -6- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methoxynicotinonitrile: To a solution of tert-butyl 8- (2- (5-cyano-4-methoxypyridin-2-yl) -2-hydroxyethyl) -2, 8-diazaspiro [4.5] decane-2-carboxylate (0.500 mg, 1.20 mmol) in dichloromethane (4.0 mL) at 0 ℃ was added trifluoromethylacetic acid (2.0 mL) . The reaction was stirred at room temperature for 30 min. The mixture was concentrated in vacuo and dried under high vacuum. The resulting residue was partitioned between DCM and saturated sodium bicarbonate solution which was adjusted with 1N NaOH to maintain pH about 9. The aqueous layer was extracted with iPrOH: CHCl3 (1:3, 3x) and the combined organic layers were washed with brine, dried (Mg2SO4) , filtered and concentrated to provide 6- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methoxynicotinonitrile. LC-MS (IE, m/z) : 317 [M+1] +.
INTERMEDIATE 28
To a stirred solution of iodine (484 mg, 1.91mmol) and isoamyl nitrite (410 μL, 3.05 mmol) in acetonitrile (6 mL) was added dropwise an acetonitrile (2 mL) solution of 3-methoxy-1, 2, 4-thiadiazol-5-amine (100 mg, 0.762 mmol) . The reaction mixture was monitored by TLC and LCMS. After the starting material was consumed, the reaction mixture was absorbed on silica. Purification by silica gel column chromatography (0-30% EtOAc/hex) gave 5-iodo-3-methoxy-1, 2, 4-thiadiazole. LC/MS: [ (M+1) ] += 243.
INTERMEDIATE 29
Step A: tert-butyl 2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate: A microwave vial was charged with a magnetic stir bar, tert-butyl 2, 8-diazaspiro [4.5] decane-8-carboxylate (commercially available from multiple vendors, 120 mg, 0.499 mmol) , 5-iodo-3-methoxy-1, 2, 4-thiadiazole (133 mg, 0.549 mmol) , tribasic potassium phosphate (212 mg, 0.999 mmol) , Pd2 (dba) 3 (22.9 mg, 0.025 mmol) , and XPhos (47.6 mg, 0.100 mmol) . The vial was sealed, degassed, and filled with dioxane (3.3 mL) . The reaction mixture was heated at 95 ℃ overnight, filtered and rinsed with DCM. The filtrate was concentrated and the crude product was purified by silica gel column chromatography (0-10%MeOH/DCM) to give the title compound. LC-MS 355 [M+1] +.
Step B: 3-methoxy-5- (2, 8-diazaspiro [4.5] decan-2-yl) -1, 2, 4-thiadiazole: tert-Butyl 2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate (150.9 mg, 0.426 mmol) was dissolved in DCM (2 mL) , and TFA (0.984 mL, 12.8 mmol) was added to free Boc protection and yield the TFA salt. After evaporation of the solvents, the residue was dissolved in CHCl3: IPA (3:1) . This organic phase was washed with two portions of 0.1 N NaOH, then with one portion of brine. The organic phase was collected and dried over MgSO4. Excess solvent was removed under reduced pressure to afford the title compound as a free base. LC-MS 255 [M+1] +.
The following amines provide in Table 3 were prepared in an analogous fashion to the method described for Intermediate 29, starting from intermediates specified below.
Table 3
INTERMEDIATE 33
Step A: tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxa-4, 9-diazaspiro [5.5] undecane-9- carboxylate: In the reaction vessel RuPhos Indoline Precatalyst (0.058 g, 0.079 mmol) and sodium tert-butoxide (0.305 g, 3.17 mmol) were combined, followed by 6-bromo-2-methylpyridazin-3 (2H) -one (0.300 g, 1.587 mmol) and tert-butyl 1-oxa-4, 9-diazaspiro [5.5] undecane-9-carboxylate (0.488 g, 1.905 mmol) . This mixture was then evacuated and backfilled with N2 (3 times) . Then dry, degassed
tetrahydrofuran (7.9 mL) was added to this flask. This mixture was heated at 80 ℃ overnight. The mixture was cooled and solvent was removed on a rotavapor. The residue was dissolved in 40 mL of EtOAc and 20 mL of water. After separation, aqueous layer was extracted with EtOAc (20mL x 2) . The organic layers were combined and washed with 20 mL brine. Then it was dried over Na2SO4. Removing solvent gave the crude product, wich was purifed by column chromatography (40g slica gel column, eluted with 100% EtOAc) to afford the title compound. LC-MS (IE, m/z) : 365 (M+1) +.
Step B: 2-methyl-6- (1-oxa-4, 9-diazaspiro [5.5] undecan-4-yl) pyridazin-3 (2H) -one: The title compound was prepared in a similar fashion to that described for INTERMEDIATE 27 above using TFA. LC-MS (IE, m/z) : 265 (M+1) +.
INTERMEDIATE 34
Step A: tert-butyl 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8- carboxylate: To a reaction flask was charged tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (2.00 g, 7.86 mmol) , 6-bromo-2-methylpyridazin-3 (2H) -one (1.64 mg, 8.65 mmol) , Pd2 (dba) 3 (180 mg, 0.197 mmol) , Xantphos (341 mg, 0.590 mmol) , and Cs2CO3 (5.12 g, 15.7 mmol) . The flask was sealed, degased, and filled with anhydrous dioxane (26 mL) . The reaction mixture was heated at 90 ℃ overnight, diluted with EtOAc and DCM, then filtered through After solvent evaporation, the crude product was purified by silica gel column chromatography (0-10% MeOH/DCM as eluent) to afford the title compound.
LC/MS: (M+1) +: 363.0. 1H NMR (500 MHz, CDCl3) , δ 8.50 (d, J = 10.0 Hz, 1H) , 6.97 (d, J = 10.0 Hz, 1H), 4.02 (br s, 2H) , 3.86 (t, J = 7.0 Hz, 2H) , 3.74 (s, 3H) , 3.05-3.00 (m, 2H) , 2.06-2.02 (m, 2H) , 1.98-1.94 (m, 2H) , 1.58-1.50 (m, 2H) , 1.49 (s, 9H) .
Step B: 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one:tert-Butyl 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (2.55 g, 7.04 mmol) in DCM (12 mL) was treated with TFA (8.1 mL, 106 mmol) at 0 ℃ to free Boc protection and give TFA salt. Then two 10 g Bond Elut SCX columns were first rinsed with MeOH, load sample with MeOH, washed with MeOH dropwise to remove TFA, finally rinsed with 2N NH3/MeOH to get the title compound as a free amine.
LC/MS: (M+1) +: 263.05
INTERMEDIATE 35
5-iodo-3-methyl-1, 2, 4-thiadiazole_was prepared by the same condition as INTERMEDIATE 28 starting from 3-methyl-1, 2, 4-thiadiazol-5-amine. 1H NMR (500 MHz, CDCl3) δ 2.72 (s, 3H) .
INTERMEDIATE 36
6-Bromo-3-pyridazinol (200 mg, 1.14 mmol) , potassium carbonate (316 mg, 2.29 mmol) , and anhydrous acetonitrile (5.7 mL) were charged to a round-bottom flask equipped with a rubber septum and magnetic stir bar. Ethyl iodide (102 μL, 1.26 mmol) was charged dropwise via syringe. The flask was then equipped with a reflux condenser, then heated at reflux for 3 h. The flask was cooled to room temperature and then monitored by TLC and LCMS. The reaction mixture was filtered through and the flask was rinsed with methanol. The filtrate containing the crude product was concentrated and purified on silica gel column chromatography (0-10% MeOH: DCM) to afford 6-bromo-2-ethylpyridazin-3(2H) -one. LC/MS: (M+2) +: 204.81.
INTERMEDIATE 37
6-Bromopyridazin-3 (2H) -one (100 mg, 0.571 mmol) , cyclopropylboronic acid (73.6 mg, 0.857 mmol) , diacetoxycopper (208 mg, 1.14 mmol) , pyridine (368 μL, 4.57 mmol) , triethylamine (399 μL, 2.86 mmol) and anhydrous THF (2.8 mL) were charged to a microwave vial equipped with a rubber septum and magnetic stirbar. Under air, the reaction mixture was microwaved at 140 ℃ for 10 min. The flask was cooled to room temperature and then monitored by TLC and LCMS. The reaction mixture was filtered through and the flask was rinsed with methanol. The filtrate containing the crude product was concentrated and purified on silica gel column chromatography (0-10% MeOH: DCM) to afford 6-bromo-2-cyclopropylpyridazin-3 (2H) -one. LC/MS: (M+2) +: 216.85.
INTERMEDIATE 38
Step A: 5-bromopyridin-2-ol: Into a 10 L round-bottom flask, was placed a solution of H2SO4 (480 ml) in H2O (6000 ml) . 5-Bromopyridin-2-amine (400 g, 2.31 mol, 1.00 equiv) was added to the mixture. The reaction mixture was allowed to react with stirring for 10 minutes and it was cooled to –10 ℃. A solution of NaNO2 (180 g, 2.61 mol, 1.09 equiv) in H2O (1200 ml) was added drop-wise to the mixture with stirring, while cooling the reaction mixture to a temperature of 0-5 ℃. The resulting solution was allowed to react, with stirring, for 0.5 hours while the temperature was maintained at 0-5 ℃ and an additional 0.5 hours while the temperature was maintained at room temperature. The reaction mixture was filtered and the filter cake was washed three times with water; this resulted in the title compound
Step B: 5-bromo-1- (difluoromethyl) pyridin-2 (1H) -one: A solution of 5-bromopyridin-2-ol (200 g, 1.15 mol, 1.00 equiv) in DMSO (2 L) was placed into a 3 L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen. To this mixture was added 60% NaH (50 g) and the
mixture was allowed to react for 15 minutes. Sodium 2-chloro-2, 2-difluoroacetate (200 g, 1.32 mol, 1.14 equiv) was added to the mixture and the resulting solution was allowed to react, with stirring, for 3.5 hours while the temperature was maintained at 55-65 ℃ in a bath of oil. The reaction mixture was cooled in a bath of H2O. The reaction mixture was then quenched by the adding 5 L of H2O. The resulting solution was extracted three times with 3 L of EtOAc and the organic layers combined and dried over Na2SO4. A filtration was performed and the filtrate was concentrated by evaporation under vacuum using a rotary evaporator. The residue was purified by eluting through a column with a 1: 10 EtOAc/PE solvent system. This resulted in the title compound. 1H NMR (300 MHz, CDCl3) : δ 6.50 (1H, d) , 7.41 (1H, d) , 7.56 (1H, s) , 7.60 (1H, m) ; 13C NMR (75 MHz, CDCl3) : δ 99.53, 107.2, 122.9, 129.3, 144.2, 159.2.
INTERMEDIATE 39
To a flask was charged 3-bromo-6-chloropyridazine (300 mg, 1.55 mmol) , 2, 2-difluoro-2-(fluorosulfonyl) acetic acid (829 mg, 4.65 mmol) , and sodium hydrogencarbonate (130 mg, 1.55 mmol) . The flask was filled with acetonitrile (7.8 mL) . The reaction mixture was heated at 50 ℃ for 3 h, and filtered through. The filtrate was evaporated to give the crude product, which was purified by silica gel column chromatography (0-100% EtOAc/Hex) to afford 6-bromo-2- (difluoromethyl) pyridazin-3(2H) -one. LC/MS: (M+1) +: 224.86.
INTERMEDIATE 40
5-Iodopyridazin-3 (2H) -one (200 mg, 0.90 mmol) , potassium carbonate (249 mg, 1.80 mmol) , and anhydrous acetonitrile (4.5 mL) were charged to a round-bottom flask equipped with a rubber septum and magnetic stirbar. Methyl iodide (62.0 μL, 0.991 mmol) was charged dropwise via syringe. The flask was then equipped with a reflux condenser and heated at reflux for 1 hour. The reaction mixture was filtered through. The filtrate was evaporated to give the crude product, which was purified by silica gel column chromatography (0-10% MeOH/DCM) to afford 5-iodo-2-methylpyridazin-3 (2H) -one. LC/MS: (M+1) +: 236.80.
INTERMEDIATE 41
5-Iodopyridazin-3 (2H) -one (200 mg, 0.901 mmol) and methanol (54.7 μL, 1.35 mmol) were charged to a microwave vial equipped with a magnetic stirbar. This was dissolved in THF (4.5 mL) . To this solution was charged di-tert-butyl azodicarboxylate (311 mg, 1.35 mmol) and triphenylphosphine (354 mg, 1.35 mmol) . The reaction mixture was then equipped with a rubber septum and then stirred at room temperature overnight. The reaction mixture was quenched with MeOH and then then concentrated
under reduced pressure to give the crude product, which was purified by silica gel column chromatography (0-10% MeOH/DCM) to afford 5-iodo-3-methoxypyridazine. LC/MS: (M+1) +: 236.83.
INTERMEDIATE 42
6-Chloro-2, 4-dimethylpyridazin-3 (2H) -one was prepared with the same condition as INTERMEDIATE 40 using 6-chloro-4-methylpyridazin-3 (2H) -one. LC/MS: (M+1) +: 158.90.
INTERMEDIATE 43
Step A: 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate: At 0 ℃ to a dioxane (10 mL) and water (5 mL) solution of commercially available (ChemBridge Building Block Library catalog # 4042448; Aldrich catalog # CDS019358) tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-9-carboxylate (1.00 g, 3.71 mmol) was added sodium bicarbonate (0.624 g, 7.43 mmol) , followed by 9-fluorenylmethyl chloroformate (0.960 g, 3.71 mmol, drop wise over 30 min period with syringe pump) . The reaction mixture was allowed to stir at ambient temperature for 2 hours and then concentrated in vacuo (dioxane removal) . The remaining aqueous layer was then extracted with DCM (3 X 15 mL) . The combined organic layers were then dried over sodium sulfate, filtered and concentrated in vacuo. The crude residue was purified via MPLC (0-100% EtOAc/Hex gradient) to afford the title compound. LC/MS: (M+1) +: 492.11.
Step B: 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo- 1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate: The title compounds was prepared in an analogous fashion to INTERMEDIATE 34 (Step A) starting from 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate and and 6-bromo-2-methylpyridazin-3 (2H) -one. LC/MS: (M+1) +: 600.28.
Step C: (9H-fluoren-9-yl) methyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo-1, 4, 9- triazaspiro [5.5] undecane-1-carboxylate: To a solution of 1- ( (9H-fluoren-9-yl) methyl) 9-tert-butyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1, 9-dicarboxylate (33 mg, 0.055 mmol) in MeOH (10 mL) was added HCl (0.069 mL, 4 M in dioxane, 0.275 mmol) . After 4 h, the reaction mixture was evaporated to afford the HCl salt of the title compound. LC/MS: (M+1) +: 500.07.
INTERMEDIATE 44
Step A: tert-butyl 1-oxo-2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate: To a microwave vial was charged tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (80 mg, 0.315 mmol) , 4-iodopyridine (64.5 mg, 0.315 mmol) , copper (I) iodide (3.00 mg, 0.016 mmol) , (1R, 2R) -N1, N2-dimethylcyclohexane-1, 2-diamine (9.92 μL, 0.063 mmol) , and potassium phosphate (134 mg, 0.629 mmol) . The vial was sealed, degased, and filled with toluene (1.6 mL) . The reaction mixture was heated at 110 ℃ for 24 h, diluted with water, and extracted with EtOAc. The organic layer was washed with brined, dried, evaporated to give the crude product, which was purified by silica gel column chromatography (0-10% MeOH/DCM) to give the title compound. LC/MS: (M+1) +: 332.05.
Step B: 2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one: The title compounds was prepared in an analogous fashion to INTERMEDIATE 34 (Step B) starting from tert-butyl 1-oxo-2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decane-8-carboxylate. LC/MS: (M+1) +: 232.05.
The amines intermediates were prepared in an analogous fashion to the method described for Intermediate 34 or 44, using the starting materials specified below.
Table 4
INTERMEDIATE 77
Step A: tert-butyl 2- (isothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: To a microwave vial was charged tert-butyl 1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (INTERMEDIATE 15, 120 mg, 0.472 mmol) , 5-bromoisothiazole (77 mg, 0.472 mmol) , Pd2 (dba) 3 (8.64 mg, 9.44 μmol) , Xantphos (16.4 mg, 0.028 mmol) , and cesium carbonate (231 mg, 0.708 mmol) . The vial was sealed, degased, and filled with dioxane (2.4 mL) . The reaction mixture was heated at 95 ℃ overnight, and diluted with water, extracted with EtOAc. The organic layer was washed with brined, dried, evaporated to give the crude product, which was purified by silica gel column chromatography (0-100% EtOAc/hex as eluent) to afford the title compound. LC/MS: (M+1) +: 338.26.
Step B: tert-butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: To tert-butyl 2- (isothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (65 mg, 0.193 mmol) in DCM (1.9 mL) was added NBS (41.1 mg, 0.231 mmol) . The reaction mixture was heated at 40 ℃ for 2 h, and diluted with water, extracted with EtOAc. The organic layer was washed with brined, dried, evaporated to give the crude product, which was purified by silica gel column chromatography (0-10% MeOH/DCM as eluent) to afford the title compound. LC/MS: (M+2) +: 417.99.
Step C: 2- (4-bromoisothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one: tert-Butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (65 mg, 0.156 mmol) in DCM (1.6 mL) was treated with TFA (0.36 mL, 4.68 mmol) at 0 ℃ to free Boc protection and give TFA salt. The reaction mixture was concentrated, and treated with 0.1N NaOH aqeous solution, and extracted with IPA/CHCl3 (1/3) to give the title compound as a free base after concentration. LC/MS: (M+1) +: 317.22.
INTERMEDIATE 78
Step A: tert-butyl 2- (4-methylisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate: To a microwave vial was charged with tert-butyl 2- (4-bromoisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate (product of Step B of INTERMEDIATE 77, 50 mg, 0.120 mmol) , 2, 4, 6-trimethyl-1, 3, 5, 2, 4, 6-trioxatriborinane (60.3 mg, 0.240 mmol) , Pd (dtbpf) Cl2 (3.91 mg, 6.00 μmol) , and potassium phosphate (102 mg, 0.480 mmol) . DMF (1.1 mL) and water (0.1 mL) were added. The reaction mixture was degased and microwaved at 100 ℃ for 2 h. The reaction mixture was evaporated, and the crude product was purified by prep-TLC (2000 μm, 5% MeOH/DCM as eluent) to provide the title compound. LC/MS: (M+1) +: 352.20.
Step B: 2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one: The title compound was prepared in an analogous fashion to Step C of INTERMEDIATE 77 starting from tert-butyl 2- (4-methylisothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate. 1H NMR (500 MHz, CDCl3) : δ 7.98 (s, 1H) , 4.18 (t, J =7.0 Hz, 2H) , 3.24-3.19 (m, 2H) , 2.89-2.84 (m, 2H) , 2.40 (s, 3H) , 2.20 (t, J = 7.0 Hz, 2H) , 1.94-1.88 (m, 2H), 1.67-1.63 (m, 2H) .
INTERMEDIATE 79
2- (4-chloroisothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one: The title compound was prepared in an analogous fashion to INTERMEDIATE 77 starting from tert-butyl 2- (isothiazol-5-yl) -1-oxo-2, 8-diazaspiro [4.5] decane-8-carboxylate and NCS. LC/MS: (M+1) +: 272.
INTERMEDIATE 80
Step A: 9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] undecane-1, 5-dicarbonitrile: A mixture of 1-benzylpiperidin-4-one (1 kg) and ethyl cyanoacetate (1.195 kg) in a saturated ethanolic ammonia solution (3 L) was stirred for 12 h at about 0-2 ℃. After completed detected by TLC, the reaction mixture was filtered and the solid was dried in vacuo to afford the title compound which was used for next step directly without further purification.
Step B: diethyl 2, 2'- (1-benzylpiperidine-4, 4-diyl) diacetate: The crude 9-benzyl-2, 4-dioxo-3, 9-diazaspiro [5.5] undecane-1, 5-dicarbonitrile in con H2SO4 (1.2 L) and water (1 L) was refluxed for 3 days until the starting material was consumed. The reaction mixture was neutralized by sodium carbonate (1.9 kg) and extracted with ethyl acetate. The combined organic layer was washed with brine, dried and concentrated in vacuo to afford the title compound.
Step C: diethyl 2, 2'- (1- (tert-butoxycarbonyl) piperidine-4, 4-diyl) diacetate: A mixture of diethyl 2, 2'- (1-benzylpiperidine-4, 4-diyl) diacetate (500 g, 1.44 mol) , Boc2O (380 g) and Pd (OH) 2/C (50 g) in methanol (500 mL) under H2 atmosphere (50 psi) was stirred for 24 hours at RT. The mixture was filtered and the filtrate was concentrated in vacuo to afford the title compound.
Step D: tert-butyl 4, 4-bis (2-hydroxyethyl) piperidine-1-carboxylate: To a suspension of LiAlH4 (81.9 g, 2.15 mol) in dry THF (6 L) at -40 ℃ was added a solution of diethyl 2, 2'- (1- (tert-butoxycarbonyl) piperidine-4, 4-diyl) diacetate (478 g, 1.34 mol) in dry THF (2 L) for 2 hours, the reaction mixture was stirred for 0.5h at this same temperature and warmed to RT slowly. Then the mixture was cooled to 0 ℃, water (85.8 mL) , 1N sodium hydroxide solution (171.6 mL) and water (195 ml) was added slowly, the mixture was stirred for 0.5 h and filtered, washed with THF (150 mL x 3) . The filtrated was concentrated in vacuo to afford the title compound.
Step E: tert-butyl 4, 4-bis (2- ( (methylsulfonyl) oxy) ethyl) piperidine-1-carboxylate: To a solution of tert-butyl 4, 4-bis (2-hydroxyethyl) piperidine-1-carboxylate (329 g, 1.21 mol) in dry DCM (3.5 L) at -25 ℃ was added TEA (505 mL, 3.62 mol) followed by addition of DMAP (32.9 g, 0.27 mol) and MsCl (310 g) . The reaction mixture was stirred for 0.5 h at the same temperature. Then a solution of 10% citric acid was added, the organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried and concentrated in vacuo to afford the title compound.
Step F: tert-butyl 9-benzyl-3, 9-diazaspiro [5.5] undecane-3-carboxylate
A mixture of tert-butyl 4, 4-bis (2- ( (methylsulfonyl) oxy) ethyl) piperidine-1-carboxylate (500 g, 1.17 mol) and BnNH2 (508 g, 4.75 mol) in ethanol (5 L) was refluxed for 20 h. The solvent was removed in vacuo, the residue was diluted with ethyl acetate and filtered to remove the salt. The filtrate was concentrated in vacuo and purified by column chromatography on silica gel (PE/EA = 10/1) to afford the title compound.
Step G: tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate: A mixture of tert-butyl 9-benzyl-3, 9-diazaspiro [5.5] undecane-3-carboxylate (240 g, 0.7 mol) and Pd (OH) 2/C (24 g) in methanol (1.5 L) under hydrogen atmosphere (60 psi) at 40 ℃ for 24h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was treated with 1N HCl/methanol and filtered to afford compound the title compound as the HCl salt. 1H NMR (400 MHz, DMSO-d6) δ 8.91 (br s, 1H) , 3.28 (t, J = 4.8 Hz, 4H) , 2.99 (t, J = 5.6 Hz, 4H) , 1.62 (t, J = 6 Hz, 4H) , 1.42-1.33 (m, 4H) , 1.38 (s, 9H) .
INTERMEDIATE 81
Step A: (R) -tert-butyl 9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9- diazaspiro [5.5] undecane-3-carboxylate: To a solution of tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate hydrochloride (114 g, 0.39 mol) in ethanol (1 L) was added Et3N (60 mL) . The mixture was stirred for 2 hours. Next, (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (75 g, 0.39 mol) was added. The mixture was heated to reflux for 24 h. The mixture was concentrated, washed with brine, dried over Na2SO4 and concentrated to provide the crude product. The crude product was purified by SFC separation to provide the title compound. 1H NMR (400 MHz, CDCl3) δ 7.80-7.75 (m, 2H) , 5.23 (s, 2H), 5.14-5.11 (m, 1H) , 3.39-3.36 (m, 5H) , 3.18-3.10 (m, 1H) , 3.05-2.99 (m, 1H) , 2.82-2.72 (m, 2H) , 2.60-2.35 (m, 4H) , 2.25 (s, 3H) , 1.83-1.80 (m, 1H) , 1.65-1.55 (m, 3H) , 1.50-1.35 (m, 18H. )
Step B: (R) -5- (1-hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one: To a solution of (R) -tert-butyl 9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (83 g, 0.19 mol) in CH2Cl2 (1 L) was slowly added a 4 M HCl solution (300 mL) . The mixture was stirred for 8 h. The mixture was filtered. The solid was washed with CH2Cl2, dried to give product as HCl salt. NMR showed there was DEA remained. The product was dissolved in methanol, NaHCO3 was added. The mixture was stirred for 3 h. After filtration, the filtrate was concentrated, washed with ethyl acetate. The residue was concentrated in vacuo to give the title compound.
1H NMR (400 MHz, CDCl3) δ 7.79 (m, 2H) , 5.30 (s, 1H) , 5.25 (s, 2H) , 5.07 (m, 1H) , 4.03 (s, 1H) , 3.14 (m, 4H) , 2.76 (m, 2H) , 2.55 (m, 1H) , 2.41 (m, 3H) , 2.26 (s, 3H) , 1.80 (m, 4H) , 1.65 (m, 4H) .
INTERMEDIATE 82
Step A: (R) -tert-butyl 9- (2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2-hydroxyethyl) -3, 9- diazaspiro [5.5] undecane-3-carboxylate: To a solution of tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (11.6 g, 0.04 mol) in EtOH (104 mL) was added TEA (6 mL) . The mixture was stirred for 3h at 25 degree. (R) -5- (oxiran-2-yl) -2- (1H-tetrazol-1-yl) pyridine (7.56 g, 0.04 mol) was added. The mixture was heated to reflux for 48 h., concentrated, washed with brines, dried over Na2SO4, and concentrated to provide the crude product. Further purified by chiral SFC (Column: AD, 250×30mmI.D. 20um; Mobile phase: A: supercritical CO2, B: EtOH (0.05%NH3. H2O) ; flow rate: 80 mL/min; Back pressure: 100bar; wavelength: 220nm; column temperature: 38 ℃) to afford the title compound. 1H NMR (400 MHz, CDCl3) δ 9.53 (s, 1H) , 8.51 (d, J = 1.6 Hz, 1H) , 8.08-8.02 (m, 2H) , 4.84 (dd, J1 = 10.8 Hz, J2 = 3.6 Hz, 1H) , 3.38 (t, J = 2.4 Hz, 4H) , 2.74 (t, J = 4.8 Hz, 2H) , 2.61 (dd, J1 = 12.4 Hz, J2 = 3.6 Hz, 1H) , 2.47-2.41 (m, 3H) , 1.55 (dd, J1 = 10.8 Hz, J2 = 6.8 Hz, 4H) , 1.42 (s, 13H) .
Step B: (R) -1- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethanol: To a solution of (R) -tert-butyl 9- (2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2-hydroxyethyl) -3, 9-diazaspiro [5.5] undecane-3-carboxylate (15 g, 0.032 mol) in CH2Cl2 (187 mL) was slowly added a 4 M HCl solution (57 mL) . The mixture was stirred for 3 h. The mixture was filtered. The solid was washed with CH2Cl2, dried to give the title compound as the HCl salt. 1H NMR (400 MHz, D2O) δ 9.72 (s, 1H) , 8.53 (d, J = 1.6 Hz, 1H) , 8.08 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H) , 7.97 (d, J = 8.4 Hz, 1H) , 5.31-5.27 (m, 1H) , 3.62 (d, J = 13.2 Hz, 1H) , 3.45 (d, J = 13.2 Hz, 1H) , 3.35 (d, J = 6.8 Hz, 2H) , 3.23-3.10 (m, 6H) , 1.97-1.61 (m, 8H) .
INTERMEDIATE 83
Step A: 5-iodo-2-methylpyridazin-3 (2H) -one: 5-Iodopyridazin-3 (2H) -one (1000 mg, 4.50 mmol) , potassium carbonate (1245 mg, 9.01 mmol) , and anhydrous acetonitrile (22 mL) were charged to a roundbottom flask equipped with a rubber septum and magnetic stir bar. Methyl iodide (310 μL, 4.96 mmol) was charged dropwise via syringe. The flask was then equipped with a reflux condenser, heated at reflux for 3 hours. The reaction mixture was filtered through , and the filtrate containing the crude product was concentrated and purified on column chromatography (0-100% EtOAc: hex) to afford the title compound. 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 2.0 Hz, 1H) , 7.44 (d, J = 2.0 Hz, 1H) , 3.70 (s, 3H) .
Step B: tert-butyl 9- (1-methyl-6-oxo-1, 6-dihydropyridazin-4-yl) -3, 9-diazaspiro [5.5] undecane-3- carboxylate: To a MW vial was charged tert-butyl 3, 9-diazaspiro [5.5] undecane-3-carboxylate (220 mg, 0.756 mmol) , 5-iodo-2-methylpyridazin-3 (2H) -one (196 mg, 0.832 mmol) , Pd2 (dba) 3 (17.32 mg, 0.019 mmol) , Xantphos (32.8 mg, 0.057 mmol) , and Cs2CO3 (493 mg, 1.513 mmol) . The vial was sealed, degassed, and filled with anhydrous dioxane (2.5 mL) . The reaction mixture was heated at 90 ℃overnight, and filtered through . The crude product was purified by column chromatography (0-10% MeOH/DCM) to afford the title compound. LC/MS: [ (M+1) ] + = 363.
Step C: 2-methyl-5- (3, 9-diazaspiro [5.5] undecan-3-yl) pyridazin-3 (2H) -one
Step C was conducted in a similar fashion to Step C of INTERMEDIATE 77. LC/MS: [ (M+1) ] + = 263.
EXAMPLE 1
5- [ (1R) -2- (2, 8-diazaspiro [4.5] dec-8-yl) -1-hydroxyethyl] -4-methyl-2-benz ofuran-1 (3H) -one (30 mg, 0.091 mmole) , 5-chloro-3-methyl-1, 2, 4-thiadiazole (15mg, 0.109 mmole) and diisopropyl ethylamine (0.048 ml, 0.272 mmole) were mixed in 0.5 ml of N, N-dimethylacetamide in a vial. The mixture was stirred at 80 ℃ overnight. The mixture was then cooled down to room temperature, diluted with 0.5 ml of DMSO and then purified by reverse phase mass directed HPLC system using acetonitrile and water to give 5- { (1R) -1-hydroxy-2- [2- (3-methyl-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] dec-8-yl] ethyl} -4-methyl-2-benzofuran-1 (3H) -one. LC-MS (IE, m/z) : 429.43 [M+1] +.
The compounds in Table 5 were prepared in an analogous fashion to EXAMPLE 1 starting from the amine intermediate and commercially available halides.
Table 5
EXAMPLE 7
In a 1 dram vial were added (R) -8- ( 2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl)ethyl) -2, 8-diazoniaspiro [4.5] decane chloride (52 mg, 0.13mmol) , cesium carbonate (101 mg, 0.311 mmol) , tris (dibenzylideneacetone) dipalladium (0) (5 mg, 0.005 mmol) , (9, 9-dimethyl-9H-xanthene-4, 5-diyl) bis (diphenylphosphine) (12 mg, 0.021 mmol) , 5-bromoisothiazole (26 mg, 0.156 mmol) and 1mL of degassed (nitrogen) DMA. The vial was purged with nitrogen gas, sealed and placed on a heating/stir
block at 85 ℃ for 16 hours. The solutions from the reaction was filtered and the product purified by semi-preparative HPLC (gradient of 0-40% acetonitrile over 12 min.) . The solvent was removed from the fractions containing the pure product (Genevac) and the resulting film was reconstituted in 1mL of water/acetonitrile (9:1) and lyophilized to provide (R) -5- (1-hydroxy-2- (2- (isothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one. LC-MS (IE, m/z) : 414.3 [M+1] +.
EXAMPLE 8
While working in an inert atmosphere glove box, to a 4 mL 1 dram containing 1 mL t-amyl alcohol, which had been degassed under nitrogen for 1 hour, was charged 5-bromo-1, 2, 4-thiadiazole (25 mg, 0.15 mmol) , (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (0.040 g, 0.121 mmol) , [dicyclohexyl (2', 6'-diisopropoxybiphenyl-2-yl) phosphine [RuPhos] (2.82 mg, 6.05 μmol) and {2- [2- (azanidyl-kN) ethyl] phenyl-kC1} { [2', 6'-bis (propan-2-yloxy) biphenyl-2-yl] (dicyclohexyl) phosphane-kP} chloropalladium (1+) [RuPhos-precatalyst] (4.94 mg, 6.05 μmol) and cesium carbonate (0.158 g, 0.484 mmol) . The vial was fitted with a stir bar, capped and placed in a heating block at 95℃ with stirring for 16 hours. After 16 hours, the solvents were removed (Genevac) , and the product was dissolved in 1.5 mL of DMSO, the solution was filtered and the product was purified by semi-preparative HPLC (gradient of 0-40% acetonitrile over 12 min.) . The solvent was removed from the fractions containing the pure product (Genevac) and the resulting film was reconstituted in 1mL of water/acetonitrile (9:1) and lyophilized to dryness to provide (R) -5- (2- (2- (1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-8-yl) -1-hydroxyethyl) -4-methylisobenzofuran-1 (3H) -one. LC-MS (IE, m/z) : 415.4 [M+1] +.
EXAMPLE 9
While working in an inert atmosphere glove box, to a 4 mL 1 dram vial containing 1 mL of 1, 4-dioxane, which had been degassed under nitrogen for 1 hour, was charged (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (40 mg, 0.121 mmol) , tris (dibenzylideneacetone) dipalladium (0) (5.5 mg, 0.006 mmol) , (9, 9-dimethyl-9H-xanthene-4, 5-diyl) bis (diphenylphosphine) (14 mg, 0.024 mmol) , 4-chloro-6- (trifluoromethyl) pyrimidine (27 mg, 0.15 mmol) and potassium tert-butoxide (1M in THF) (145uL, 0.145 mmol) . The vial was purged with nitrogen gas, sealed and placed on a heating/stir block at 85 ℃ for 16 hours. The solutions from the
reaction was filtered and the product purified by semi-preparative HPLC (gradient of 0-40% acetonitrile over 12 min) . The solvent was removed from the fractions containing the pure product (Genevac) and the resulting film was reconstituted in 1mL of water/acetonitrile (9: 1) and lyophilized to dryness to provide (R) -5- (1-hydroxy-2- (2- (6- (trifluoromethyl) pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one. LC-MS (IE, m/z) : 477.5 [M+1] +.
EXAMPLE 10
To a microwave vial was charged (R) -5- (1-hydroxy-2- (2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (40 mg, 0.121 mmol) , 4-bromo-2, 6-dimethoxypyrimidine (26.5 mg, 0.121 mmol) , tris (dibenzylideneacetone) dipalladium (0) (5.54 mg, 6.05 μmol) , 2-dicyclohexylphosphino-2′, 4′, 6′-triisopropylbiphenyl (11.5 mg, 0.024 mmol) , and potassium phosphate (51.4 mg, 0.242 mmol) . The vial was sealed, degased, and filled with dioxane (0.60 mL) . The reaction mixture was heated at 100 ℃ overnight, diluted with water, extracted with EtOAc. The organic layer was washed with brined, dried, evaporated to give the crude product, which was purified by silica gel column chromatography (0-10% MeOH/DCM) to afford (R) -5- (2- (2- (2, 6-dimethoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-8-yl) -1-hydroxyethyl) -4-methylisobenzofuran-1 (3H) -one. LC-MS (ESI, m/z) : 469 [M+1] +.
The compounds in Table 6 were prepared in an analogous fashion to EXAMPLES 7-10 starting from the indicated amine intermediate and commercially available halides.
Table 6
EXAMPLE 13
A microwave vial was charged with (R) -4-methyl-5- (oxiran-2-yl) isobenz ofuran-1 (3H) -one (97 mg, 0.510 mmol) , 3-methoxy-5- (2, 8-diazaspiro [4.5] decan-2-yl) -1, 2, 4-thiadiazole (108 mg, 0.425 mmol) , and ethanol (1.5 mL) . The vial was sealed and heated via a microwave at 145 ℃ for 35 min. The solvent was evaporated and the residue was purified by prep-TLC (silica, 1000 μm, 7% MeOH: EtOAc as eluent) to afford (R) -5- (1-hydroxy-2- (2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-8-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one. LC/MS: [ (M+1) ] + = 445.
The compounds In Table 7 were prepared in an analogous fashion to EXAMPLE 13 starting from epoxide and amine intermediates specified below.
Table 7
EXAMPLE 20
To a microwave vial was added 5-ethenyl-4-methyl-2-benzofuran-1 (3H) -one (133 mg, 0.762 mmol) , 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one (INTERMEDIATE 34, 50 mg, 0.191 mmol) , bis (2-diphenylphosphinophenyl) ether (10.3 mg, 0.019 mmol) and bis (1, 5-cyclooctadiene) rhodium (I) tetrafluoroborate (7.74 mg, 0.019 mmol) . The vial was sealed, evacuated, and back filled with N2 (repeat this twice) . Toluene (0.5 mL) was added. The reaction mixture was heated at 70 ℃ for 48 h, filtered through , rinsed with DCM, and the crude product was purifed with silica gel column chromatography (0-10% MeOH/DCM) to afford 8- (2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one. LC/MS: 437M+1] +.
EXAMPLE 21
8- (2- (6- (1H-tetrazol-1-yl) pyridazin-3-yl) ethyl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2,8-diazaspiro [4.5] decan-1-one was prepared from 3- (1H-tetrazol-1-yl) -6-vinylpyridazine (INTERMEDIATE 13) and 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one (INTERMEDIATE 34) following the same procedure as described above for Example 20. LC-MS: 408.8 [M+1-28] +.
EXAMPLE 22
To 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one (30 mg, 0.114 mmol) and 2- (6- (1H-tetrazol-1-yl) pyridin-3-yl) acetaldehyde (32.5 mg, 0.172 mmol) in THF (4.6 mL) was added acetic acid (39 μL, 0.686 mmol) and MP-cyanoborohydride (2.19 mmol/g) (172 mg, 0.377 mmol) . The reaction mixture was put on shaker overnight, filtered, and rinsed with MeOH. The filtrate was concentrated, and purified by prep-TLC (5% MeOH/DCM) to give 8- (2- (6- (1H-tetrazol-1-yl) pyridin-3-yl)ethyl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one. LC/MS: [ (M+1-28)] + = 408.0.
EXAMPLE 23
(R) -9- (2-Hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-one (180 mg, 0.50 mmol) and 4-iodo-2-methoxypyridine (129 mg, 0.55 mmol) , CuI (96 mg, 0.50 mmol) , K3PO4 (106 mg, 0.50 mmol) , (1R, 2R) -N1, N2-dimethylcyclohexane-1, 2-diamine (71 mg, 0.50 mmol) in toluene (6 mL) was stirred at 110 ℃ for 20 hours. The mixture was concentrated and the residue was purified by column chromatography to afford (R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -4- (2-methoxypyridin-4-yl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-one. LC-MS (ESI, m/z) : 468 [M+1] +.
EXAMPLE 24
The mixture of (R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-one (400 mg, 1.11 mmol) and 4-bromo-2-methoxypyrimidine (420 mg, 2.22 mmol) , Xantphos (40 mg, 10%) , Pd2 (dba) 3 (40 mg, 10%) , Cs2CO3 (545 mg, 1.67 mmol) in toluene (6 mL) was stirred at 110 ℃ for 20 hours. The mixture was concentrated and the residue was purified by prep-TLC (DCM/MeOH: 10/1) to afford (R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -4- (2-methoxypyrimidin-4-yl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-one. LC-MS (ESI, m/z) : 469 [M+1] +.
EXAMPLE 25
To a mixture of (R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2, 8-diazaspiro [4.5] decan-1-one (30 mg, 0.087 mmol) , 2-chloropyrazine (20 mg, 0.174 mmol) , RuPhos pre-catalyst (3.2 mg, 4.4 μmol) and RuPhos (4.1 mg, 8.8 μmol) was added anhydrous 2-methyl-2-butanol (1 ml) in a glove box. Then solid Cs2CO3 (85 mg, 0.261 mmol) was added. This reaction mixture was heated at 80 ℃ for 16 hr and then cooled to ambient temperature. The solution was filtrated and the solvent was
evaporated under reduced pressure. The residue was dissolved in DMSO (1.5 mL) and the solution was filtered. The crude product was purified by reversed-phase HPLC (acetonitrile with 0.1% TFA: water with 0.1% TFA from 10% to 60%) to give (R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (pyrazin-2-yl) -2, 8-diazaspiro [4.5] decan-1-one. LC-MS (IE, m/z) : 423 [M+1] +.
The compounds in Table 8 were prepared in an analogous fashion to EXAMPLE 23-25 starting from spirolactam prepared as described above and other commercially available intermediates.
Table 8
EXAMPLE 56
To 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one (INTERMEDIATE 34, 100 mg, 0.381 mmol) in ethanol (2 mL) was added (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (INTERMEDIATE 4A, 87 mg, 0.457 mmol) . The reaction mixture was heated at 90 ℃ overnight. The reaction mixture was evaporated, and the crude product was purified by prep-TLC (2000 μm, 8% MeOH/EtOAc as eluent) to provide (R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2,8-diazaspiro [4.5] decan-1-one. 1H NMR (500 MHz, CDCl3) , δ 8.51 (d, J = 10.0 Hz, 1H), 7.81 (ABq, J =14.4 Hz, Δδ = 8.0 Hz, 2H) , 6.97 (d, J = 10.0 Hz, 1H) , 5.26 (s, 2H) , 5.12 (dd, J = 10.6, 3.1 Hz, 1H) , 3.86 (t, J = 7.0 Hz, 2H) , 3.74 (s, 3H) , 3.21-3.18 (m, 1H) , 2.90-2.86 (m, 1H) , 2.62-2.55 (m, 2H) , 2.46-2.41 (m, 1H) , 2.34-2.31 (m, 1H) , 2.30 (s, 3H) , 2.16-2.06 (m, 4H) , 1.66-1.60 (m, 2H) . LC-MS (IE, m/z) : 453.08 [M+1] +.
The compounds in Table 9 were prepared in an analogous fashion to EXAMPLE 57 starting from epoxides and amines specified below.
Table 9
EXAMPLE 106
To (9H-fluoren-9-yl) methyl 4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -5-oxo-1, 4, 9-triazaspiro [5.5] undecane-1-carboxylate (INTERMEDIATE 43, 29.5 mg, 0.055 mmol) in ethanol (2 mL) was added (R) -4-methyl-5- (oxiran-2-yl) isobenzofuran-1 (3H) -one (INTERMEDIATE 4A, 10.5 mg, 0.055 mmol) and triethylamine (0.023 mL, 0.165 mmol) . The reaction mixture was heated at 80 ℃ overnight. The reaction mixture was evaporated, and the crude product was purified by prep-TLC (2000 μm, 10%MeOH/DCM as eluent) to remove unreacted starting materials. The partially purified product was further purified by SFC-HPLC using a OD column to provide (R) -9- (2-hydroxy-2- (4-methyl-1-
oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -4- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -1, 4, 9-triazaspiro [5.5] undecan-5-one. LC-MS (IE, m/z) : 468.06 (M+1) +.
EXAMPLE 107, 108, 109
Syn isomer, fast eluting 107: 8- ( (1R, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5- yl) propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one Anti isomer, fast eluting 108: 8- ( (1R, 2R) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-
yl)propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one Anti isomer, slow eluting 109: 8- ( (1S, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-
yl)propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one
To a MW vial was charged with 5- (1, 2-dihydroxypropyl) -4-methylisobenzofuran-1 (3H) -one (INTERMEDIATE 5, 150 mg, 0.675 mmol) , 2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one (INTERMEDIATE 34, 212 mg, 0.810 mmol) , 2- (dicyclohexylphosphino) -1-phenyl-1H-pyrrole (41.2 mg, 0.121 mmol) , ruthenium carbonyl (25.9 mg, 0.040 mmol) and tert-amyl alcohol (1.4 mL) . The MW vial was sealed, degassed, and heated at 145 ℃ for 60 h. The reaction mixture was diluted with DCM, dry-loaded to silica gel column, purified by silica gel column (0-10%MeOH/DCM as eluent) to give the syn and anti products, which were then respectively resolved by SFC-HPLC using a AS-H column to provide the title compounds. LC-MS (IE, m/z) : 466.88 (M+1) +.
EXAMPLE 110
(R) -5- (9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9-diazaspiro [5.5] undecan-3-yl) -2-methylpyridazin-3 (2H) -one
Example 110 was prepared in an analog fashion to Example 56 using Intermediates 4A and 83. LC/MS [(M+1) ] + = 453.
Preparative TLC separation (5% MeOH in CH2Cl2) provided the free base, which was dissolved in DCM and treated with 1N HCl in ether (1.05 eq. ) . After 1 h, the solvent was evporated and the product dried under high vacuum to provide the title compound. LC/MS: [ (M+1) ] + = 449
EXAMPLE 111
9-(5-fluoropyridin-3-yl) -3- [ (2R) -2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl] -9- aza-3-azoniaspiro [5.5] undecane: To a solution of (R) -5- (1-hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl)ethyl) -4-methylisobenzofuran-1 (3H) -one (INTERMEDIATE 81, 35 mg, 0.102 mmol) in anhydrous DMSO (1 mL) was quickly added Cu (OAc) 2 (10 mg, 0.055 mmol) , (5-fluoropyridin-3-yl) boronic acid (29 mg, 0.204 mmol) and then DBU (50 μL, 0.31 mmol) . The reaction was sealed and heated at 100 ℃ in microwave for 30 min. LC-MS showed that the product was formed. The reaction was cooled to ambient temperature and partitioned between EtOAc (4 mL x 2) and ammonium (2N, 2 mL) . The organic phase was combined and evaporated in vacuum. The residue was dissolved in DMSO (1.5 mL) . The crude product was purified by using reversed-phase HPLC (acetonitrile with 0.1% formic acid: water with 0.1% formic acid from 10% to 60% ) to give the product as a yellow solid. LC-MS (IE, m/z) : 440 [M+1] +.
EXAMPLE 112
3- [ (2R) -2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydro-2-benzofuran-5-yl) ethyl] -9-pyridin-2-yl-9-aza-3-
azoniaspiro [5.5] undecane: To a solution of (R) -5- (1-hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (INTERMEDIATE 81, 25 mg, 0.073 mmol) and 2-fluoropyridine (14 mg, 0.146 mmol) in anhydrous NMP (1mL) was added NaHCO3 (26 mg, 0.363 mmol) . The resulting suspension was heated to 120℃ and shaked for 8 h. The reaction was cooled to ambient temperature and filtered. The crude product was purified by using reversed-phase HPLC (acetonitrile with 0.1% TFA: water with 0.1% TFA from 10% to 60% ) to give the product as a yellow syrup. LC-MS (IE, m/z) : 422 [M+1] +.
EXAMPLE 113
(R) -6- (9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -3, 9- diazaspiro [5.5] undecan-3-yl) -2-methylpyridazin-3 (2H) -one: In 2 dram vial (8 mL) were added (R) -5- (1-
hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one dihydrochloride (INTERMEDIATE 81 45, 25 mg, 0.060 mmol) , cesium carbonate (58.5 mg, 0.180 mmol) , 6-bromo-2-methylpyridazin-3 (2H) -one (22.64 mg, 0.120 mmol) , 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (6.93 mg, 0.012 mmol) and tris (dibenzylideneacetone) dipalladium (0) (2.74 mg, 2.99 μmol) in THF (2 ml) . The vial was degassed with N2 and than stirred at 95℃ over night. The reaction mixture was filtered and purified with prep. LC/MS to give (R) -6- (9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl)ethyl) -3, 9-diazaspiro [5.5] undecan-3-yl) -2-methylpyridazin-3 (2H) -one. LC-MS (IE, m/z) : 453 [M+H] +.
The compounds in Table 10 were prepared in an analogous fashion to EXAMPLE 111-113 starting from (R) -5- (1-hydroxy-2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethyl) -4-methylisobenzofuran-1 (3H) -one (INTERMEDIATE 81) or (R) -1- (6- (1H-tetrazol-1-yl) pyridin-3-yl) -2- (3, 9-diazaspiro [5.5] undecan-3-yl) ethanol (INTERMEDIATE 82) and other commercially building intermediates.
Table 10
The following Thallium Flux Assay was performed on each of the final product compounds in the Examples.
Thallium Flux Assay
Cell Culture Conditions-HEK293 cells stably expressing hROMK (hKir1.1) were grown at 37℃ in a 10%CO2 humidified incubator in complete growth media: Dulbecco's Modified Eagle Medium supplemented with non-essential amino acids, Penicillin/Streptomycin/Glutamine, G418 and FBS. At >80% confluency, the media was aspirated from the flask and rinsed with 10 mL calcium/magnesium-free PBS. 5 mL of 1X trypsin (prepared in Ca/Mg Free PBS) was added to T-225 flask and flask was returned to 37℃/CO2 incubator for 2-3 minutes. To dislodge the cell, the side of the flask was gently banged with one’s hand. The cells completely titrated and then the cells were transferred to 25 mL complete media, centrifuged at 1,500 rpm for 6 min followed by resuspension in complete growth media and determine cell concentration. For typical re-seeding, 4E6 cells/T-225 flask will attain >80% confluency in 4 days. Under ideal growth conditions and appropriate tissue culture practices, this cell line is stable for 40-45 passages.
FluxOR Kit Components (Invitrogen F10017)
·FluxORTM Reagent (Component A)
·FluxORTM Assay Buffer (Component B) -10X Concentrate
·PowerLoadTM Concentrate (Component C) -100X Concentrate
·Probenecid (Component D) –Lyophilized sample is kept at -20℃. Water soluble, 100X after solubilization in 1 mL water. Store at 4℃.
·FluxORTM Chloride-free Buffer (Component E) -5X Concentrate
·Potassium sulfate (K2SO4) Concentrate (Component F) -125 mM in water. Store at 4℃.
·Thallium sulfate (Tl2SO4) Concentrate (Component G) -50 mM in water. Store at 4℃
·DMSO (dimethyl sulfoxide, Component H) –1 mL (100%)
Reagent preparation: FluxOR Working Solutions
·1000X FluxORTM Reagent: Reconstitute a vial of component A in 100 μl DMSO; Mix well; Store 10 μl aliquots at -20℃
·1X FluxORTM Assay Buffer: Dilute Component B 10-fold with water; Adjust pH to 7.4 with Hepes/NaOH; Filter and store at 4℃
·Probenecid/Assay Buffer: 100 mL of 1X FluxORTM Assay Buffer; 1 mL of reconstituted component D; Store at 4℃
·Loading Buffer (per microplate) : 10 μl 1000X FluxORTM Reagent; 100 μl component C; 10 mL Probenecid/Assay Buffer
·Compound Buffer (per microplate) : 20 mL Probenecid/Assay Buffer; 0.3 mM ouabain (10 mM ouabain in water can be stored in amber bottle/aluminum foil at room temperature) ; Test compound
·1X FluxORTM Chloride-Free Buffer: Prepare 1X working solution in water. Can be stored at room temperature
·Stimulant Buffer (prepared at 5X final concentration in 1X FluxORTM Chloride-Free Buffer) : 7.5 mM thallium sulfate and 0.75 mM potassium sulfate (to give a final assay concentration of 3 mM Thallium/0.3 mM potassium) . Store at 4℃ when not in use. If kept sterile, this solution is good for months.
Assay protocol-The ROMK channel functional thallium flux assay was performed in 384 wells, using the FLIPR-Tetra instrument. HEK-hKir1.1 cells were seeded in Poly-D-Lysine microplates and kept in a 37℃-10%CO2 incubator overnight. On the day of the experiment, the growth media was replaced with the FluxORTM reagent loading buffer and incubated, protected from light, at ambient temperature (23-25℃) for 90 min. The loading buffer was replaced with assay buffer ± test compound followed by 30 min incubation at ambient temperature, where the thallium/potassium stimulant was added to the microplate.
Step Protocol
1.Seed HEK-hKir1.1 cells (50 μl at 20, 000 cells/well) in 384-well PDL coated Microplates
2.Allow cells to adhere overnight in humidified 37℃/10% CO2 incubator
3.Completely remove cell growth media from microplate and replace with 25 μl loading buffer
4.Incubate Microplate at room temperature, protected form light, for 90 min
5.Remove loading buffer and replace with 25 μl 1x Assay Buffer ± test compound.
6.Incubate microplate at room temperature, protected from light, for 30 min
7.At FLIPR-Tetra 384: Add stimulant (thallium/potassium) solution to microplate and monitor fluorescence. Excitation = 400 nm, Emission = 460 & 580 nm. Collect data for~10 min.
Data Calculation-The fluorescence intensity of wells containing 3 μM of a standard control ROMK inhibitor of the present invention was used to define the ROMK-sensitive component of thallium flux. Fluorescence in the presence of test compounds was normalized to control values to provide %fluorescence change. IC50 values represent the concentration of compound that inhibited 50% of the ROMK thallium flux signal.
Assay Standard-Normally, a control compound is included to support that the assay is giving consistent results compared to previous measurements, although the control is not required to obtain the results for the test compounds. The control can be any compound of Formula I of the present invention, preferably with an IC50 potency of less than 1 μM in this assay. Alternatively, the control could be another compound (outside the scope of Formula I) that has an IC50 potency in this assay of less than 1 μM.
Data collected for compounds in the Examples of the present invention using the Thallium Flux Assay are shown in Table 11 below. All of the tested final product compounds in the Examples (diastereomeric mixtures and individual diastereomers) had IC50 potencies less than1 μM the Thallium Flux Assay.
Table 11
While the invention has been described with reference to certain particular embodiments thereof, numerous alternative embodiments will be apparent to those skilled in the art from the teachings described herein. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole. Recitation or depiction of a specific compound in the claims (i.e., a species) without a specific stereoconfiguration designation, or with such a designation for less than all chiral centers, is intended to encompass the racemate, racemic mixtures, each individual enantiomer, a diastereoisomeric mixture and each individual diastereomer of the compound where such forms are possible due to the presence of one or more asymmetric centers. All patents, patent applications and publications cited herein are incorporated by reference in their entirety.
Claims (21)
- A compound of the formulaor a pharmaceutically acceptable salt thereof,wherein:X isY is –O-, -NH-or a bond;Z isR is independently H, alkyl or haloalkyl;R1 is H, D or-OH ;R2 is H or D;R3 is H, D or alkyl;R4 is H or D;R5 is independently oxo or alkyl optionally substituted by 1-5 fluorine atoms;R6 is H or alkyl;R7 is H or alkyl;R8 is H; halo; alkyl optionally substituted by –OR, –C (O) OR12, -OC (O) -R12, or 1-5 halogen atoms; -OR; phenyl; -C (O) OR13; -N (R14) (R15) ; furanyl; or –OCD3;R9 is H, alkyl optionally substituted by 1-5 halogen atoms, or cycloalkyl;R10 is H, halo, or alkyl optionally substituted by 1-5 halogen atoms;R11 is H, alkyl optionally substituted by 1-5 halogen atoms, or -OR;R12 is H or alkyl;R13 is H or alkyl ;R14 is H or alkyl;R15 is H or alkyl;n is 0, 1 or 2;o is 1, 2 or 3; andp is 1 or 2.
- A compound of claim 1 which is:(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (isothiazol-5-yl) -2,8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methylisothiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methyl-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-oneR)-8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (isothiazol-4-yl) -2,8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyridin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (pyridin-4-yl) -2, 8-diazaspiro [4.5] decan-3-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2-methoxypyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one (methoxy-d3) ;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (2- (methylamino) pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -2- (1-methyl-6-oxo-1,6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;(R) -8- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl-d3) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;8- ( (1R, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one;8- ( (1S, 2S) -1-hydroxy-1- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) propan-2-yl) -2- (1-methyl-6-oxo-1, 6-dihydropyridazin-3-yl) -2, 8-diazaspiro [4.5] decan-1-one; or(R) -9- (2-hydroxy-2- (4-methyl-1-oxo-1, 3-dihydroisobenzofuran-5-yl) ethyl) -4- (3-methoxy-1, 2, 4-thiadiazol-5-yl) -1-oxa-4, 9-diazaspiro [5.5] undecan-5-oneor a pharmaceutically acceptable salt thereof.
- A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- The pharmaceutical composition as defined in claim 16, which further comprises a therapeutically effective amount of at least one additional therapeutic agent.
- The pharmaceutical composition as defined in claim 17, wherein the additional therapeutic agent is losartan, valsartan, candesartan, olmesartan, telmesartan, eprosartan, irbesartan, amlodipine, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril, amiloride, spironolactone, epleranone or triamterene, or a pro-drug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
- A method for causing natriuresis or both, comprising administering a compound of claim 1 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient in need thereof.
- A method for the treatment of one or more disorders selected from hypertension, acute heart failure, chronic heart failure, pulmonary arterial hypertension, cardiovascular disease, diabetes, endothelial dysfunction, diastolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eclampsia, cerebral edema, nephropathy, nephrotic syndrome, acute kidney insufficiency, chronic kidney disease, hypercalcemia, Dent's disease, Meniere's disease, or edematous states in a patient in need thereof comprising administering an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof to said patient.
- A method for inhibiting ROMK comprising administering in a patient in need thereof which comprises administering an effective amount of a compound of the formulaor a pharmaceutically acceptable salt thereof,wherein:X isY is –O-, -NH-or a bond;Z isR is independently H, alkyl or haloalkyl;R1 is H, D or -OH ;R2 is H or D;R3 is H, D or alkyl;R4 is H or D;R5 is independently oxo or alkyl optionally substituted by 1-5 fluorine atoms;R6 is H or alkyl;R7 is H or alkyl;R8 is H; halo; alkyl optionally substituted by –OR, –C (O) OR12, -OC (O) -R12, or 1-5 halogen atoms; -OR; phenyl; -C (O) OR13; -N (R14) (R15) ; furanyl; or –OCD3;R9 is H, alkyl optionally substituted by 1-5 halogen atoms, or cycloalkyl;R10 is H, halo, or alkyl optionally substituted by 1-5 halogen atoms;R11 is H, alkyl optionally substituted by 1-5 halogen atoms, or -OR;R12 is H or alkyl;R13 is H or alkyl ;R14 is H or alkyl;R15 is H or alkyl;n is 0, 1 or 2;o is 1, 2 or 3; andp is 1 or 2.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/089930 WO2016065582A1 (en) | 2014-10-30 | 2014-10-30 | Inhibitors of the renal outer medullary potassium channel |
US15/505,254 US20170275298A1 (en) | 2014-10-30 | 2015-10-26 | Inhibitors of the renal outer medullary potassium channel |
PCT/US2015/057283 WO2016069430A1 (en) | 2014-10-30 | 2015-10-26 | Inhibitors of the renal outer medullary potassium channel |
EP15854604.4A EP3212616A4 (en) | 2014-10-30 | 2015-10-26 | Inhibitors of the renal outer medullary potassium channel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/089930 WO2016065582A1 (en) | 2014-10-30 | 2014-10-30 | Inhibitors of the renal outer medullary potassium channel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016065582A1 true WO2016065582A1 (en) | 2016-05-06 |
Family
ID=55856400
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/089930 WO2016065582A1 (en) | 2014-10-30 | 2014-10-30 | Inhibitors of the renal outer medullary potassium channel |
PCT/US2015/057283 WO2016069430A1 (en) | 2014-10-30 | 2015-10-26 | Inhibitors of the renal outer medullary potassium channel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/057283 WO2016069430A1 (en) | 2014-10-30 | 2015-10-26 | Inhibitors of the renal outer medullary potassium channel |
Country Status (3)
Country | Link |
---|---|
US (1) | US20170275298A1 (en) |
EP (1) | EP3212616A4 (en) |
WO (2) | WO2016065582A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
EP3212618A4 (en) * | 2014-10-31 | 2018-05-09 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
KR20190025682A (en) * | 2016-07-07 | 2019-03-11 | 브리스톨-마이어스 스큅 컴퍼니 | Spirolactam as an inhibitor of ROCK |
CN111484507A (en) * | 2019-01-29 | 2020-08-04 | 南京药石科技股份有限公司 | Preparation method of oxazaspiro compounds |
CN113121537A (en) * | 2021-04-13 | 2021-07-16 | 南通药明康德医药科技有限公司 | Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016008064A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014018764A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Spiro - fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160255A1 (en) * | 2005-07-29 | 2010-06-24 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
EP2755656B1 (en) * | 2011-09-16 | 2016-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9493474B2 (en) * | 2011-10-31 | 2016-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014085210A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2968288B1 (en) * | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
-
2014
- 2014-10-30 WO PCT/CN2014/089930 patent/WO2016065582A1/en active Application Filing
-
2015
- 2015-10-26 WO PCT/US2015/057283 patent/WO2016069430A1/en active Application Filing
- 2015-10-26 EP EP15854604.4A patent/EP3212616A4/en not_active Withdrawn
- 2015-10-26 US US15/505,254 patent/US20170275298A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014018764A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Spiro - fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3212618A4 (en) * | 2014-10-31 | 2018-05-09 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
KR20190025682A (en) * | 2016-07-07 | 2019-03-11 | 브리스톨-마이어스 스큅 컴퍼니 | Spirolactam as an inhibitor of ROCK |
KR102491994B1 (en) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Spirolactam as an inhibitor of ROCK |
WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
EP3929194A1 (en) | 2017-06-01 | 2021-12-29 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
USRE49700E1 (en) | 2017-06-01 | 2023-10-17 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
CN111484507A (en) * | 2019-01-29 | 2020-08-04 | 南京药石科技股份有限公司 | Preparation method of oxazaspiro compounds |
CN111484507B (en) * | 2019-01-29 | 2022-05-17 | 南京药石科技股份有限公司 | Preparation method of oxazaspiro compounds |
CN113121537A (en) * | 2021-04-13 | 2021-07-16 | 南通药明康德医药科技有限公司 | Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate |
Also Published As
Publication number | Publication date |
---|---|
EP3212616A1 (en) | 2017-09-06 |
EP3212616A4 (en) | 2018-05-16 |
US20170275298A1 (en) | 2017-09-28 |
WO2016069430A1 (en) | 2016-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3027625B1 (en) | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure | |
US8952166B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3092230B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
US9765074B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2016065582A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2013066714A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3250204B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2014015495A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212618B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3087077A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212619B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2016060941A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2015095097A2 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212617A1 (en) | Inhibitors of the renal outer medullary potassium channel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14904788 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14904788 Country of ref document: EP Kind code of ref document: A1 |